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Resumo 
 
 
 
 
 
Atualmente é reconhecido que a insuficiência cardíaca (IC) diastólica (ICD) constitui 
uma importante causa de morbilidade e mortalidade cardiovascular atingindo cerca de 
50% dos casos de IC. O aumento da incidência de comorbilidades, tal como a 
obesidade são fatores de risco que se associam a um pior prognóstico em pacientes 
com ICD. De facto, atualmente ao tecido adiposo é atribuído um importante papel de 
modulação da função cardíaca. As adipocinas, citocinas pró-inflamatórias assim como 
outras substâncias libertadas por este tecido aparentam desempenhar um papel 
predominante na indução da disfunção cardíaca. Assim, considerando a elevada 
prevalência de obesidade em pacientes com disfunção diastólica e a falta de 
informação sobre esta relação, o objetivo deste trabalho é caracterizar o perfil de 
substâncias libertadas pelo tecido adiposo em condições de ICD, recorrendo a uma 
abordagem proteómica. Neste sentido utilizou-se o tecido adiposo visceral (TAV) e 
epicárdico (TAE) de animais obesos com ICD (n=3 , ZSF1 obesos) e os respetivos 
controlos magros sem ICD (n=3, ZSF1 magros). Primeiro procedeu-se à otimização da 
metodologia para análise do proteoma dos tecidos onde foram testados 3 protocolos 
distintos de extração de proteínas. A seleção do protocolo foi feita considerando o 
número de proteínas extraídas, uma vez que não existiram diferenças significativas nas 
avaliações realizadas. Após a execução do protocolo de extração elegido, efetuou-se 
eletroforese de primeira dimensão e cromatografia líquida de alta resolução para a 
separação de proteínas e péptidos e procedeu-se à identificação dos fragmentos por 
espectrometria de massa. No TAV, os resultados demonstraram, na obesidade, uma 
diminuição das proteína catalase e um aumento das proteínas superóxido dismutase, 
peroxirredoxina-1 e anexina-A1 e A2 levando a crer que existe inflamação, stress 
oxidativo mas, simultaneamente, uma resposta compensatória do tecido adiposo para 
prevenir o aumento de produção de espécies reativas de oxigénio e a progressão da 
inflamação. Observou-se ainda uma diminuição da proteína aldeído desidrogenase 
mitocondrial, o que sugere maior suscetibilidade ao stress oxidativo. No TAE dos ZSF1 
obesos, os resultados demonstraram uma redução da enzima 3-cetoacil-CoA tiolase 
sugerindo um mecanismo compensatório a fim de inibir a oxidação dos ácidos gordos, e 
ainda um aumento das proteínas colagénio-alfa1(I) e lumican, sugerindo uma ligação 
entre a inflamação causada pela obesidade e alterações da matriz extracelular do 
tecido adiposo. Curiosamente, os dois tecidos demonstraram o aumento de proteínas 
contrácteis cardíacas nos obesos ZSF1, as quais são consistentes com várias 
alterações miofilamentares apresentadas na ICD. Por fim, a análise das diferenças 
entre o TAV e o TAE revela claras diferenças no proteoma de cada um destes tecidos. 
Este trabalho apresenta uma abordagem generalista da composição proteica dos 
tecidos adiposos visceral e epicárdico do modelo animal ZSF1, indicando importantes 
diferenças no proteoma do tecido adiposo entre animais obesos com ICD e os 
respetivos controlos e direcionando o desenvolvimento futuro de investigações mais 
específicas focadas no papel funcional das proteínas mais alteradas na ICD.  
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Abstract 
 
 
 
 
 
 
Currently, diastolic heart failure (DHF) is recognized an important cause of 
cardiovascular mortality and morbidity reaching approximately 50% of HF cases. The 
growing incidence of cardiovascular risk factors, such as obesity and overweight are 
associated with a worse prognosis in patients with cardiovascular disease, prompting 
the onset of diastolic dysfunction. In fact, currently the adipose tissue is considered an 
important modulator of cardiac function. Adipokines, pro-inflammatory cytokines and 
other important substances are released by this tissue and seem to play an important 
role in the induction of the cardiac dysfunction. Thus, considering the high prevalence of 
obesity in patients with diastolic dysfunction and lack of information about this relation, 
the aim of this work is to characterize the profile of substances released by adipose 
tissue under conditions of DHF, using a proteomic approach. The visceral (VAT) and 
epicardial (EAT) adipose tissue from obese animals with diastolic HF (n=3, obese ZSF1) 
with their respective lean controls without diastolic HF (n=3, lean ZSF1) were analysed. 
Firstly, the optimization of methodology for analysis of tissues proteome was performed, 
testing three different extraction protocols. The selection of protocol was made 
considering the larger number of extracted proteins, since it there were no significant 
differences in performed evaluations. After execution of the extracted protocol elected, it 
was performed the separation of proteins and peptides by one-dimension gel 
electrophoresis and high-performance liquid chromatography and tryptic digestion used 
to further mass spectrometry identification. In VAT, the results showed in obesity a 
decrease of catalase protein and increase of superoxide dismutase, peroxiredoxin-1 and 
A1 and A2-annexin proteins leading to believe that there are inflammation, oxidative 
stress and, at the same time, a metabolism protection in order to prevent the increase of 
reactive oxygen species and progression of inflammation. In addition, it was also was 
evidenced a decrease of the aldehyde dehydrogenase, mitochondrial suggesting greater 
susceptibility to oxidative stress. In EAT of the obese ZSF1, the results presents a 
decrease of 3-ketoacyl-CoA thiolase protein enzyme as a compensatory mechanism in 
order to inhibit fatty acid oxidation and an increase of lumican and collagen-alpha-1(I) 
proteins suggesting a link between inflammation caused by obesity and increases of 
adipose tissue extracellular matrix. Curiously, both tissues demonstrated the increase of 
cardiac contractile proteins in obese adipose tissue, which are consistent with several 
reported myofilamentary changes in DHF. Finally, it was analysed differences between 
the VAT and EAT, which suggest that both tissues present a different proteome. 
This work is a general approach to the protein composition of the epicardial and visceral 
adipose tissue of the animal model ZSF1, providing importants differences in adipose 
tissue proteome between obese animals with DHF and respective controls and helping 
the future development researches more focused on the functional role of proteins 
changes in DHF. 
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Metabolic changes in diastolic heart failure: a proteomic approach 
1.1 - Introduction 
 Heart failure (HF) is a syndrome that occurs in individuals due to inherited or 
acquired cardiac abnormalities. These patients develop a set of clinical signs and 
symptoms consecutive of the hemodynamic failure [1]. Worldwide it is estimated that 
approximately 26 million people suffer from heart failure and its prevalence tends to 
increase [2, 3]. A significant proportion of patients with this condition have a normal left 
ventricular systolic function with preserved ejection fraction. In this subgroup of patients, 
heart failure is the result of diastolic dysfunction. This condition is, therefore, frequently 
referred as diastolic heart failure (DHF) [3, 4]. While heart failure with impaired left 
ventricular systolic function has been extensively studied, patients with preserved systolic 
function have been grossly under-investigated, and the underlying mechanisms and 
diagnostic criteria have been controversial [4, 5]. Clinical trials addressing DHF treatment 
have been quite disappointing [1], possibly because the determinants of this syndrome are 
still unclear, it is not a homogeneous disease and DHF therapeutic targets remain to clarify. 
In fact, its treatment remains largely empirical, mostly based on blood pressure control, 
treatment of symptoms caused by congestion, maintenance of normal atrial contraction and 
withholding ventricular remodeling or any increase in cardiac dimensions [6] 
 Diastolic heart failure is associated with delayed left ventricle relaxation and/or 
increased chamber stiffness (increased diastolic pressure without volume change) [7]. All 
these myocardial dysfunction can be caused by myocardial abnormalities or by 
maladaptive cardiac remodelling. Obesity represents an important cause of diastolic 
dysfunction and its excessive deposition of adipose tissue causes deregulation of the 
adipokines, which contribute to maladaptive cardiac remodelling. Thus, due to an increase 
in obesity prevalence together with a shift of the profile of substances released by 
adipocytes, a substantial amount of research has been devoted to studying the relationship 
between adipocytes-derived substances and obesity-linked pathologies, such as diabetes 
mellitus. However, the focus of this relationship relative to diastolic dysfunction has been 
scarce, once there is no study about changes in adipocytes-derived substances profile in 
diastolic dysfunction.  
 In conclusion, unravelling these mechanisms will be of upmost important since they 
will contribute to a better characterization of diastolic dysfunction pathophysiology, 
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4 
particularly focusing on the interesting crosstalk between adipose tissue and the 
myocardium. Furthermore, the comprehension of this “dialogue” may target novel 
therapies for diastolic heart failure or even specific biomarkers of this disease. 
1.2 – Heart failure definition 
 Heart failure is an abnormality of cardiac structure or function leading to failure of 
the heart to deliver oxygen at an adequate rate to the requirements of the metabolizing 
tissues, despite normal filling pressures (or only at the expense of increased filling 
pressures) [1]. Heart failure is a syndrome associated to typical symptoms (e.g. 
breathlessness, dyspnoea on exertion, fatigue and peripheral oedema) [8] and signs (e.g. 
elevated jugular venous pressure, pulmonary crackles, and displaced apex beat) [1].  
Figure 1 - Differences between healthy and a failing heart. This figure was produced using Servier Medical Art   
and it was adapted from [9] 
Heart failure constitutes an important medical, social, and economic problem [2]. The 
prevalence of heart failure is estimated as 1%-3% of the adult population in developed 
countries, with the prevalence rising up to more than 10% among patients older than 70 
years [1]. Over 26 million people suffer from heart failure around the world and over 3.5 
million people are newly diagnosed with HF every year in Europe [2]. 
Heart failure is categorized as either systolic or diastolic heart failure (SHF and DHF, 
respectively) [10], with similar prevalence, despite their different pathophysiologic 
mechanisms and differences of age and gender incidence [11]. SHF is characterized by 
progressive left ventricular dilation, eccentric hypertrophy, abnormal left ventricular 
The Normal Heart has 
strong muscular walls that 
contract to pump blood 
out to all parts of the body 
  
Heart muscle pumps 
blood out of the left 
ventricle 
  
Heart Failure is a condition that 
causes the muscle in the heart wall to 
slowly hypertrophy, preventing the 
heart from pumping enough blood 
(SHF) or only at the expense of 
increased filling pressures (DHF) 
  
Weakened muscle 
prevents left ventricle 
from pumping enough 
blood 
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systolic properties and decreased left ventricular ejection fraction, whereas in DHF, the 
hearts generally exhibit concentric hypertrophy, normal or reduced LV volume, abnormal 
diastolic function and normal left ventricular ejection fraction [5, 12]. Differences and 
similarities between systolic and diastolic heart failure are presented in Table 1. 
Table 1 - Differences and similarities between systolic and diastolic heart failure. !- Increased; "- Decreased; N – 
Normal. Reprinted with permission from Gaash WH, Zile MR. Left ventricular diastolic dysfunction and diastolic 
heart failure. Annu Rev Med 2004; 
Signs and symptoms Systolic heart failure Diastolic heart failure 
BNP ! ! 
Exercise testing 
Duration " " 
Systolic blood pressure ! !! 
Pulse pressure ! !! 
Oxygen consumption "" " 
Left ventricle remodelling 
End-diastolic volume !! N 
End-systolic volume !! " 
Myocardial mass ! Eccentric LV hypertrophy ! Concentric LV hypertrophy 
Relative wall thickness " !! 
Cardiomyocyte ! Length ! Diameter 
Extracellular matrix 
(collagen) 
" !! 
Left ventricle systolic function 
Ejection fraction "" N - ! 
Stroke volume N - " N - " 
Myocardial contractility "" " 
Left ventricle diastolic function 
Chamber stiffness N - " !! 
Myocardial stiffness N - ! ! 
Relaxation time – constant ! ! 
Filling dynamics Abnormal Abnormal 
End-diastolic pressure !! !! 
Preload reserve Exhausted Limited 
 Although SHF and DHF share many clinical features, it is clear the underlying 
causes and pathophysiological mechanisms are different. In contrast to SHF, for which 
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knowledge has advanced rapidly over the past decade, little is known about the 
pathophysiology and mechanism targeted therapy for DHF [5]. 
1.2.1 - Diastolic dysfunction and diastolic heart failure 
 Currently, there is an increasing recognition that abnormalities in diastolic function 
represent a major contributor to congestive heart failure [13]. However, there has been a 
considerable controversy over the definition of diastolic dysfunction and diastolic heart 
failure [7].  
 As already stated, heart failure is a condition in which the heart is no longer able to 
pump out enough oxygen-rich blood or achieves this at the expense of increased 
ventricular filling pressures [14]. When heart failure is accompanied by a predominant or 
isolated abnormality in diastolic function, this clinical syndrome is called diastolic heart 
failure. Diastolic dysfunction refers to a condition in which abnormalities in mechanical 
function are present during diastole. That is, diastolic function encompasses ventricular 
relaxation, distensibility and filling. Therefore, the diastolic dysfunction occurs when these 
processes are prolonged, retarded, or incomplete [7, 14, 15] leading to slower and/or stiffer 
ventricles [7]. On the other hand, diastolic heart failure represents an advanced stage of 
diastolic dysfunction that leads to HF. DHF is defined as a clinical syndrome characterized 
by the following conditions: 1) symptoms and signs of heart failure, 2) preserved ejection 
fraction and 3) abnormal diastolic function [7]. So, if diastolic dysfunction refers to an 
abnormal mechanical property, the diastolic heart failure describes a clinical syndrome. 
 
1.2.2 - Epidemiology and prevalence of diastolic heart failure 
 In 1998, the European Study Group on Diastolic Heart Failure published a set of 
criteria for the diagnosis of DHF [16]. At that time, DHF was presumed to account for 
approximately one-third of all patients with heart failure and its natural history was 
considered to be more benign than systolic heart failure with a lower mortality and 
morbidity rate [16, 17]. Over the last two decades, these perspectives have changed 
substantially. Currently it is accepted that DHF accounts for 40% to 50% of all HF cases 
and it has a prognosis, which is as ominous as SHF [18]. 
 Although HF is traditionally associated with reduced left ventricular ejection 
fraction, it has become widely recognized that it can occur even when ejection fraction is 
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preserved, constituting the syndrome of HF with preserved ejection fraction (HFPEF) or 
DHF. Notwithstanding the prevalence mentioned before, several clinical studies suggest 
that the frequency of DHF among patients with HF ranges from 13% to 74%, and there are 
several reasons for this apparent inconsistency [3]; the prevalence of HF and the frequency 
of DHF vary dramatically according to age, sex, methods and criteria used to diagnose 
DHF and the value of ejection fraction that is used as a cut off value. Whereas these factors 
are largely interdependent, the most important appears to be age (in patients > 70 years old 
the prevalence of DHF is of 50%) [7]. Thus, because of population demographics 
continuous changes, the number of persons with HF has and will continue to increase 
dramatically, contributing to the perception of HF as an epidemic problem (Figure 2) [3]. 
Figure 2 - Demographics of patients with heart failure over time. Rectangles: percentage of the population; 
Triangles: number of persons (in millions) aged 65 years and older in the United States. The number of persons 
with HF (grey) will increase dramatically in the next 3 decades [3]. 
 Furthermore, a recent study of Kuznetsova et al. [18] showed that in general 
population, the overall prevalence of LV diastolic dysfunction, estimated from 
echocardiographic measurements was as high as 27.3% and increased with age. These 
authors also showed that higher age, body mass index, heart rate, systolic blood pressure, 
serum insulin and creatinine were significantly associated with a higher risk of LV 
diastolic dysfunction in the general population. Badelek et al. [19] showed that in Europe 
the prevalence of diastolic heart failure in the total population is over 20%.  
1.2.3 - Risk factors  
 As previously mentioned, the incidence and prevalence of HF and its associated 
mortality is increasing at alarming rates [3]. Despite the progress made in the development 
of several new HF therapies, the overall 5-year mortality rate for HF remains extremely 
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high, nearly 50% [20]. Epidemiologic evidence derived from the Framingham Heart Study 
[21] indicates that overweight and obesity are potent indicators and predictors of 
subsequent clinical HF. Moreover, the same study showed that heart failure had developed 
in 8.4% of the study population, and that the risk of developing HF increases 
approximately twofold in people with obesity when compared with the non-obese 
population. 
 Evidence suggests that age, hypertension and obesity play a central role in the 
development of diastolic dysfunction [11]. In fact the majority of patients with high blood 
pressure are overweight. Furthermore, hypertension is about 6 times more frequent in 
obese than in lean individuals [22]. Thus, obesity becomes one of the most important 
features of DHF [23].  
Obesity typically causes worsening of cardiac relaxation and it is associated with several 
changes in cardiovascular function related to the increase of cardiac work parameters such 
as LV filling pressures and left ventricular mass (LVM) [24, 25]. These changes can lead 
to diastolic heart failure. Moreover, Powell et al. [26] examined the relationship among 
body mass index, LV structure, systolic and diastolic function and showed that a higher 
body mass index was associated with greater LVM, LV thickness and LV end-diastolic 
diameter. These findings are consistent with other reports that support obesity as a 
contributing factor for ventricular remodelling, impaired LV relaxation and higher LV 
filling pressure, which lead to diastolic dysfunction and consequently DHF [11]. It is 
important to note, that gender differences in obesity may also influence the development of 
DHF because overweight and obese postmenopausal women experience DHF at higher 
numbers compared with overweight and obese men [27]. 
 1.3 - Obesity and metabolic syndrome 
 In the last decades, the worldwide prevalence of obesity has increased strikingly 
and will likely lead to a rising incidence of insulin resistance (IR), cardiovascular disease 
(CVD), type II diabetes (T2D) as well as metabolic syndrome (MeS) [28]. Experts claim 
that the MeS would never have been formulated if the obesity epidemic had not become 
the public health concern that it is today [29]. 
 Obesity is a metabolic disease of pandemic proportions. The World Health 
Organization estimates that 300 million of adults worldwide are obese and more than 1 
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billion are overweight. Obesity can be defined as an excess of adipose tissue. Generally, 
the body mass index (BMI) has been used to identify obese individuals, which is 
determined by weight (kilograms) divided by height squared (square meters) [30]. In 
clinical terms, a BMI of 25–29 kg/m2 is called overweight and BMIs over 30 kg/m2 is 
called obesity (Table 2).  
Table 2 - Classification of obesity according to BMI [30] 
Classification BMI Risk of comorbidities 
Underweight <18.50 
Low (but risk of other 
clinical problems increased) 
Normal range 18.50 – 24.99 Average 
Overweight #25.00 Increased 
Preobese 25.00 – 29-99 Increased 
Obese class I 30.00 – 34.99 Moderate 
Obese class II 35.00 – 39.99 Severe 
Obese class III # 40.00 Very severe 
 
 However, the best way to estimate obesity in clinical practice is to measure waist 
circumference, because an excess of abdominal fat is most tightly associated with the 
metabolic risk factors than other type of fat [31]. Abdominal fat is located in two major 
compartments: subcutaneous and intraperitoneal fat, which is also known as visceral 
adipose tissue (VAT). Although subcutaneous adipose tissue is a much larger compartment 
than visceral fat, the latter is more strongly related to metabolic risk factors than any other 
fat compartment [32]. Indeed, the increased prevalence of excessive visceral obesity and 
obesity-related cardiovascular risk factors is closely associated with the rising incidence of 
cardiovascular diseases and T2D. This clustering of vascular risk factors in visceral obesity 
is often referred to as metabolic syndrome [33].  
 Metabolic syndrome involves a combination of clinically specific risk features 
including obesity (central adiposity), IR, glucose intolerance or diabetes mellitus, 
dyslipidaemia (specifically high triglycerides (TG), low levels of high-density lipoprotein 
(HDL), and low-density lipoprotein (LDL)), hypertension and atherosclerotic disease [34]. 
However, several conditions have been proposed to define MeS, as depicted in Table 3. 
Table 3 - Four definitions more commonly used in metabolic syndrome. W - women; M - men; Rx - pharmacologic 
treatment. *IGT – impaired glucose tolerance; IFG – Impaired fasting glucose; Urinary albumin excretion of #20 
µg/min or albumin-to-creatinine ratio of # 30mg/g. *** Reliable only patients without T2D. ****Criteria for 
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central obesity (waist circumference) are specific for each population; values given are for Europe men and 
women. 
 WHO (1998) [35] EGIR (1999) [36] 
NCEP ATP III (2005 
revision) [37] IDF (2005) [38] 
Absolutely 
required 
Insulin resistance* (IGT, 
IFG, T2D or other 
evidence of IR) 
Hyperinsulinemia *** 
(plasma insulin > 75th 
percentile) 
none 
Central obesity (Waist 
circumference****): 
"94cm (M) or "80cm 
(W) 
Criteria 
Insulin resistance or 
diabetes plus 2 of the 5 
criteria below  
Hyperinsulinemia, plus 2 of 
4 criteria below 
Any 3 of the 5 criteria 
below 
Obesity, plus 2 of the 
4 criteria below 
Obesity 
Waist/hip ratio: < 0.90 
(M), > 0.85 (W); or BMI 
> 30Kg/m2 
Waist circumference >94 
(M) or >80 (W) 
Waist circumference 
>40 in or >35 in (W) 
Central obesity 
already required 
Hyperglycaemia Insulin resistance already required 
Insulin resistance already 
required 
Fasting glucose " 
100mg/dl or Rx 
Fasting glucose " 
100mg/dl 
Dyslipidaemia 
TG "150mg/dl; 
HDL<35(M), 
HDL<39(W) 
TG "177mg/dl; HDL<39 
mg/dl TG " 150 mg/dl or Rx TG"150mg/dl or Rx 
Dyslipidaemia 
(second separate 
criteria)   
HDL cholesterol: < 40 
mg/dl (M), < 50mg/dl 
(W); or Rx 
HDL cholesterol: < 40 
mg/dl (M), < 50mg/dl 
(W); or Rx 
Hypertension "140/90mmHg "140/90mmHg or Rx 
> 130 mmHg systolic 
or >85 mmHg 
diastolic or Rx 
> 130 mmHg systolic 
or >85 mmHg 
diastolic or Rx 
 
1.3.1 – Adipose tissue  
 There has been a revolution on the perception of the adipose tissue, which has 
evolved from being recognized as a mere deposit of fat to a highly metabolically active 
organ [39].  
 Based on morphology, the expression of specific genes and on the predominant 
type of adipocytes, the adipose tissue is classified into two main forms, brown and white 
adipose tissue [40]. Brown adipose tissue (BAT) is especially abundant in hibernating 
mammals. It has a large number of mitochondria and is specialized in heat production and, 
therefore, energy expenditure. Nevertheless, in humans, BAT is present only in newborns 
for regulating thermogenic processes [40, 41]. White adipose tissue (WAT) is the major 
cellular component of the visceral and subcutaneous depots in humans (25% in adults) and 
stores excess energy in the form of TG [40].  
 The adipose tissue is an endocrine organ with many functions: heat insulation, 
mechanical cushioning and storage site for fat in the form of TG [39]. Furthermore, 
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adipocytes secrete a multiplicity of protein signals and factors, termed adipokines or 
adipocytokines as well as other adipocytes-derived substances that can affect the function 
of the organs [42]. The diversity of these adipocytes-derived substances is considerable, in 
terms of both protein structure and function [43]. The adipokines encompass classical 
cytokines (e.g., TNF-a, IL-6), chemokines (e.g., MCP-1), proteins of the alternative 
complement system (e.g., adipsin), and proteins involved in vascular hemostasis (e.g., 
PAI-1), the regulation of blood pressure (angiotensinogen), lipid metabolism (e.g., retinol 
binding protein), glucose homeostasis (e.g., adiponectin), and angiogenesis (e.g., VEGF) 
[44]. Disturbed production of these bioactive molecules contributes to the development of 
obesity-linked metabolic disorders and cardiovascular disease. A dysregulation of these 
adipokines can be observed under conditions of excessive adipose tissue, such as obesity 
(Figure 3) [45, 46].   
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Figure 3 - Effects of obesity-induced changes in adipokine secretion that lead to the development of systemic 
insulin resistance, metabolic syndrome, type II diabetes, and cardiovascular disorders. Over-nutrition that results 
from a combination of increased food intake and reduced energy expenditure leads to adipose tissue expansion, 
increased adipocyte size and number, and increased macrophage infiltration that, together, lead to increased free 
fatty acid release, deregulated secretion from adipocytes of a variety of adipokines, including adiponectin, leptin, 
resistin, and retinol binding protein 4 (RBP4), and increased release from resident macrophages of the 
inflammatory cytokines, tumor necrosis factor $ (TNF-$) and interleukin 6 (IL6). Deregulated secretion of these 
adipokines elicits a variety of adverse effects on numerous tissues including the hypothalamus, liver, skeletal 
muscle, pancreas, and vasculature that further increase food intake and reduce energy expenditure and lead to the 
development of systemic insulin resistance that increases the risk for development of the metabolic syndrome, type 
II diabetes, and a variety of cardiovascular disorders. Adapted from [46]. 
The normalization of the adipokines secretion profile associated with weight loss due to 
long-term caloric restriction correlates well with the normalization of metabolic 
parameters. This is consistent with the idea that adipokines play an important role as 
molecular messengers and regulators of whole body energy balance [47]. Therefore, the 
proteins secreted by a particular type of cell, in this case adipocytes, play an important role 
in the regulation of many physiological processes via paracrine/autocrine mechanisms, and 
they are of increasing interest as potential biomarkers and therapeutic targets in CVD [48].  
 The VAT is recognized as a predictor of metabolic syndrome and may contribute to 
the risk of CVD via adipokines production. However, the risk of this depends on adipose 
tissue distribution in the body, and mainly on the increase and ectopic accumulation of 
visceral fat [49]. Increased VAT not only involves greater adipocyte size, but also an 
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increased expression of pro-inflammatory adipokines with harmful effects at both local and 
systemic levels. The expression of adipokines varies depending on the site of an adipose 
tissue depots (Figure 4) [50].  
 
Figure 4 - Different sites of adipose tissue depots [50]. 
 However, scientific interest has been focused on the study of certain extra-
abdominal visceral fat deposits, namely epicardial adipose tissue (EAT). Indeed, its close 
relation to the myocardium and coronary arteries has provided a new understanding of the 
association between obesity and cardiovascular disease [51].  
1.3.1.1 - Epicardial and visceral adipose tissue 
 Currently, as already known increased VAT is a better predictor of incidence of 
cardiovascular disease when compared to subcutaneous adipose tissue [52]. Anatomically, 
VAT is present mainly in the mesentery and omentum, and drains directly through the 
portal circulation to the liver. Nevertheless, visceral adipose tissue is vascular, innervated 
and contains a large number of inflammatory and immune cells, a great percentage of large 
adipocytes and it has a great capacity to generate free fatty acids and to uptake glucose. 
VAT adipocytes are metabolically active and sensitive to lipolysis [33].  
 The detection of VAT might be important for CVD risk stratification. However, it is 
difficult to obtain an accurate measurement and characterization of VAT. Several methods 
are applied as surrogates for estimation of VAT. Anthropometric measurements are the 
most used, but are frequently imprecise. Imaging techniques are certainly more precise and 
reliable than anthropometric measurements. Nonetheless, although the magnetic resonance 
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imaging (MRI) is the gold standard technique to estimate VAT accurately, it is quite 
expensive [53]. Thus, Iacobellis et al. [54, 55] have proposed epicardial fat as a true 
visceral fat tissue deposited around the heart. They suggested that it might serve as a new 
indicator of visceral adiposity and its echocardiographic assessment allows identifying 
patients with high cardiovascular risk. Its metabolic and secretory functions are thought to 
be similar to VAT, with which it shares common embryonic origin [56]. Interestingly, 
although EAT and VAT share the same embryological origin, there are no studies that 
compare the adipocytes-derived substances secreted and the differences of expression of 
them among these tissues. 
 Cardiac fat tissue resides in four locations: intracellular, perivascular, pericardial, and 
epicardial fat [57]. Epicardial fat is present on the surface of the heart between the 
myocardium and visceral pericardium and covers more than three quarters of the heart 
surface (approximately 20% of the heart mass) [57, 58]. In the adult human heart, 
epicardial fat is commonly found in the atrioventricular and interventricular grooves, along 
the major branches of the coronary arteries, around the atria, over the free wall of the right 
ventricle (RV) and over the apex of the left ventricle (LV) (Figure 5) [57]. In rodents 
however, epicardial fat is absent. Only overweight or obese animals present a scarce fat 
depot such as pericardium adipose tissue [59]. 
Figure 5 - Macroscopic appearance of epicardial adipose tissue in adult human heart. (A) Anterior view of a 
normal heart. (B) Posterior view of a normal heart. (C) Anterior view of a hypertrophic heart. (D) Posterior view 
of a hypertrophic heart; In the normal heart, the fat distribution is limited to the atrioventricular and 
interventricular grooves, and along the major coronary branches (A, B); In the hypertrophic heart—the 
hypertrophy is mainly on the right-hand side—the adipose tissue also fills the epicardial spaces between these 
sites. Scale bar = 4 cm [56]. 
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 EAT increases in obese people [60] and may therefore cover the spaces between 
the ventricles and eventually all the epicardial surface. As epicardial fat volume increases, 
the coronary arteries become compressed between the fat and the myocardium. It’s 
important to note that when epicardial fat increases, it extends over the anterior surface of 
the heart (more on the RV than on the LV) and over the LV midway between the apex and 
base [61]. Furthermore a small amount of adipose tissue extends from the epicardial 
surface to the myocardium, often following the adventitia of coronary artery branches [56]. 
It also should be noted that there is no fascia or similar tissue separating epicardial fat from 
the myocardium or even from coronary vessels, which means that there is a strong 
interaction between these structures [51]. Therefore, EAT can locally modulate both 
myocardium and coronary arteries [57]. Because of its anatomical proximity and the 
absence of fascial boundaries, epicardial adipose tissue can interact locally with the 
myocardium through secretion of adipokines and cytokines via two mechanisms, paracrine 
and vasocrine (Figure 6) [58]. Paracrine signalling can be defined as when adipokines 
secreted from epicardial adipocytes overlying the lipid core of atherosclerotic plaques 
diffuse in interstitial fluid across the adventitia, media, and intima and interact respectively 
with vasa vasora, vascular smooth muscle cells and endothelium. On the other hand, 
vasocrine signalling can be defined as when adipokines secreted by epicardial adipocytes 
are released from epicardial tissue directly into vasa vasorum and then they are transported 
downstream to react with cells in the media and the intima around plaques [62]. 
Figure 6 - Representative scheme of the paracrine (pathway 1) and vasocrine (pathway 2) mechanisms [62]. 
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1.3.1.2 – Adipokines  
 Adipokines are proteins synthesized by adipose tissue and over 50 have already 
been identified [63]. The increased visceral adiposity is associated with a chronic low 
inflammatory state due to changes in function of adipocytes and macrophages. This 
indicates that there is not only an increase in the secretion of proteins but also a 
pathological state, i.e. inflammation, which results from changes in the secretory function 
disturbing the adipokines secretion [33, 61] (Figure 7). The term adipose tissue 
dysfunction is used for inflammatory-related hypersecretion of pro-atherogenic, pro-
inflammatory and pro-diabetic adipokines [33].  
 In 1987, it was discovered adipsin and it was identified as an adipokine [64]. In 
1993, tumour necrosis factor-alfa (TNF-$) was identified as a pro-inflammatory product of 
adipose tissue and it showed the existence of a link between obesity and inflammation 
[65]. In 1994, the discovery of leptin established beyond doubt the adipose tissue as an 
endocrine organ [66]. Likewise, the recognition of plasminogen activator inhibitor 1, an 
inhibitor of fibrinolysis, as an adipokine strongly up regulated in visceral adipose depots in 
obesity, established a linkage between obesity and thrombotic disorders [67]. Other 
adipokines produced by adipose tissue have also been identified, including interleukin 6 
(IL-6), monocyte chemotactic protein 1 (MCP-1), resistin, visfatin and adiponectin [68]. 
Contrarily to these pro-inflammatory adipokines, adiponectin is the most abundant 
adipose-derived protein in the circulation (5–30 µg/ml) and its decline has been observed 
in obesity [50, 68]. Adiponectin has cardioprotective effects that were confirmed by the 
reduced apoptosis and inflammation levels observed in cultured cardiomyocytes and 
animals exposed to hypoxia-reoxygenation cycle after its administration [69]. Studies in 
experimental organisms showed that adiponectin protects against several metabolic and 
cardiovascular disorders that are associated with obesity [70]. Adiponectin decreased the 
size of cardiac lesion through modulation of pro-survival reactions, cardiac energy 
metabolism and inhibition of hypertrophic remodelling [71]. In fact, experimental studies 
on rodents have demonstrated that adiponectin inhibits hypertrophic signalling in the 
myocardium, suggesting that a decrease in the blood adiponectin levels could cause cardiac 
muscle hypertrophy and so that hypoadiponectinemia contributes to the worsening of 
diastolic dysfunction in hypertension-induced diastolic HF patients [72]. In addition to 
these adipokines, there is another that has had a great interest in research, fatty acid-
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binding protein 4 (FABP4). Adipocyte fatty acid-binding is a member of the cytosolic fatty 
acid-binding protein family and is highly expressed in adipose tissue by means of 
adipocytes and macrophages [73]. Several animal-based and clinical studies have 
demonstrated that FABP4 has an important role in obesity-related insulin resistance, 
inflammation and atherosclerosis, suggesting FABP4 as a potential link between obesity 
and cardiometabolic diseases [74-76]. Moreover, the FABP4 has also been shown to 
directly suppress cardiomyocyte contraction in vitro suggesting a pathogenetic role of 
FABP4 in heart dysfunction [77]. According with these in vitro data, serum concentrations 
of FABP4 are elevated in HF patients and are associated with the incidence and severity of 
HF [78]. A recent study showed that increase of circulating FABP4 may contribute to LV 
diastolic dysfunction in obesity and affirm that FABP4 is a novel target for prevention of 
heart failure [79]. These data suggest that FABP4 may have a causal role in the 
pathogenesis of HF, particularly in obese subjects with metabolic alterations. 
 Low grade inflammation that accompanies obesity and its relation to plasma 
adipokines concentration have been shown to be associated with increased LVM and 
abnormalities of diastolic function [80]. A brief overview of the most important actions of 
adipokines is illustrated in Figure 7.  
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Figure 7 - Contribution of adipokines to obesity and metabolic syndrome abnormalities. The schematic overview 
illustrates some adipokines’ actions with peripheral and central metabolic processes. IL-6 - interleukin-6; ROS - 
reactive oxygen species; RAS - Renin-angiotensin System; TNF-$ - tumor necrosis factor-$. Adapted from [69]. 
1.3.1.3 - Impact of epicardial adipose tissue and diastolic function  
 In cases of extreme obesity, the epicardial fat can completely cover the heart and 
may extend up to 2 cm or more in thickness [62]. In addition, increased LVM, a hallmark 
of left ventricular diastolic dysfunction, is associated with increased epicardial fat 
thickness [81, 82]. Indeed, a strong correlation between increase epicardial fat thickness, 
enlarged atria and impaired RV and LV diastolic filling in morbidly obese subjects has 
been reported [83]. Additionally, in high-risk cardiac patients, EAT is described as a 
source of pro-inflammatory mediators, such as IL-6, TNF-$, MCP-1 and resistin as well as 
a source of protective anti-inflammatory and anti-atherogenic proteins, such as adiponectin 
[84, 85]. These facts show the potential role of epicardial adipose tissue as a reliable 
indicator of CV risk.  
 The epicardial adipose tissue can mechanically and functionally modulate the 
myocardium and vasculature thereby possibly playing a role not only in obesity-related 
atherosclerosis [57] but also in cardiac dysfunction. Adiponectin, resistin and leptin are 
molecules involved in the induction of endothelial dysfunction, mostly by modulation the 
inflammatory reaction [86, 87]. Piestrzeniewicz et al. [88] established a relation between 
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adiponectin, resistin and leptin with LV hypertrophy and abnormal LV relaxation. They 
highlighted the impact of leptin on the risk of abnormal LV relaxation, which was stronger 
after adjustment for obesity, suggesting that its deleterious effect is more significant in 
obese subjects. Barouch et al. [89] stated that leptin deficiency in obese mice leads to left 
ventricular hypertrophy. Moreover, Hong et al. [90] showed a negative correlation 
between the protective adipokine adiponectin and LVM, that is, the results presented a 
decrease in plasma adiponectin concentration associated with the progression of left 
ventricular hypertrophy with diastolic dysfunction. Therefore, leptin and adiponectin can 
be biochemical markers of obesity related to left ventricular hypertrophy and abnormal left 
ventricular relaxation.  
 Overall, the metabolic dysfunction that is due to excessive adipose tissue may partly 
result from an unbalance between the expression of pro- and anti-inflammatory adipocytes-
derived substances thereby contributing to the development of obesity-linked 
complications [50] such as diastolic heart failure.  
1.4 - Animal model of diastolic heart failure 
 The incidence of DHF continues to rise and its prognosis fails to improve partly 
because of lack of specific therapeutic approaches [91]. A comprehensive examination of 
cardiac structure and function and its association with morbidity and mortality is an 
important and necessary step toward meeting the drawbacks of diagnosis, prognosis, and 
treatment of patients with DHF [92]. Moreover, the absence of an appropriate animal 
model of DHF was restraining the progression on diastolic dysfunction comprehension. 
Recently, a full description of a rat model that meets the criteria of DHF was described, the 
obese ZSF1 [91]. ZSF1 rats were generated by crossing non-hypertensive lean female 
Zucker Diabetic Fatty rats (ZDF, +/fa) with lean spontaneously hypertensive HF prone 
male rats (SHHF/Mcc, +/facp) that share a common genetic background with Wistar Kyoto 
(WKY) rats and derive from spontaneously multifactorial hypertensive rats [93-98]. Both 
lean and obese ZSF1 animals inherit a hypertensive gene from the spontaneously 
hypertensive rat strain and show elevated blood pressure [94]. 
 ZSF1 rats have myocardial hypertrophy induced by hypertension, more notorious 
in obese than in lean ZSF1 rats. The obese ZSF1 rats present considerable diastolic 
abnormalities such as increased left atrial area, prolonged time constant of isovolumetric 
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relaxation, elevated arterial elastance and end-diastolic pressure as well as an upwards shift 
of end-diastolic pressure-volume relation, thus highlighting a worse ventricular-vascular 
coupling. Systolic function remained preserved in lean and obese ZSF1 rats [91]. 
 In terms of metabolic disturbances, obese ZSF1 animals developed obesity, 
abdominal adiposity, oral glucose intolerance, hyperglycemia and glycosuria, consistent 
with type II diabetes mellitus phenotype [99] and thus represent a good animal model of 
metabolic syndrome. 
1.5 – Proteomic advances in cardiovascular diseases 
 The prevalence of DHF continues to rise more and more and its prognosis fails 
because of lack of knowledge about its underlying mechanisms [100]. Alterations of the 
CV system (or heart) in response to any pathology or acute injury have a major impact on 
the cellular environment, changing the proteins profiles. Proteins are involved in many 
cardiac cellular functions as well as its regulatory mechanisms. Additionally, they are 
modified in diseases as the cause or effect [101]. Proteomic technology enables detection 
of these changes, in either tissues, cells or associated biologic fluids [102]. “Proteomic” 
derived from “proteome” which was used at first time by Mark Wilkins in 1995 [103]. He 
used the term proteome to describe the entire complement of proteins expressed in a cell, 
tissue or organism. Specifically, the proteomic is the large-scale characterization of 
proteins and it provides detailed information about the changes in gene regulation, protein 
transcription, protein quantity, and protein post-translational modifications [104]. Thus, 
proteomic can be a tool of great value for studying changes in cardiac proteome.  
 As outlined in Figure 8, numerous steps are involved in proteomic: sample 
preparation, protein separation, quantification and identification.  
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Figure 8 - Overview of the main differential proteomic strategies. LC – Liquid chromatography; MS – mass 
spectrometry; MS/MS – Tandem MS; MALDI - Matrix-Assisted Laser Desorption/Ionization; ESI - Electrospray 
Ionisation 
1.5.1 - Methodological approaches 
 Current proteomic techniques can be categorized into two classes: (1) gel-based 
proteomic approaches, which include separation of proteins by gel electrophoresis (e.g. 2-
dimensional gel electrophoresis (2DE)) followed by mass spectrometry (MS) analysis for 
identification of proteins, (2) and gel-free proteomics, which relies in the utilization of 
protein and peptide separation using liquid chromatography (Figure 8). These techniques 
have provided orientation for the study of changes in adipose tissue proteome involved in 
disorders related to cardiovascular diseases (Table 4). 
 Gel-based proteomics includes classical 1-dimensional (1D), native PAGE, and 2-
dimensional (2D) electrophoresis (1DE and 2DE) [105]. A 1DE is especially more 
straightforward and simpler than any previous method of protein analysis, mainly, because 
it can be used to separate any proteins regardless of their inherent solubility in aqueous 
solution [106]. This approach was used by Salgado-Somoza et al. [107] and allowed to 
detect 41 proteins related with coronary artery disease (Table 4). However, due to its high 
resolution and sensitivity, the 2DE technique is a powerful tool for the analysis and 
detection of proteins from complex biological sources [108]. It is a protein profiling 
technique that carries out separation using the combination of two different separation 
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strategies. In the first dimension, proteins are separated based on their charge properties by 
isoelectric focusing (pI). Then, in the second dimension, proteins are resolved based on 
their molecular weight (MW) by sodium dodecylsulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) [105]. The result is a set of spots to which can be assigned 
specific X and Y coordinates, unlike protein bands obtained in one-dimensional techniques. 
Each spot of the gel contains one or a very small number of proteins, depending on the 
complexity of the sample [109]. Thus, thousands of proteins can be separated in a single 
gel, allowing the determination of the pI values, MW and relative abundance [110]. 
Another aspect of 2DE is the ability to separate proteins based on the presence of post-
translational modifications (PTMs) [105]. This technique has been applied in to adipose 
tissue, being generally employed on comprehension of mechanisms related with CVD 
[111] and obesity [112, 113] (Table 4). 
 Accordingly to Bland et al. [114] to obtain reliable and confident data with 2DE 
several replicates per sample are required to achieve a low variability. However, an 
improvement in 2DE, applying fluorescent labels to samples, named two-dimensional 
difference gel electrophoresis (2D-DIGE), has allowed the analysis of two or three marked 
protein samples in the same gel, reducing gel-to-gel variation and increasing 
reproducibility [115, 116]. This strategy enabled to identify and evaluate eleven proteins 
involved in the progression of type II diabetes in pre-obese subjects [117] (Table 4). 
Although 2DE can provide valuable information, it suffers from many limitations, such as 
difficulty to detect low abundance proteins and analyse hydrophobic proteins or proteins 
with extreme pI or MWs (e.g. cannot detect proteins below the 10kDa) [118].  
 Face to the constrains and limitations presented in gel-based approaches, gel-free has 
been developed to improve protein characterization with respect to biological function or 
biochemical structure, allowing specific protein classes and protein modifications to be 
isolated [119]. This technique solves some limitations of 2DE, i.e., it has greatest depth of 
protein coverage and widest dynamic range of size of proteins identified [120]. This 
technique can be used to separate proteins according to their molecular mass, isoelectric 
point or hydrophobicity [105]. There are two strategies using gel-free, 1D-LC and 2D-LC. 
1D-LC can be used to separate proteins according to their molecular mass, isoelectric point 
or hydrophobicity. On the other hand, in 2D-LC the proteins are separated in first 
dimension by an isoelectric point and in second dimension by hydrophobicity [121]. 
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Adopting this strategy, Kim et al [122] identified 2338 proteins in visceral adipose tissue 
in type II diabetes (Table 4). In addition to these approaches, the gel-free can be combined 
with gel-based to improve the protein separation. Alvarez-Llamas et al. [123] used this 
method identifying 295 proteins (Table 4). First the sample was submitted to 1DE and next 
it was applied 1D-LC to separate proteins from each gel band with more specificity.
 Liquid chromatography technologies help to reduce sample complexity, being a 
common strategy the use of a preparative chromatography previous to LC-MS/MS 
analysis. Moreover, it enables the sample fractionation and increase substantially proteome 
coverage [124]. The combination of successive chromatography steps for peptides 
separation, according to various physicochemical properties and/or affinity interactions, is 
named multi-dimensional protein identification technology (MudPIT) and from this 
principle results the increase of dynamic range of protein identification and several 
samples with less complexity [105]. 
 After proteins separation, it follows the respective detection and identification. The 
traditional approach to identify proteins is its enzymatic digestion (e.g. trypsin) and 
analysis of peptides by mass spectrometry. Three approaches are generally used for 
identifying of proteins: peptide mass fingerprint (PMF), peptide fragment fingerprinting 
(PFF) and de novo sequencing [125]. The most common protein identification technique is 
PMF. In this case, the m/z ratio obtained for each peptide after enzymatic or chemical 
digestion is accurately measured and compared with all theoretical masses present in 
databases obtained by in silico proteolytic digestion [126].  
 Mass spectrometry techniques are the most widely used tools for protein analysis 
and identification. Different mass spectrometry methods are classified in distinct ionization 
processes, and two of them are widely applied in the study of proteomics [125]. In matrix-
assisted laser desorption/ionization (MALDI), the sample that will be analysed is 
incorporated into a matrix that promotes ionization containing acid components such as #-
cyano-4-hydroxycinnamic acid, which is activated by laser and results in the formation of 
sample ions. These enter into the gas phase and are analysed [127]. The peptide mass-to-
charge ratios are matched to theoretical fingerprints, derived from sequence databases, in 
order to identify the protein of interest. These theoretical fingerprints are based on the 
peptides that are expected to produce when digesting proteins with a specific protease. For 
example, digestion with trypsin will always cleave a protein in the carboxylic side of lysine 
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and arginine residues, resulting in a predictable peptide mass fingerprint [128]. Another 
technique is electrospray ionisation (ESI) and is achieved by spraying a solution through a 
charged needle at atmospheric pressure towards the inlet to the mass spectrometry; the 
voltage applied to the needle tip and a pressure differential result in the formation of ions 
for mass analysis and their transfer into the mass spectrometer [129]. This approach is 
good to analyse compound multi-loaded [125]. 
 The analysis of proteins/peptides by MS produces a considerable amount of data, 
being necessary the use of bioinformatics [130]. There are several programs able to 
perform the analysis, of which are examples SEQUEST and MASCOT [125]. These 
programs are powerful search engines that correlate un-interpreted MS spectra of peptides 
with amino acid sequences from protein and nucleotide databases to identify proteins. 
[130, 131].  
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Table 4 - Summary of proteomic analysis methodologies used for epicardial and visceral adipose tissue 
Methodologies Goal Sample Pathology Results Main findings Ref. 
2DE-MALDI-
TOF/TOF-MS 
Identification of the protein 
expression profiles of EAT and SAT 
and analysis of molecules that 
characterize EAT in patients with 
cardiovascular disease.  
EAT of the 
right ventricle 
and SAT of 
the thorax 
human 
Patients undergoing 
heart surgery (valve 
replacement or 
coronary artery 
bypass graft) 
8 proteins identified 
In cardiac patients the expression of proteins 
in EAT were: Up-regulated: GSTP1; PDIA1; 
PGAM1and Down-regulated: CATA  
[111] 
2DE-MALDI-
TOF/TOF-
MS/MS 
Characterization of the secretome of 
rat adipose tissue explants from 
different anatomical localizations and 
its differential analysis. 
Visceral, 
subcutaneous 
and gonadal 
adipose tissue 
of the Sprague 
Dawley rat 
Obesity 
106 proteins of the 
visceral fat identified; 
49 proteins of the 
subcutaneous fat; 53 
proteins of the 
gonadal fat 
Proteins more abundant in visceral fat: 
Transgelin, Heat shock protein 60KDa, 
Peptidyl-prolul cis-trans isomerase A, Actin, 
Omega-amidase NIT2, Enoyl-CoA hydratase, 
Gelsolin, Thrombospondin-1. 
[112] 
SDS-PAGE-LC-
MS/MS 
Characterization of the adipose tissue 
secretome 
Human 
visceral 
adipose tissue 
secretome 
Non-carcinogenic 
gynaecologic 
disorders 
259 proteins 
identified 
This study revealed that 108 of 259 proteins 
were secreted following a classical pathway 
(endoplasmic reticulum/Golgi-dependent 
pathway). Of 108 secreted proteins, 70 
proteins (such as adiponectin, adipsin, 
gelsolin, macrophage colony-stimulating 
factor-1 (MCSF), pigment epithelium-derived 
factor, plasma retinol-binding protein, and 
PAI-1 among others) were considered 
genuine adipose tissue-secreted proteins. 
[123] 
2DE-MALDI-
TOF 
Assessment of differences in the 
proteome and the secretome between 
epicardial and subcutaneous adipose 
tissue (SAT) from patients with and 
without CAD. 
Human 
epicardial 
adipose tissue 
Coronary artery 
disease 41 proteins identified 
This study showed that in CAD patients, the 
expression of proteins in EAT were: Up-
regulated: ALB; FABP4; GPI and 
SERPINA1 and Down-regulated: APOA1 
[107] 
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Table 4 - (Continue…) 
 
Methodologies Goal Sample Pathology Results Main findings Ref. 
2DE-LC-MS/MS - 
Western Blot 
Comprehension about proteomic 
analysis of VATs in drug naive, early 
T2DM patients and subjects with 
normal glucose tolerance 
Human visceral 
adipose tissue 
Type II diabetes 
mellitus 
2338 proteins 
identified 
This analysis revealed that 444 up-
regulated proteins were mainly involved 
in inflammatory/immune responses, 
cytoskeleton, organization-related 
processes, responses to ROS and 
oxidative stress while 328 down-
regulated proteins were mainly involved 
in glucose and fatty acid metabolic 
processes that highly contribute to T2DM 
pathogenesis 
[122] 
2D-DIGE-
MALDI-
TOF/TOF 
Comprehension the mechanisms 
involved in the progression to overt 
diabetes in pre-obese subjects 
Human visceral 
adipose tissue 
Type II diabetes 11 proteins identified Diabetic patients showed increased VAT 
abundance of glutathione S-transferase 
Mu 2, peroxiredoxin-2, antithrombin-III, 
apolipoprotein A-IV, Ig ! chain C region, 
mitochondrial aldehyde dehydrogenase 
and actin, and decreased abundance of 
annexin-A1, retinaldehyde 
dehydrogenase-1, and vinculin, compared 
with their non-diabetic counterparts. 
[117] 
2DE-MALDI-
TOF/TOF 
Investigate differentially expressed 
proteins of visceral adipose tissues 
between low-fat diet-fed obesity-
resistant and obesity-prone c57Bl/6 
mice 
Visceral adipose 
tissue of c57Bl/6 
mice 
Obesity 14 proteins identified Proteomic analysis showed that 
ubiquinol-cytochrome c reductase core 
protein 1 (Uqcrc1) and enolase 3, " 
muscle were decreased in the visceral 
adipose tissues of the obesity- prone 
mice, while monoglyceride lipase (MGll) 
and glucose-6-phosphate dehydrogenase 
(G6PdH) X-linked were increased. 
[113] 
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 The studies of Table 4 present several proteins matched between them (Appendix 
A - Supplemental Table A1). The main proteins shared between the studies of Table 4 are 
actin cytoplasmic-1 (ACTB), glutatione-S-transferase-P (GSTP1), fatty acid-binding 
protein 4 (FABP4), protein DJ-1 (PARK7), peroxiredoxin-2 (PRDX2), peroxiredoxin-3 
(PRDX3), Ig kappa chain C region (IGKC), retinal dehydrogenase (ALDH1A1), L-lactase 
dehydrohenase B chain (LDHB) and alpha-2-macroglobulin (A2M) (Table 5). Table 5 
presents the genes of the respective proteins and its expression in each study.  
Table 5 - Genes of the main proteins shared between studies of the Table 4 and their expressions.!- Proteins up-
regulated; "- Proteins down-regulated; ! - Proteins not identified; NPEA – no protein expression was analysed. 
Reference of the study 
Gene name [111] [112] [123] [107] [122] [117] [113] 
ACTB －! － NPEA － !! !! －
GSTP1 !! － NPEA !! NPEA － －
FABP4 －! !! NPEA !! !! － －
PARK7 －! NPEA NPEA NPEA － － －
PRDX2 －! NPEA NPEA NPEA NPEA !! －
PRDX3 －! NPEA NPEA ! NPEA － －
IGKC －! NPEA NPEA NPEA !! !! －
ALDH1A1 －! NPEA NPEA － NPEA "! －
LDHB －! NPEA NPEA － NPEA － －
A2M －! － NPEA NPEA NPEA － －
 
In Table 5 it is possible to observe that independently of the pathophysiology, the majority 
of proteins are up-regulated in relation to their controls. This fact is consistent with the 
notion that metabolic dysfunction may partly result from an imbalance in the expression of 
pro- and anti-inflammatory adipokines thereby contributing to the development of obesity-
linked complications [50], such as diastolic heart failure. It is also important to note in 
Table 5, that although these (and many others) proteins have been identified, its relative 
abundance analysis is missing. This can be a problem regarding the comprehension of 
many mechanisms involved in metabolic disorders. In this way, its research is important. 
 Studies using proteomic technologies have yielded examples of novel insights into 
the mechanisms of obesity-related diseases, particularly in type II diabetes mellitus and 
coronary disease (Table 4). However, as observed in Table 4, there are no studies focusing 
on the impact of epicardial or visceral adipose tissue on diastolic heart failure. Thus, the 
integration of proteomics is needed to clarify complex protein changes associated not only 
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with diastolic dysfunction but also with pharmacological interventions taken in response to 
this dysfunction. 
1.6-Objective  
 Diastolic heart failure is more and more an important cause of cardiovascular 
mortality and morbidity. Although the knowledge of metabolic changes may help in 
comprehension of the mechanisms involved in this pathophysiology, its proteome and 
respective expression remain unknown. Therefore the aim of the present work is to 
understand the changes in proteins that occur in the diastolic dysfunction during obesity. In 
order to achieve this goal we intend to: 
• Characterize epicardial and visceral adipose tissue proteome of the obese animals 
presenting DHF and to compare them with lean control rats  
• Assess and quantify proteome profile and association of their expression changes 
with diastolic dysfunction. 
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CHAPTER 2 
MATERIALS AND METHODOLOGY 
  
  
  
 
  
 
2.1. - Experimental Design 
 In order to achieve the proposed aims for this study, the experimental approach 
shown in Figure 9 was performed. Briefly, first the optimization of a protocol for protein 
extraction from different tissues (epicardial and visceral fat) was performed. After that, it 
was done the study of the visceral adipose tissue proteome in obese and lean ZSF1 rats in 
order to compare them. Six ZSF1 rats were divided into two groups: obese animals with 
diastolic dysfunction (n=3) and the correspondent lean animals (n=3). After 20 weeks of 
age, animals were sacrificed and epicardial and visceral fat was collected. The tissue 
samples were immediately frozen and stored at -196 °C. The experimental groups and 
methodological approaches used are described in the following sections. 
 
Figure 9 - Scheme of the methodological procedures used in the analysis of different tissues of ZSF1 rats 
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2.2 – Methods 
2.2.1 – Animal Protocol 
 All animal experiments were performed according to the Portuguese law for animal 
welfare and accordingly to the Guide for the Care and Use of Laboratory Animals 
published by the National Institutes of Health (NIH Publication 85-23, Revised 2011). The 
Faculty of Medicine of Porto is a governmental institution, granted approval by the 
Portuguese government to perform animal experiments.  
 The animal protocol was accomplished using six ZSF1 rats (Lean ZSF1, n= 3; 
obese ZSF1, n= 3). The animals were obtained at the age of 9 weeks from Charles River 
(Barcelona, Spain). During the experimental protocol, animals were housed in groups of 
two rats/cage in individually ventilated cages (IVCs), maintained on a 12-hour light-dark 
cycle, with full access to the recommended diet (LabDiet® 5008, International Product 
Supplies Ltd.) and water ad libitum. The IVCs were maintained under controlled 
environment temperature (22°C), relative humidity (30–70%), and air exchange rate (40–
50 air changes per hour). For metabolic characterization, animals were periodically 
subjected to metabolic cage studies, oral glucose-tolerance and insulin-resistance tests. For 
cardiac function assessment, terminal hemodynamic evaluations were performed by rats’ 
20th weeks of age. The Physiology and Cardiothoracic Surgery Department of Faculty of 
Medicine of Porto provided all this information about the animal characterization.  
2.2.1.1 - Metabolic studies and renal-function assessment  
 After 24-hours of metabolic cages adaptation (Techniplast, Buguggiate), the hydric 
and energetic ingestion as well weight gain and urinary output was registered and 24-hour 
urine specimen collected. Twenty-four hours later and 12 hours of fast, the animals were 
successively submitted to oral glucose-tolerance and insulin-resistance tests. Glycaemia 
was assessed after 15, 30, 60, 90 and 120 minutes following the administration of glucose 
(1g.Kg-1) and insulin (0.5 U.Kg-1) by gavage and intraperitoneal injection, respectively. 
2.2.1.2 - Echocardiography evaluation 
 An echocardiography evaluation was performed at the beginning of the study, at 
the 10th week, and repeated at the 14th and 18th week. The animals were sedated (mixture 
of 8% of and 1-2.5% of sevoflurane with oxygen, for induction and maintenance, 
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respectively), endotracheally intubated and mechanically ventilated (150 min!1, 100% O2, 
14–16 cmH2O inspiratory pressure, with tidal volume adjusted to animal weight, and 4 
cmH2O end-expiratory pressure (TOPO Small Animal Ventilator, Kent Scientific Inc.). 
Two-dimensionally (2D)-guided M-mode echocardiography and pulse-wave Doppler 
echocardiography were performed using an echocardiographic system equipped with a 15-
MHz linear-transducer (Sequoia 15L8W), and the exams were performed with the animals 
placed over a heating pad, in the prone left lateral decubitus position with a full chest 
shaving.  
Parasternal long-axis images of the aorta, left atrium and LV were first obtained; 90° 
rotation from the long-axis view produced a short axis view of the heart. M-Mode short-
axis view at the level of the papillary muscle was used to assess wall thickness as well as 
systolic and diastolic left ventricular cavity dimensions. From these measurements end 
diastolic and end systolic volumes, (EDV and ESV, respectively), fractional shortening 
(FS), ejection fraction (EF) of the LV, stroke volume (SV) and cardiac output (CO) were 
derived. The following Doppler and tissue Doppler measurements were taken using the 
apical four-chamber early diastolic filling peak velocity (E wave), late diastolic peak 
velocity (A wave), E/A ratio, deceleration time (DT), isovolumic relaxation time (IVRT) , 
isovolumic contraction time (IVCT) , early peak diastolic filling velocity (E’), late peak 
diastolic filling velocity (A’) and mitral annular systolic velocity (S’). Three representative 
cycles were measured per rat and their average was calculated. 
2.2.1.3 - Hemodynamic instrumentation  
 At their 20th weeks of age, after intraperitoneal sedation by a mixture of fentanyl 
and midazolam (100"g.kg-1 e 5mg.kg-1, respectively), rats were anaesthetized (with a 
mixture of 8% and 1-2.5% sevoflurane with oxygen for induction and maintenance, 
respectively), endotracheally intubated, (mechanically ventilated (150 min!1, 100% O2, 
14–16 cmH2O inspiratory pressure, with tidal volume adjusted to animal weight, and 4 
cmH2O end-expiratory pressure; TOPO Small Animal Ventilator, Kent Scientific Inc.) and 
placed over a heating pad (38°C). 
  To compensate for perioperative fluid losses, the femoral vein was cannulated and 
warm Ringer lactate’s solution fluid was administered with a perfusion pump (Multi-
Phaser™, NE-1000, New Era Pump Systems). Under surgical microdissection (Wilde 
M651, Leica microsystems), left thoracotomy was performed, pericardium was widely 
 
 
 
Chapter 3 – Results 
34 
opened and pressure–volume (PV) catheters were implanted through the apex along the 
LV and the RV (SPR-838 and PVR-1045, Millar Instruments, Houston, TX, respectively). 
After 15 min of stabilization, recordings were done at the end-expiration under basal 
conditions and transient IVC and aortic occlusions in order to assess PV relationships. The 
systemic blood pressure was recorded by advancing the LV catheter to the aorta. Parallel 
conductance and field inhomogeneity were estimated by 50µL 10% saline injections and 
cardiac output (CO) measurement (Perivascular Flowmeter Module, AD Instruments 
Technology), respectively. Data were continuously acquired (MPVS 300, Millar 
Instruments), digitally recorded at 1000 Hz (ML880 PowerLab 16/30, Millar Instruments), 
and analyzed (PVAN 3.5™, Millar Instruments). Heart rate, stroke volume, end-diastolic 
volume (LVEDV), end-systolic volume (LVESV), EF, end-diastolic pressure (LVPED) 
and end-systolic pressure (LVPES) were determined from the pressure–volume tracings. 
Effective systemic arterial elastance, as a measure of LV afterload, was calculated dividing 
LVPES by stroke volume. Maximal LV wall-stress [LVWSTRESS] was calculated from LV 
pressure [P(t)] and volume [V(t)] and LV wall volume (Vwall) according to the following 
formula: LVWSTRESS=P(t)1+3[V(t)/Vwall. LV wall volume (Vwall) was approximated as 
the sum of the LV free wall mass and half of the interventricular septum mass. Relaxation 
rate was estimated with the time constant # using the Glantz method. 
 At the end the animals were euthanized under anaesthesia (100 mg.kg-1 
pentobarbital sodium endovenous). Heparinised blood was used for volume calibration 
using a cuvette with standard wells (910-1048, Millar instruments). The heart, the RV, the 
LV, the interventricular septum, and the lungs were weighed, snap frozen in liquid 
nitrogen and stored at !196°C. The weights were normalized to tibial length given the 
body weight differences observed between groups. Moreover, visceral adipose tissue (from 
intestinal region) and epicardial adipose tissue were collected and were immediately frozen 
and stored at -196 °C. 
2.2.1.4 - Statistical analysis. 
 Statistical analysis was performed using Prim (version 5.0) and SigmaStat (version 
3.5). Analysis by two-way repeated-measures ANOVA was performed when repeated 
measures were performed to the same animal and one-way ANOVA for comparison 
among groups. When treatments were significantly different, the Holm-Sidak test and 
Bonferroni test was selected to perform pairwise comparisons. After a logarithmic 
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transformation, a four-parameters logistic curve was used to determine adipokines levels 
accordingly to ELISA manufacturer instructions. Correlations between two continuous 
variables were assessed with Pearson correlation analysis. Group data are presented as 
means ± SEM. Statistical significance was set at P < 0.05.  
2.2.2 – Optimization of Protein Extraction 
 2.3.2.1 - Protein extraction solution 
  Before protein extraction protocol, the samples were divided in similar weights. 
Frozen samples (EAT and VAT) were slowly thawed in the ice and then were washed 
three times by cold phosphate buffer saline (PBS) to remove excessive blood 
contamination. Then these fat tissues (with ~0.100 – 0.200g wet weight) were submitted to 
three protein extraction protocols (Figure 10). In protein extraction protocol – TRIS 
(PT), the fat samples were homogenized in 125mM Tris-HCL, 2% sodium dodecyl sulfate 
(SDS), 50mM dithiothreitol (DTT) and 10µL of phenyl methyl sulfonyl fluoride (PMSF) 
by Potter-Elvehjem with Teflon pestle. Then, samples were sonicated (Sonics vibra cell 
sonicator - Time-30s, Pulse-10 01 and Amplitude-70%) to better disrupt the cells. The 
lysate was centrifuged (Centrifuge 2-16 KC, Sigma, Germany) at 14000g for 30 min at 4ºC 
and the supernatant was carefully recovered to a new microtube. The removal of the lipidic 
pellet is crucial since it interferes with proteins solubilisation and subsequent separation of 
proteins from lipids [122]. In protein extraction protocol – UREA (PU), fat tissues were 
homogenized in 8M urea, 2M thiourea, 2% 3-[(3-cholamidopropyl) dimethylammonio] 
propane sulfonate (CHAPS), 2% ampholytes (pH 3-10), 1% NP-40, 50mM DTT and 10µL 
PMSF. Afterwards samples were sonicated and the lysate was treated similarly to protocol-
Tris. Finally, in protein extraction protocol – TRIS and UREA (PTU), the samples were 
submitted first to the extract solution of PT and then its pellet was submitted to PU.  
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Figure 10 - Scheme of three proteins extraction protocols. Protein extraction PT – protein extraction protocol-
Tris; Protein extraction PU – protein extraction protocol-Urea; Protein extraction PTU – protein extraction 
protocol-Tris and Urea. 
 2.2.2.2 – Protein quantification by RC DC assay 
 The amount of total protein was determined in adipose tissue samples by the RC 
DC assay (Bio-Rad, Hercules, CA, USA). This assay is based in Lowry et al. [132] and 
allows quantifying  proteins in the presence of reducing agents and detergents. 
 A calibration curve was prepared using eight bovine serum albumin (BSA) 
dilutions ranging from 0.05mg/mL to 1mg/mL. Ten µL of each samples and standard 
solutions were pipetted to separate microtubes 125µL of reagent I and IIwere added and 
this solution was stirred in a vortex, followed by a centrifugation (Microcentrifuge, 
Centurion scientific) at 16000g for 5 minutes. The supernatant was carefully removed and 
the microtubes were placed in SpeedVac (Speed Vac Plus SC 210 A, Thermo Savant, 
USA) removing liquid in totality. Posteriorly, 20µL of S reagent from the Bio-Rad kit were 
added to 1mL of A reagent (to make A ! reagent). Then, 50µL of A ! reagent and 400µL of 
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B reagent were added to samples and standard solutions and incubated at room temperature 
for 15 minutes. Finally, the absorbance of samples and standard solutions was measured at 
750nm in a microplate reader (Multiskan GO, ThermoScientific). 
 2.2.2.3 – One dimensional electrophoresis (1DE) 
 In order to evaluate the expression of proteins, these were separated according to 
their molecular weight on polyacrylamide gels in denaturing and reducing conditions. The 
1DE was performed simultaneously for all samples (under study) in order to reduce inter-
assay variability. Firstly, a given sample volume corresponding to 50µg of protein of the 
each sample were precipitated with frozen acetone (with an amount of 6 times the amount 
of proteins sample) during 2 hours. The precipitated sample was centrifuged at 14000g for 
30 minutes at 4ºC and the supernatant was carefully removed with micropipette. 
Posteriorly, the pellet was dissolved in a 15µL of loading buffer and was placed in the 
Thermocell mixing block MB-102 at 100ºC during 5 minutes at 600rpm. After solubilizing 
the pellet in loading buffer, each sample was loaded on a 15% SDS-PAGE. A 200V 
electrophoresis was performed up to the point where the dye reached the bottom of the gel. 
For bands visualization, the gel was revealed with Blue safe for 1 hour and then the gel 
was placed in distilled water. 
2.2.3 - Analysis of the 1DE data  
 The gels were scanned using a Gel Doc XR+System (Bio- Rad) and bands intensity 
quantified by Image Lab software. The quantification of each protein band was performed 
on images of 1DE gels based on optical densities. All data were exported to Graphpad 
Prism 6 for statistical analysis. 
2.2.4 – Protein identification 
 2.2.4.1 – Protein digestion with trypsin 
 The protocol of the digestion with trypsin was carried out using modified bovine 
trypsin - N-tosyl-L-phenylalanine chloromethyl ketone (TPCK, AB Sciex, USA). Protein 
bands were excised from the gel, cut into small pieces, and transferred into a 96-well 
microliter plate. Each gel piece was subjected to tryptic digestion. Briefly, each gel piece 
was washed and aspired by vacuum twice with 50µL of 28.3mM ammonium bicarbonate 
and 100% acetonitrile, dried in the Speedvac and rehydrated with 20µL of trypsin (25 
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µg/2mL H2O) and 30µL of 50mM of ammonium bicarbonate and, lastly, incubated at 37°C 
overnight. After digestion, the gel pieces were washed and aspired by vacuum with 10% 
formic acid. Then, they were washed and aspired by vacuum twice with a solution 
containing 100% acetonitrile (ACN) and 10% formic acid in a proportion 1:1. Finally, the 
peptides were extracted to new 96-well microliter plate and were completely dehydrated in 
the SpeedVac and stored at -80ºC. 
 2.2.4.2 –Liquid chromatography separation of peptides 
 Samples were rehydrated with 5µL of a solution of 50% ACN and 0.3% 
trifluoroacetic acid (TFA). The samples were sonicated for 3 minutes and then spined 
down. Twenty-five µL of 0.1% TFA and was executed the sonication and spin again. 
Finally, 11µL of each sample was transferred for a new 96-well microliter plate and was 
analysed.  
 The nano-HPLC separation was performer on the Ultimate 3000 module (LC 
Packings) using a capillary column (Zorbax SB C18 300; 0.75µm an internal diameter, 
15cm length). It was used the solvent A, water/ACN/TFA (95:5:0.05 v/v/v) and solvent B, 
water/ACN/TFA (10:90:0.05, v/v/v). 8µL of the sample was injected. The separation was 
performed using a linear gradient (5-55% A for 30 min, 55-80% over 10 minutes, 80-5% 
during 5 minutes) with a flow rate of 0.3uL/min. The various fractions separated were 
applied on a plate for MALDI analysis. 
 2.2.4.3 – Mass spectrometry analysis and database searching 
 The MALDI-TOF/TOF MS analysis was performed using a 4800 MALDI-
TOF/TOF Analyser (Applied biosystems, Foster City, CA, USA) with reflectron in 
positive mode and spectra obtained in the mass range from 700 to 4000Da, with 1500 laser 
shots. The spectra were processed using T2S software (v.1.0; Matrixscience) and analysed 
by internal Mascot software (Version 2.1.0.1, Matrix Science Ltd, UK) for protein/peptide 
identification based on peptide mass fingerprints and MS/MS data. Searches were 
performed based on the SwissProt protein database for Rattus. The parameters defined 
were a peptide tolerance of 40ppm, two missed cleavages and propionamide (C) as 
variable modification. 
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3.1 Characterization of the animal model 
3.1.1. Weight gain, energy intake, body composition and metabolic function 
 As presented in Table 6, animals showed considerable body weight differences, 
therefore, most of the morphometric parameters measured were normalized to tibial length. 
The obsese ZSF1 present higher body weight than ZSF1 lean, and shows hypertrophic 
heart, with a significant increase in heart and LV+septum weight normalized to tibial 
length. As for body composition, differences were observed in obese group showing a 
substantial increase in kidney, liver, lungs, perigonadal and perirenal fat pad weights 
normalized to tibial length compared to the non-obese group (Table 6).  
Table 6 - Morphological data. Left ventricle (LV); inter-ventricular septum (IVS); right ventricle (RV) tibial 
length (TL). The values are represented as means ± S.E.M. P<0.05: * vs ZSF1 Ln. 
 
 ZSF1 Ln ZSF1 Ob  
Weight/TL(mg.mm-1)  416 ± 8 601 ± 10*  
TL (mm)  42.1 ± 0.4 40.9 ± 0.4*  
Heart weight/TL (mg.mm-1)  34.4 ± 1.2 40.0 ± 1.3*  
LV+IVS weight/ TL (mg.mm-1)  16.6 ± 0.8 19.7 ± 1.1  
Cardiomyocyte area ("m2)  536±15 628±14*  
RV weight/ TL (mg.mm-1)  4.5 ± 0.3 5.5 ± 0.3  
Lung weight/ TL (mg.mm-1)  53 ± 2 75 ± 3*  
Liver weight/ TL (mg.mm-1)  314 ± 12 906 ± 55*  
Kidney weight/ TL (mg.mm-1)  26.0 ± 0.8 37.1 ± 0.9*  
Perirenal fat weight/ TL (mg.mm-1)  58 ± 6 362 ± 12*  
Perigonadal fat weight/ TL (mg.mm-1)  56 ± 5 161 ± 6*  
Gastrocnemius weight/ TL (mg.mm-1)  63 ± 2 53 ± 1*  
 
Regarding to metabolic function, ZSF1 Ob shows hyperlipidemia, proteinuria, impaired 
glucose tolerance, insulin resistance, hyperglycemia, consistent with the diagnosis of 
metabolic syndrome (Table 7).   
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Table 7 - Metabolic function data. Oral glucose tolerance test (OGT); Insulin resistance (IR); AUC: area under 
curve. The values are represented as means ± S.E.M. P<0.05: * vs ZSF1 Ln. 
 
ZSF1 Ln ZSF1 Ob 
Proteinuria level (mg.dL-1) 29±1 174±9* 
Glycaemia level (mg.dL-1) 73±5 134±10* 
OGT AUC (mg.dL-1.h-1) 105±5 224±10* 
IR AUC (mg.dL-1.h-1) 105±5 152±9* 
Cholesterol level (mg.dL-1) 68±3 240±21* 
 
3.1.2. Cardiac functional and structural changes 
 In both echocardiographic (Table 8) and terminal hemodynamic evaluation (Table 
9) ZSF1 Ln, ZSF1 Ob showed preserved cardiac index, ejection fraction and indexed end-
diastolic volume (Table 9). In the ZSF1 groups the maximum rate of pressure rise and the 
slope of the end-systolic pressure-volume relationship were increased, denoting 
hypercontractility (Table 9). However, when left ventricular mass was accounted, as in 
preload-recruitable stroke work, this increase was no longer significant (Table 9). Overall 
cardiac performance as assessed by the Tei myocardial performance index was also not 
altered (table 8). The raise in arterial elastance with preserved systolic function indexes 
indicates worse in ventriculo-vascular coupling ZSF1 Ln, ZSF1 Ob due to the hypertension 
displays by both groups (Table 9).  
 Contrarily, significant disturbances of diastolic function were observed in ZSF1 Ob 
compared with ZSF1 Ln (Tables 8 and 9). Namely, an increase in the maximum velocity of 
early diastolic transmitral flow to maximum velocity of myocardial displacement ratio at 
the lateral mitral annulus also in early diastole (E/E’) during echocardiographic evaluation 
(Table 8) and prolonged time constant of isovolumetric relaxation #, elevation of end-
diastolic pressures and an upward shift in the end-diastolic pressure-volume relationship in 
terminal haemodynamic evaluation (Table 9). Additionally, and also only in ZSF1 Ob it 
was observed increased left atrial area on echocardiography (Table 8) and an increased 
lung weight on terminal morphometric evaluation (Table 6).  
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Table 8 - Echocardiographic assessment of diastolic parameters. Ejection fraction (EF); Ratio of mitral velocity to 
early diastolic velocity of the mitral annulus (E/E’); Early and late LV filling velocities ratio (E and A, 
respectively); Heart rate (HR); left ventricle (LV). The values are represented as means ± S.E.M. P<0.05: * vs 
ZSF1 Ln. 
 
ZSF1 Ln ZSF1 Ob 
EF (%) 74 ± 2 75 ± 2 
Cardiac index (ml.min-1.cm-2) 212 ±16 255 ± 22 
HR (bpm) 336 ± 9 328 ± 16 
LV mass (mg) 517 ± 29 714 ± 33* 
E/E’ 12 ± 0.60 17.20 ± 0.80* 
E/A 1.61 ± 0.12 1.32 ± 0.08 
Left atrium area (mm) 2.60 ± 0.20 3.60 ±0.20* 
MPI (Tei) 0.76 ± 0.05 0.78 ± 0.02 
 
Table 9 - Hemodynamic data.  Arterial elastance indexed (EAI); Body surface area (BSA); Cardiac Index (CI); 
Constant time of isovolumic relaxation ("); Diastolic arterial pressure (DAP); End-diastolic pressure (EDP); End-
diastolic pressure-volume relations (EDPVR); End-diastolic volume indexed (EDVI); End-systolic volume indexed 
(ESVI); Ejection fraction (EF); Heart rate (HR); Maximal velocity of pressure rise and decrease (dP/dtmax, 
dP/dtmin, respectively); Mean arterial pressure (MAP); Preload recruitable stroke work (PRSW); Systolic 
arterial pressure (SAP); Stroke volume indexed (SVI); Stroke work indexed (SWI); The values are represented as 
means ± S.E.M. P<0.05: * vs ZSF1 Ln. 
 
ZSF1 Ln ZSF1 Ob 
BSA (cm2) 508 ± 7 651 ± 5* 
SAP (mmHg) 146 ±6 181 ± 6* 
MAP (mmHg) 127 ± 6 149 ± 5* 
DAP (mmHg) 106 ± 7 125 ± 6 
HR (bpm) 391 ± 9 354 ± 12* 
EDP (mmHg) 4 ± 1 9 ± 1* 
dP/dtmax (mmHg.s-1) 11700 ± 964 13000 ± 680 
dP/dtmin (mmHg.s-1) -12600 ± 686 -11700 ± 541 
# (ms) 7.6 ± 0.4 10.5 ± 0.6* 
SVI (mL.cm-2) 0.33 ± 0.03 0.34 ± 0.01 
CI (mL.min-1.cm-2) 128 ± 11 120 ± 8 
EF (%) 55 ± 3 59 ± 4 
EDVI (mL.cm-2) 0.65 ± 0.07 0.63 ± 0.05 
ESVI (mL.cm-2) 0.37 ± 0.05 0.33 ± 0.04 
SWI (mmHg.mL.cm-2) 35.4 ± 4.2 45.0 ± 2.6 
EAI (mmHg.mL-1.cm-2) 466 ± 65 526 ± 31 
ESPVR (mmHg. mL-1.cm-2) 2.49 ± 0.71 2.00 ± 0.39 
PRSW (mmHg) 79 ± 14 86 ± 8 
EDPVR (mL-1.cm-2) 0.023 ± 0.002 0.028 ± 0.002 
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3.2 - Optimization of methodology for analysis of the epicardial 
and visceral adipose tissue proteome 
 The current proteomic state of the art shows only a few studies comparing 
epicardial to visceral adipose tissue protein expression profile with a huge variability 
regarding protein extraction protocols. Therefore a selection and optimization of the 
extraction protocol were performed. This optimization was based in three different 
protocols (PT, PU and PTU (Figure 10)) whose analysis allowed defining the best protocol 
to study proteome changes. Analysis of different protocols is performed in the present 
chapter. 
 The tryptic peptide digests of epicardial and visceral fat of the obese animals, 
separated by nano-HPLC, were analysed in the mass spectrometer MALDI-TOF/TOF have 
been identified 291 proteins in the VAT (Appendix B – Supplemental Table B1-3) and 216 
proteins in the EAT (Appendix B – Supplemental Table B4 - 6). In order to assess the best 
protocol in each tissue, the proteins were distributed according to the protocol in a Venn 
diagram.  
Figure 11 - Venn diagram representing the distribution of identified proteins per protocol evidencing the 
overlapped and unique proteins. VAT – Visceral adipose tissue; EAT – Epicardial adipose tissue; PT – Protocol-
Tris; PU – Protocol-Urea; PTU – Protocol-Tris and Urea.   
 The Venn diagram allows the recognition of the unique proteins extracted in each 
protocol. As it is possible to observe in Figure 11, the protocol-TRIS (PT) only extracted 1 
and 4 unique proteins in visceral and epicardial fat, respectively. On the other hand, the 
Epicardial Adipose Tissue Visceral Adipose Tissue 
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protocol –Urea (PU) and protocol – Tris and Urea (PTU) were more successful in term of 
the amount of proteins extracted. In visceral adipose tissue, it was obtained 68 and 13 
unique proteins, respectively, while in EAT was extracted 31 and 24 unique proteins. 
Evaluating the number of unique proteins extracted, the PT, in both cases, was excluded. 
In contrast, the proteins extracted by PU and PTU were assessed according to its biological 
process, molecular function and cellular component, as indicated in Figure 12 with the 
PANTHER classification system (http://www.pantherdb.org). 
 In figure 12A-left and right panel, in general and independently of the tissue and 
protocol, it is possible to observe that the proteins constitute almost the same biological 
processes. According to PANTHER bioinformatics tool the larger groups of biological 
processes of VAT proteins in PU are “cellular process” (21%), “localization” (10%) and 
“metabolic process” (28%), while in PTU are “cellular component organization or 
biogenesis” and “metabolic process” (13%), “cellular process” (23%) and “developmental 
process” (20%) (Figure 12A – left panel, blue and red bar respectively). However, there 
are minor differences between biological processes groups. Observing figure 12A-left 
panel is possible to see that the main difference between them is the presence the group 
“localization” in the PU. “Localization” refers to any process in which a cell, a substance, 
or a cellular entity, such as a protein complex or organelle, is transported to, and/or 
maintained in a specific location [133]. Similarly, the larger groups of EAT proteins in PU 
are “cellular component organization or biogenesis” and “cellular process” (13%), 
“developmental process” (14%) and “metabolic process” (25%), whereas in PTU are 
“cellular component organization or biogenesis”, “developmental process”, “localization 
and multicellular organismal process” (10%), “metabolic process” (17%) and “cellular 
process” (19%) (Figure 12A – right panel, blue and red bar, respectively). The main 
differences in biological processes of the PU and PTU relates to “biological regulation” (in 
PU) and “reproduction” (in PTU) groups (Figure 12A – right panel).   
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Figure 12 - Distribution of visceral and epicardial unique proteins identified in protocol-Urea and protocol-Tris 
and Urea in obese ZSF1 according to its biological processes (A), molecular function (B) and cellular component 
(C). VAT-PU – Proteins extracted from Protocol-Urea of the visceral adipose tissue; VAT-PTU – Proteins 
extracted from Protocol-Tris and Urea of the visceral adipose tissue; EAT-PU – proteins extracted from Protocol-
Urea of the epicardial adipose tissue; EAT-PTU – proteins extracted from protocol-Tris and Urea of the 
epicardial adipose tissue. Blue – protocol-Urea; Red – protocol – Tris and Urea. 
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 Figure 12B describes the distribution of the proteins extracted by PU and PTU from 
visceral and epicardial tissues according to its molecular function. The left panel of figure 
12B shows that protocol VAT-PU was able to extract a large number of proteins, thus 
covering the same molecular function groups that VAT-PTU. The same happens in the 
right panel of figure 12B, in which the proteins extracted by PU cover almost the same 
groups that PTU. Nonetheless, there is an exception for “protein binding transcription 
factor activity” group, which is insignificant considering that this group has just one 
protein.  
 Lastly figure 12C shows, by PANTHER analysis of VAT and EAT, that the 
expressed proteins were classified into 7 and 5 groups, respectively. As observed in both 
panels, the predominant groups are organelle and cell part. The cell part involves the 
intracellular and plasma membrane proteins. On the other hand, the organelle group 
encompasses the cytoskeleton proteins, in which can be actin cytoskeleton or intermediate 
filament cytoskeleton proteins. Although these groups are typical of cardiac tissue, as 
demonstrated in analysis of the proteins obtained in studies of the Table 4 of the 
Subchapter 1.5.1 (Appendix A – Supplemental Figure A1), these results are also 
commonly obtained from epicardial and visceral fat. Moreover, and once again, both 
panels of Figure 12C shows that PU protocol extracts proteins from more “cellular 
component” groups. 
 After the classification of proteins according to their biological processes, 
molecular function and cellular components, the hydrophobicity level and molecular 
weight of the epicardial and visceral adipose tissue proteins extracted by both protocols 
was evaluated. Figure 13 presents, the level of hydrophobicity and hydrophilicity of the 
proteins extracted by PU and PTU in VAT and EAT according to GRAVY Score 
(http://www.gravy-calculator.de/). 
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Figure 13 –Gravy index score (average hydrophobicity and hydrophilicity) of visceral and epicardial adipose 
tissue proteins extracted by protocol-Urea and Tris and Urea in obese ZSF1. Hydrophobicity score below 0 are 
more likely cytoplasmic (hydrophilic protein), while scores above 0 are more likely membranous (hydrophobic). 
The bar panel represents number of proteins that exist in the respective range of gravy score. A – Visceral adipose 
tissue; B- Epicardial adipose tissue. VAT-PTU – Proteins extracted from Protocol-Tris and Urea of the visceral 
adipose tissue; EAT-PU – proteins extracted from Protocol-Urea of the epicardial adipose tissue; EAT-PTU – 
proteins extracted from protocol-Tris and Urea of the epicardial adipose tissue. Blue – protocol-urea; Red – 
protocol – Tris and Urea.  
 As presented in Figure 13, there is no significant difference between proteins 
extracted by PU and PTU in both tissues, that is, the large majority of proteins, in both 
tissues and protocols, present a gravy score between -0.25 and -0.50, followed by 0 and -
0.25. This means that both visceral and epicardial adipose tissue have mainly cytoplasmic 
hydrophilic proteins. 
 Lastly, Figure 14 represents the distribution of proteins in each tissue and protocol 
according to their molecular weight.   
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Figure 14 - Distribution of proteins of the epicardial and visceral adipose tissue according to their molecular 
weight in the different protocols.  A – Protocol-urea and protocol-Tris and Urea of the visceral adipose tissue; B – 
Protocol -urea and protocol-Tris and Urea of the epicardial adipose tissue. VAT-PTU – Proteins extracted from 
Protocol-Tris and Urea of the visceral adipose tissue; EAT-PU – proteins extracted from Protocol-Urea of the 
epicardial adipose tissue; EAT-PTU – proteins extracted from protocol-Tris and Urea of the epicardial adipose 
tissue. Blue – protocol-Urea; Red – protocol – Tris and Urea. 
 Independently of the tissue or protocol, the most abundant proteins were below of a 
molecular weight of 60kDa (low-molecular-weight). Additionally the protocol-urea 
presents a greater number of proteins extracted and, as previously seen, it could cover a 
range of molecular weights equal or greater than PTU.  
3.3 – Characterization of obese and lean ZSF1 epicardial and 
visceral adipose tissue proteome. 
 Subsequent to optimization of methodology of the proteins extraction in both 
tissues, we performed the evaluation of its expression in order to understand the metabolic 
changes involved in diastolic dysfunction. To achieve this, one-dimensional 
electrophoresis, nano-HPLC and MALDI-TOF/TOF were performed in order to separate 
and analyse proteins. To identify diastolic dysfunction-related proteins in epicardial and 
visceral adipose tissue, it was performed 1DE-LC-MS/MS approaches for quantitative 
comparison among subjects. Figure 15 shows the SDS-PAGE of epicardial and visceral 
adipose tissue proteins of obese and lean subjects with two replicates each and respective 
optical density (OD) bands analysis.  
Molecular weight 
B – Epicardial adipose tissue 
 
A – Visceral adipose tissue 
 
!" #" $!" $#" %!" %#"&%!"
%!'(!"(!')!")!'#!"
#!'*!"*!'+!"+!',!"
,!'-!"-!'$!!".$!!"
!"#$%&'()'*&(+%,-.'
/
(0
%1
"0
2&
'3
%,
45
+'6
78
29
'
/01"'"213" /01"'"23"
!" #!" $!" %!" &!"'$!"
$!(%!"%!(&!"&!()!"
)!(*!"*!(+!"+!(,!"
,!(-!"-!(#!!".#!!"
!"#$%&'()'*&(+%,-.'
/
(0
%1
"0
2&
'3
%,
45
+'6
78
29
'
/01"(""213" /01"("23"
 
 
 
Chapter 3 – Results 
50 
Figure 15 - Representation of the Sodium dodecylsulphate-polyacrylamide gel electrophoresis of (A) visceral and 
(B) epicardial adipose tissue of the obese and lean ZSF1 rats. The gel sections with significant optical density 
variations among groups are highlighted in the bottom graphs. **P !  0.01 vs Lean ZSF1; ns – P > 0.05 vs Lean 
ZSF1. Ln – visceral adipose tissue of lean ZSF1 rat; Ob – visceral adipose tissue of obese ZSF1 rat; MW – 
molecular weight; OD – Optical density. 
 As described in Figure 15A, the band OD analysis only highlighted section 6 
(estimated MW of 37-38 kDa), presenting significant variations between groups. LC-
MS/MS analysis of this section retrieved 10 distinct proteins. From this 10 VAT proteins 
detected in section 6, heterogeneous nuclear ribonucleoproteins A2/B1, A1 and A2-
annexin and lumican were the most prevalent (Appendix C – Supplemental Table C1 – 
C3). Likewise, in Figure 15B (in epicardial adipose tissue), the band OD analysis just 
highlights section 3 (estimated MW of 72-90 kDa) with significant variations between 
groups. LC-MS/MS analysis of this section recovered 19 distinct proteins (Appendix C – 
Supplemental Table C4 – C6). From these 19 proteins, the chaperone activity of bc1 
complex-like, stress-70 protein, annexin-A6, serotransferrin, trifunctional enzyme subunit 
alpha, membrane primary amine oxidase, aconite hydratase and gelsolin were the most 
common proteins in all samples. 
 The large-scale LC-MS/MS analysis of all gel bands retrieved 195 and 260 proteins 
in visceral and epicardial adipose tissue, respectively (Appendix C). All identified proteins 
were distributed per group in a Venn diagram, as described in Figure 16A and 16B. From 
all visceral proteins detected, 126 were common to both types of adipose tissue studied 
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(Appendix C – Supplemental Table C3). On the other hand, 35 proteins were only 
identified in visceral of lean ZSF1 rats while 34 proteins were only identified in visceral of 
obese ZSF1 (Appendix C – Supplemental Table C1 – C2). Regarding epicardial adipose 
tissue, 102 identified proteins were common between obese and lean ZSF1, while 99 and 
59 proteins were only identified in obese and lean respectively (Appendix C – 
Supplemental Table C4 – C6). 
Figure 16 – Venn diagram representing the distribution of identified proteins per group evidencing the 
overlapped and unique proteins. A – Visceral adipose tissue; B – Epicardial adipose tissue; Lean – proteins 
identified in adipose tissue of lean ZSF1; Obese – Proteins identified in adipose tissue of obese ZSF1. 
 To understand the main differences between identified proteins of lean and obese 
ZSF1, the unique proteins of each tissue were assessed according to their biological 
processes and molecular function (Figure 17 and Figure 18) with PANTHER classification 
system.  
Figure 17 - Distribution of (A) visceral and (B) epicardial unique proteins identified in obese and lean ZSF1 rats 
according to its biological process. Bar chart represents the biological processes categories. Red –Proteins 
identified in obese ZSF1 model; Green –Proteins identified in lean ZSF1 model. VAT – Visceral adipose tissue; 
EAT – Epicardial adipose tissue 
 In biological process of VAT the main differences between obese and lean ZSF1 
are in “multicellular organismal process” (6 proteins in obese and none in lean ZSF1), 
“metabolic process” (17 proteins in obese and 21 in lean ZSF1), “developmental process” 
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(13 proteins in obese and 4 in lean ZSF1) and biological regulation (8 proteins in obese 
and 3 in lean ZSF1) groups (Figure 17A). Moreover, these last three groups are the more 
prevalent of the biological processes involving majority of the identified proteins (Figure 
17A). Observing Figure 17A the “developmental processes” and “biological regulation” 
seem to be the main groups involved in metabolism dysfunction in VAT of obese ZSF1.  
 The EAT analysis stand out four groups in obesity, “developmental process” (24 
proteins in obese and 6 in lean ZSF1), “cellular process” (49 proteins in obese and 11 in 
lean ZSF1), “biological regulation” (16 proteins in obese and 2 in lean ZSF1) and “cellular 
component organization” (24 proteins in obese and 5 in lean ZSF1) (Figure 17B). 
However, observing the Figure 17B, the principal groups involved in metabolism 
dysfunction seem to be the cellular and developmental processes.  
Figure 18 - Distribution of (A) visceral and (B) epicardial unique proteins identified in obese and lean ZSF1 model 
according to its molecular function. Bar chart represents the molecular function categories. Red –Proteins 
identified in obese ZSF1 model; Green –Proteins identified in lean ZSF1 model. VAT – Visceral adipose tissue; 
EAT – Epicardial adipose tissue 
 PANTHER classification of proteins by molecular function (Figure 18) revealed 
that in VAT, the majority of proteins are involved in “binding”, “catalytic activity”, 
“structural molecule activity” groups and “enzyme regulatory activity” (Figure 18A). 
However, the main distinctions between obese and lean ZSF1 model are in “catalytic 
activity” (16 proteins in obese and 9 in lean ZSF1) and “enzyme regulatory activity” (5 
proteins in obese and 2 in lean ZSF1) (Figure 18A).  
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 Observing the Figure 18B, in EAT the main groups of molecular function are 
“binding”, “catalytic activity”, “structural molecule activity” groups and “enzyme 
regulatory activity” (Figure 18B). Nevertheless, the major differences between obese and 
lean subjects are in “enzyme regulatory activity” (8 proteins in obese and 1 in lean ZSF1), 
“structural molecule activity” (25 proteins in obese and 6 in lean ZSF1) and “binding” (38 
proteins in obese and 5 in lean ZSF1) groups (Figure 18B). Taken together, figure 21 
shows that there are three groups involving the most proteins, “catalytic activity”, 
“binding” and “structural molecule activity”. Indeed, a research showed that these groups 
are typical signs of cardiac hypertrophy [134]. In addition to these analyzes, it was also 
performed a graphical presentation of the cellular components of all proteins identified in 
obese and lean ZSF1 (Figure 19). 
Figure 19 - Distribution of (A) visceral and (B) epicardial proteins identified in obese and lean ZSF1 model 
according to its cellular component. Bar chart represents the cellular component categories. Red – unique 
proteins of obese ZSF1 model; Green – unique proteins of lean ZSF1 model; Blue – common proteins of lean and 
obese ZSF1 model; EAT – epicardial adipose tissue; VAT – Visceral adipose tissue  
 In visceral adipose tissue, PANTHER classification showed that the majority of 
expressed proteins comprised “organelle group” in which 95.5% are cytoskeletal and 4.5% 
are mitochondrial proteins, and “cell part” group in which 94% are intracellular and 6% are 
plasma membrane proteins (Figure 19A). In the same way, in epicardial adipose tissue the 
main groups in cellular components are also “organelle” in which 80% are cytoskeletal and 
20% are mitochondrial, and “cell part” in which 6% are plasma membrane and 94% 
intracellular (Figure 19B). The cytoskeletal proteins are quite typical of myocardium, 
however, as already observed in Chapter 3.2, observing the graphical presentation of the 
cellular components of the proteins identified in the studies of Table 4 in Subchapter 1.5.1 
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(Appendix A – Supplemental Figure A1), it is possible to conclude that these percentages 
are expected.  
 The comparison of abundances of the 126 and 102 proteins common between obese 
and lean ZSF1 in visceral and epicardial adipose tissue, respectively, was performed based 
on the normalization of the exponentially modified protein abundance index (emPAI) 
(Figure 20 and Figure 22, respectively). The normalized abundance analysis in VAT 
evidence nucleoside diphosphate kinase-B, collagen-alpha-2(I) chain and serotransferrin as 
the top 3 most abundant proteins in obese ZSF1 and alpha-enolase, ubiquitin-conjugating 
enzyme E2 N and perilipin-1 as the less abundant ones (Figure 20). On the other hand, 
EAT highlights fibrinogen-beta chain, heterogeneous nuclear ribonucleoproteins A2/B1 
and alpha-1-macroglobulin as the top 3 most abundant proteins in obese ZSF1 and 2-
oxoglutarate dehydrogenase mitochondrial, aconitate hydratase mitochondrial and electron 
transfer flavoprotein subunit alpha mitochondrial as the less abundant ones (Figure 22). 
To evaluate the protein-protein interaction, the ClueGo and CluePedia program was 
performed, considering the threshold emPAI ratios values higher than 0.5 and lower than -
0.5 (Figure 21 and Figure 23). In VAT, the protein-protein interaction evidences in obese 
ZSF1 the prevalence of processes involved in “negative regulation of interleukin-8 
secretion” involving the annexin-A1 and A4, “response to oxidative stress”, “cellular 
response to oxygen containing compound” and other processes related to oxidative 
metabolism (Figure 21 and Appendix C – Supplemental Figure C1). The main proteins 
involved in these last processes are aldehyde dehydrogenase, nucleoside diphosphate 
kinase B, 14.3.3 protein gamma, collagen alpha-1 chain, tropomyosin alpha-1 chain, 
serotransferrin, superoxide dismutase, peroxiredoxin-1, annexin A1, alpha-antiproteinase 
and heat shock protein beta-1 (Appendix C – Supplemental Figure C1). Regarding EAT of 
the obese ZSF1, the most abundant proteins relate to “collagen fibril organization”, 
comprising annexin-A2, lumican and collagen alpha-1(I) chain proteins. Also, protein-
protein interaction in EAT highlights decreased proteins involved in oxidative (mainly 
lipid and fatty acid oxidation) and metabolic processes (mainly catabolic) such as long-
chain specific acyl-CoA dehydrogenase, 3-ketoacyl-CoA thiolase, Acyl-coenzyme A 
thioesterase 2, Enoyl-CoA hydratase, trifunctional enzyme subunit alpha and hydroxyacyl-
coenzyme A dehydrogenase (Figure 23 and Appendix C – Supplemental Figure C2).  
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Figure 20 - Distribution of normalized emPAI values of visceral adipose tissue proteins in obese and lean groups highlighting different protein abundance distribution. Entry 
name has correspondence to protein name at Appendix D – Supplemental Table D3. Values above zero correspond to values of up-regulated proteins in obese ZSF1; Values 
below zero correspond to values down-regulated proteins in obese ZSF1.  
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Figure 21 - ClueGo and CluePedia analysis of protein-protein interaction considering common proteins present in significant distinct levels (based on emPAI values) in visceral 
adipose tissue of obese and lean ZSF1 rats. Green nodes - biological processes negatively regulated (down-regulated) in obese subjects; Red nodes – biological processes 
positively regulated (up-regulated) in obese subjects. 
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Figure 22 - Distribution of normalized emPAI values of epicardial adipose tissue proteins in obese and lean groups highlighting different protein abundance distribution. 
Entry name has correspondence to protein name at Appendix D – Supplemental Table D6. Values above zero correspond to values of up-regulated proteins in obese ZSF1; 
Values below zero correspond to values down-regulated proteins in obese ZSF1. 
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Figure 23 - ClueGo and CluePedia analysis of protein-protein interaction considering common proteins present in significant distinct levels (based on emPAI values) in 
epicardial adipose tissue of obese and lean ZSF1. Green nodes - biological processes negatively regulated (down-regulated); Red nodes – biological processes positively 
regulated (up-regulated) in obese subjects.  
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 Evaluating Table 5 of the subchapter 1.5.1 and figure 21 it is possible to see the 
overexpression of Fabp4 in obese subjects. Indeed recent studies showed that Fabp4 has a 
positive association with heart failure and obesity [77, 79]. Therefore, it was assessed the 
interaction of this protein with other possible proteins with a String V9.1 program (Figure 
24). 
Figure 24 - String V9.1 analysis of protein-protein interaction considering common proteins present in obese and 
lean ZSF1 model. Red circle – show the interaction of the fabp4 with others proteins. Connections: Dark blue – 
Binding; Light blue – phenotype; Purple – catalysis; Red – inhibition; Black – reaction; Pink – Post-translational 
modification. 
 From figure 27, it is possible to conclude that Fabp4 interacts with others identified 
proteins as Perilipin-1 (Plin), Monoglyceride lipase (Mgll), Gamma-synuclein (Sncg) and 
Glyceraldehyde-3-phosphate dehydrogenase (Gapdh). Analysing its biological processes, 
they share mainly cellular and metabolic processes. The Plin and Fabp4 are involved in 
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lipid and primary metabolic processes, while Gapdh and Fabp4 are implicated in directly 
interact monocarboxylic, carboxylic and oxo acid metabolic processes However, as 
described in Figure 24 (red circle) there is not any direct relationship between them, so 
they do not directly interact.  
3.4 – Characterization and comparison of epicardial and 
visceral adipose tissue proteome 
 Although epicardial and visceral adipose tissue share the same embryological 
origin, there are no studies that compare the adipocytes-derived substances secreted and 
the differences of expression among these tissues. Therefore the present work aimed to 
present the differences between epicardial and visceral adipose tissue proteome. The 
proteins identified in epicardial and visceral adipose tissue of obese and lean subjects were 
distributed per group in a Venn diagram (Figure 25).  
Figure 25 –Venn diagram representing the distribution of identified proteins per subject evidencing the 
overlapped and unique proteins. A – Proteins identified in lean ZSF1 animal model; B – Proteins identified in 
obese ZSF1 animal model; EAT – Proteins identified in epicardial adipose tissue; VAT – Proteins identified in 
visceral adipose tissue. 
 From all visceral and epicardial adipose tissue of lean ZSF1 proteins, 85 of them 
were common to both tissues (Figure 25A), whereas 76 of them were identified as unique 
in each tissue, epicardial and visceral. On the other hand, in obese ZSF1 96 proteins were 
common between EAT and VAT, while 105 and 64 were unique in each tissue, 
respectively. 
 In order to understand the differences between unique proteins of epicardial and 
visceral adipose tissue, they were separated according to their biological process (Figure 
26) and molecular function (Figure 27).  
  
Metabolic changes in diastolic heart failure: a proteomic approach 
61 
 Figure 26 - Distribution of unique proteins identified in visceral and epicardial adipose tissue of obese (A) and 
lean (B) ZSF1 according to its biological processes. A) – Unique proteins in obese ZSF1; B) – Unique proteins in 
lean ZSF1; Blue bar – Proteins identified in visceral adipose tissue; Green bar – Proteins identified in epicardial 
adipose tissue.   
 
 Comparing both tissues in obese ZSF1 (Figure 26A), it is possible to observe that 
they share the same groups of biological processes with similar abundance of proteins. On 
the other hand, comparing VAT with EAT from lean ZSF1 (Figure 26B), the main 
difference between them is the presence of two exclusive groups in the VAT, 
“reproduction” and “apoptotic process”. However, each one of these groups presents a 
single protein, being an insignificant difference. Moreover, the EAT from lean ZSF1 
displays an additional group when compared to VAT, which is “multicellular organismal 
process”. 
 PANTHER classification allows to compare the molecular function of the unique 
proteins in both tissues (Figure 27).  
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Figure 27 - Distribution of unique proteins identified in visceral and epicardial adipose tissue of obese (A) and lean 
(B) ZSF1 according to its molecular function. A) – Unique proteins in obese ZSF1; B) – Unique proteins in lean 
ZSF1; Blue bar – Proteins identified in visceral adipose tissue; Green bar – Proteins identified in epicardial 
adipose tissue 
 Taken together, the figure 27 shows that there are three dominant groups, in both 
visceral and epicardial adipose tissue, “catalytic activity”, “binding” and “structural 
molecule activity”.  
 Comparing EAT to VAT in obese ZSF1 (Figure 27A), the main difference lies in 
the existence of an exclusive molecular function group in EAT, “nucleic acid binding 
transcription factor activity”. On the other hand, figure 27B highlights that lean ZSF1 
present two distinct groups, “nucleic acid binding transcription factor activity” exclusive of 
VAT (1 protein) and “transporter activity” exclusive of EAT (6 protein).  
 Figure 28 displays a graphical representation of the distribution of unique and 
common proteins according to their cellular component group between obese and lean 
ZSF1.  
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Figure 28 - Distribution of unique proteins identified in visceral and epicardial adipose tissue of obese (A) and lean 
(B) ZSF1 and (C) common proteins between both subjects according to its cellular component. A) – Unique 
proteins in obese ZSF1; B) – Unique proteins in lean ZSF1; C) – Common proteins between obese and lean in each 
tissue; Blue bar – Proteins identified in visceral adipose tissue; Green bar – Proteins identified in epicardial 
adipose tissue. 
 The unique proteins of obese ZSF1 in EAT and VAT share the same groups of the 
cellular components in similar abundance (Figure 28A). In the same way the common 
proteins between EAT and VAT of each subject are distributed in the same groups in 
similar abundance (Figure 28C). On the other hand, observing the Figure 28B, it is 
possible to see that the unique proteins of lean ZSF1 VAT are not present in some groups 
of the cellular component, namely “extracellular matrix”, “extracellular region” and 
“membrane”.  
 Figure 28 highlights that “cell part” group (mainly intracellular proteins) and 
“organelle” groups (mainly cytoskeletal) comprise the highest number of proteins in VAT 
and EAT. Although cytoskeletal proteins are quite typical of myocardium, as stated before, 
these results were expected. 
 The common proteins between tissues were analysed through its abundance ratio 
(based on emPAI ratio values) (Figure 29 and 31). Figure 29 represents the proteins 
identified in lean ZSF1 where it is possible to visualise that few proteins with significant 
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changes on its abundance. The proteins aconitate hydratase, mitochondrial, 60 kDa heat 
shock protein, mitochondrial and hemoglobin subunit beta-1 are the top three most 
abundant proteins in epicardial adipose tissue, while in visceral adipose tissue the proteins 
most abundant were carbonic anhydrase 3, annexin A1 and galectin-1 (Figure 31). 
 The comparison of abundances of the proteins common between epicardial and 
visceral adipose tissue in lean ZSF1 were performed with ClueGo and CluePedia program, 
considering a threshold emPAI ratios value higher than 0.5 and lower than -0.5. Figure 30 
shows that the proteins up-regulated in epicardial adipose tissue are involved mainly in 
“tricarboxylic acid cycle”, “protein oligomerization” and “gas transport” (Appendix D – 
Supplemental figure D1). On the other hand, the proteins of visceral adipose tissue 
highlight just one group, positive “regulation of vesicle function” (Appendix D – 
Supplemental figure D1). 
 Regarding to proteins identified in obese ZSF1 epicardial and visceral adipose 
tissue, the Figure 31 shows that EAT highlights aconitate hydratase, mitochondrial, citrate 
synthase, mitochondrial and alpha-enolase as the top three most abundance proteins in 
obese ZSF1 when compared with VAT. On the other hand, VAT highlights as the top three 
most abundance proteins the profilin-1, annexin A1 and galectin-1. Likewise the lean 
ZSF1, the proteins identified in VAT and EAT of the obese ZSF1 were assessed in the 
ClueGo and CluePedia program in order to evaluate the interaction of the corresponding 
proteins, considering a threshold emPAI ratios value higher than 0.5 and lower than -0.5. 
Figure 32 and Appendix D – Supplemental Figure D2 displays that proteins up-regulated 
in VAT are mainly involved in “negative regulation of blood coagulation” and “positive 
regulation of vesicle fusion”, while the proteins of the EAT highlights “response to 
inorganic substance”, “response to hydrogen peroxide”, “tricarboxylic acid cycle” and 
“metabolic processes”. 
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Figure 29 - Distribution of normalized emPAI values of visceral and epicardial adipose tissue proteins in lean groups. Entry name has correspondence to protein name in 
Appendix D – Supplemental Table D1. Values above zero correspond to values of up-regulated proteins in epicardial adipose tissue in lean ZSF1; Values below zero 
correspond to values up-regulated in visceral adipose tissue in lean ZSF1. 
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Figure 30 - ClueGo and CluePedia analysis of protein-protein interaction considering up-regulated proteins identified in visceral (blue nodes) and epicardial (green nodes) 
adipose tissue of lean ZSF1 animal model (based on emPAI values). Blue nodes – Proteins up-regulated in visceral adipose tissue in lean ZSF1; Green nodes – Proteins up-
regulated in proteins of epicardial adipose tissue in lean ZSF1. 
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Figure 31 - Distribution of normalized emPAI values of visceral and epicardial adipose tissue proteins in obese groups. Entry name has correspondence to protein name in 
Appendix D – Supplemental Table D2. Values above zero correspond to values of up-regulated proteins in epicardial adipose tissue in obese ZSF1; Values below zero 
correspond to values up-regulated in visceral adipose tissue in obese ZSF1.  
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Figure 32 - ClueGo and CluePedia analysis of protein-protein interaction considering up-regulated proteins identified in visceral (blue nodes) and epicardial (green nodes) 
adipose tissue of obese ZSF1 animal model (based on emPAI values). Blue nodes – Proteins up-regulated in visceral adipose tissue of obese ZSF1; Green nodes – Proteins up-
regulated in proteins of epicardial adipose tissue of obese ZSF1. 
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 The present study reveals the main differences of epicardial and visceral adipose 
tissue proteome from obese rats presenting diastolic heart failure and compares it to lean 
controls. A subsequent bioinformatic approach highlighted the most important signalling 
pathways that are altered in the presence of DHF associated to obesity, amongst other risk 
factors. This information might become very helpful for the diagnosis and prognosis of 
patients with this cardiac dysfunction and to clarify the pathophysiology of this disease.  
 According to the literature, there are no studies about changes in proteome profile 
of adipose tissue in diastolic dysfunction. Thus, in this study the optimization of 
methodology for analysis of visceral and epicardial adipose tissue proteome was 
performed. The differences between protocols were essentially the extraction solution of 
proteins. In the literature, VAT and EAT tissue proteome analyses are mainly based on 
2DE technique [107, 111-113]. In these studies the protein extraction solutions are similar 
to PTU [111] and PU [112, 113]. However, they present a small number of extracted 
proteins (8 – 106 identified proteins) suggesting the need for improving these protocols. In 
fact, 2DE is very restricted in the detection of low abundance, very hydrophobic, extreme 
molecular weight and extreme pI proteins [118]. This suggests that it would be interesting 
to test different protein extraction protocols in order to maximize the amount of extracted 
proteins namely PU, PT and PTU. More recent studies managed to extract a large number 
of proteins using 1DE and LC-MS/MS [122, 123]. Therefore, in this study, a 1DE-LC-
MALDI-TOF/TOF approach was used to test different proteins extraction solutions. 
Evaluating the reduced number of unique proteins extracted, the PT was immediately 
excluded. Regarding PU and PTU the main differences relied on protein distribution by the 
biological process groups, particularly in EAT. While PTU displayed “Reproduction” as an 
exclusive group in EAT, PU presented unique proteins belonging to “biological 
regulation” group. “Reproduction” means the production of new individuals that contain 
some portion of genetic material inherited from one or more parent organisms, while 
“biological regulation” is any process that modulates a measurable attribute of any 
biological process, quality or function [135, 136]. For this study the information of the 
“biological regulation” may be more useful, since an incorrect biological regulation might 
cause changes in modulation of protein expression resulting in a maladaptive cardiac 
remodelling and subsequently in diastolic dysfunction. The molecular function analysis 
shows that PU extracted a large number of proteins both in VAT and EAT, thus covering 
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the same molecular function groups that PTU. It is possible to conclude that the best 
protocol to extract proteins in the scope of this study is PU, since it displays no significant 
differences in cellular component protein distribution, gravy score, molecular weight and 
considering that it extracted more proteins, covering almost the same protein groups when 
compared to PTU.  
 To study diastolic dysfunction, a well-characterized animal model was used, the 
obese ZSF1 rat. Both obese and lean ZSF1 rats are hypertensive, as assessed by increased 
EAI and SAP, and present normal systolic function as observed by preserved ejection 
fraction and normal cardiac index values. However, only the obese ZSF1 rats present 
diastolic abnormalities displaying increased stiffness (EDP and EDPVR) and impaired 
relaxation (prolonged constant time of isovolumic relaxation). Moreover, the obese ZSF1 
rat has been considered a good model of metabolic syndrome, presenting an impressive 
amount of fat tissue depots, hyperlipidaemia, proteinuria, impaired glucose tolerance and 
insulin resistance. Indeed, the initial hypothesis of this study was that the different pattern 
of adipokines expression in adipose tissue would impose different cardiac actions in obese 
ZSF1 rats, namely diastolic dysfunction [33, 61, 74, 76, 80, 88, 89]. However, maybe due 
to the low concentration and small size of adipokines it was not possible to detect them by 
the used techniques. Therefore, the systemic/paracrine effects of adipokine in D.D will not 
be addressed. Instead, fat tissue metabolic changes in obesity will be the main focus 
throughout this discussion. The only adipokine found was fatty acid-binding protein 
(Fabp4), presenting an overexpression in VAT of obese ZSF1 animals. According to our 
findings, the overexpression of this adipokine has been strongly associated to obesity, 
metabolic syndrome and cardiovascular diseases, including the DHF [77, 78, 137, 138]. 
Considering that obese ZSF1 presents obesity and hyperlipidaemia and that Fabp4 serves 
as a carrier protein for fatty acids and other lipophilic substances between extra- and 
intracellular membranes, its increase is expected [79]. However, it raises a question, not 
yet answered in the literature, whether Fabp4 is involved in causative links between 
obesity, the metabolic syndrome and related cardiovascular complications, such as DHF.  
 In obese ZSF1 epicardial adipose tissue a significant down-regulation of proteins 
involved in catabolic and metabolic processes, mainly associated to lipid and fatty acid 
oxidation, was observed. Obesity develops when energy production/intake exceed energy 
expenditure [139]. When the balance between energy supply and demand is perturbed, the 
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adipose tissue stores the excess of energy in form of TG. Moreover, when adipocyte size is 
greatly increased, there is a “spill-over” of lipids, such that circulating free fatty acids or 
TG are elevated [140]. These elevated levels can contribute to hyperlipidaemia like obese 
ZSF1 presents [141]. Studies have demonstrated that excess of adipose tissue as in obesity 
increases cardiac dependency on fatty acid oxidation for energy production [142, 143]. 
However, it has been proposed that elevated availability of fatty acid and TG to the 
myocardium may contribute to the development of cardiac dysfunction and heart failure 
[144, 145]. Therefore, as in present work these processes are decreased, it seems to exist a 
cardiac defensive mechanism in order to decrease the metabolism stabilizing the balance 
between anabolic and catabolic processes and consequently improving contractile function. 
Thus, the inhibition of proteins involved in these processes (long-chain acyl-CoA 
dehydrogenase, enoyl-CoA hydratase and 3-ketoacyl-CoA thiolase) may be used as 
therapeutic pathways to restrain fatty acid oxidation and improve diastolic dysfunction. In 
this regard, the inhibition of 3-ketoacyl-CoA thiolase highlights its promising potential to 
improve diastolic function [146].  
 In opposite, the EAT emPAI analysis revealed proteins significantly up-regulated 
when compared with lean ZSF1. These proteins are involved in collagen fibril 
organization. The collagen alpha-1(I) chain and lumican are the highlighted proteins 
involved in this process. In obesity, the connective fibre content of adipose tissue increases 
dramatically, due to up-regulated of several collagens, including collagen alpha-1. In 
adipose tissue, fibrosis appears to be initiated in response to adipocyte hypertrophy, which 
occurs as the initial step toward fat pad expansion through enlargement of the lipid droplet 
size in existing adipocytes [147]. The extracellular matrix in adipose tissue is particularly 
crucial for maintaining structural integrity of adipocytes and plays a critical role in 
adipogenesis. There are specific sequential alterations in the extracellular matrix during 
adipocyte differentiation, with a cascade of activation and deactivation of various matrix 
metalloproteinases, complementing the creation and destruction of the collagen network 
[148, 149]. The lumican is an extracellular matrix-localized proteoglycan associated with 
inflammation and known to bind collagens [150, 151]. Moreover, a study showed that 
lumican accelerates fibril formation [150] suggesting that inflammation associated to 
obesity and the adipose tissue enlargement increases lumican and thus collagen content in 
the extracellular matrix in order to accommodate the expansion of the adipose tissue. 
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 Visceral adipose tissue of obese rats present increased response to oxidative 
metabolism including, up-regulation of proteins such as superoxide dismutase, an 
antioxidant enzyme and one of the first defences against reactive oxygen species (ROS)-
mediated cardiac injury [152]; peroxiredoxin-1, which belong to an ubiquitous family of 
thiol-based antioxidant proteins involved in controlling cellular peroxide levels and in 
redox regulation of signal transduction [153], and annexin-1 that has been proposed to be 
involved in the regulation of cell growth and differentiation, apoptosis, and inflammation 
[154] hinting at a relationship between oxidative stress processes and inflammatory 
response of adipose tissue. Contrarily, other antioxidant enzymes involved in the above 
mentioned processes were shown to be a down-regulated namely catalase and aldehyde 
dehydrogenase (Aldh2). Its decreased expression contributes to mitochondrial impairment 
and increased oxidative stress [155, 156]. Similar changes in these enzymes’ expression 
have been described in the heart resulting in diastolic dysfunction. These results suggest 
that obesity and inflammation are associated to increase of oxidative stress. Indeed, when 
obesity persists, the antioxidant sources, as catalase, can be depleted increasing the 
formation of ROS [165], which seems to be taking place in this work. However, as 
described above the increase of previous proteins suggests that this response may represent 
a compensatory mechanism to prevent the formation of ROS. Moreover, decrease of Aldh2 
is inversely related to oxidative stress, suggesting that its up-regulation might become a 
potential therapeutic target in obesity.  
 In addition to these over-regulated processes, the negative regulation of interleukin-
8 secretion, a pro-inflammatory cytokine, is also highlighted and it involves proteins A4 
and annexin-A1. Interleukin-8 is produced by a variety of cells, including adipocytes 
[157]. This pro-inflammatory cytokine plays a crucial role in the recruitment of 
inflammatory cells such as neutrophils and lymphocytes into tissues [158]. However, the 
A4 and A1-annexin are anti-inflammatory proteins and were detected in the surface of 
apoptotic human neutrophils [159, 160]. In fact, a recent study showed that these anti-
inflammatory proteins suppress IL-8 production by macrophages [160] suggesting, the 
presence of defensive mechanisms in visceral adipose tissue in order to improve the 
inflammation and possible the deleterious consequences associated to obese.  
 Thereby, all changes that occur in VAT leads to think that the main cause of 
development/progression obesity complications is oxidative stress, whereas in EAT seems 
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to be increase of catabolism and adipose tissue expansion. However, to compensate all 
these deregulations, fat metabolism seems to develop compensatory mechanisms, namely 
increasing antioxidants and anti-inflammatory proteins as well as inhibiting  fatty acid 
oxidation. Thus, in addition of increase the Aldh2, the increase of proteins and inhibitors 
stated above may become an interesting therapeutic pathway to explore. However, 
additional studies on these relationships are needed to clarify the underlying pathways. 
 An unexpected finding of the present study is related to the fact that the proteome 
changes in adipose tissue seems to mirror well-described myofilamentary changes 
associated to DHF myocardium. Interestingly, the cellular component analysis of these 
proteins shows that, likewise the myocardium, epicardial and visceral adipose tissue 
express cytoskeletal proteins. Desmin, alpha-actinin-1 and tubulin beta-2A and 5 chain are 
some of the cytoskeletal proteins found in VAT, while tubulin alpha-1B and beta-3 chain, 
alpha-actinin-4 and actin alpha cardiac muscle 1 are present in EAT. The cardiomyocytes 
cytoskeleton is composed of microtubules (tubulin), intermediate filaments (desmin), 
microfilaments (actin) and endosarcomeric proteins (alpha-actinin and titin) [15]. 
Myocardial changes in some of these cytoskeletal proteins, such as titin or desmin [161], 
or on its phosphorylation status have been shown to alter diastolic function [162, 163]. 
Thus, despite in different locations, the cytoskeletal proteins present in EAT and VAT of 
obese subjects may be involved in development of diastolic dysfunction. Moreover, 
comparing the integration of the unique proteins exclusively assigned to VAT in obese and 
lean subjects in VAT we observed that the main difference between both subjects are in 
developmental and biological processes, while in EAT are developmental and cellular 
processes. All these processes comprise mainly structural constituents of cytoskeletal and 
actin-binding proteins as mentioned above. In the myocardium, previous studies described 
that the disarrangement and accumulation of desmin increases stiffness and decreases 
compliance contributing to diastolic dysfunction. In the same way, the increase of total 
tubulin has been associated to microtubule network density derived from cardiac 
hypertrophy [162, 164-166]. Moreover, defects in actin-alpha cardiac muscle 1 gene have 
been linked to impaired ventricular filling induced by dilated and hypertrophic 
cardiomyopathy [167, 168]. Thus, the results of the proteins found exclusively in the 
adipose tissue of obese subjects are consistent with several reported myofilamentary 
changes in DHF and which are responsible for increased of myocardial and chamber 
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stiffness and suggesting that, in obesity, the majority of proteins involved in development, 
cellular and biological processes in VAT and EAT, may lead to a disorganization of 
cardiac filament and cause a change in cardiac relaxation and impaired filling and 
consequently diastolic and contractile dysfunction. However, a study using non-muscle 
cells show that the cofilin-1 promotes actin dynamics by depolymerizing and severing 
actin filaments [169], which may improve the cardiac polymerization and decrease 
stiffness. So, if these increased levels of cofilin-1 in the adipose tissue of obese ZSF1 
parallel its myocardial changes, then its up-regulation could represent an interesting 
adaptive mechanism to decrease myocardial stiffness and improve the diastolic function. 
Further studies are necessary to confirm this hypothesis. 
 Although EAT and VAT share the same embryological origin, there are no studies 
comparing either secreted adipocytes-derived substances or the differences between their 
expression levels. Previous studies have shown that, comparing to subcutaneous adipose 
tissue (SAT), the VAT is more prone to induce impaired fasting glucose [170, 171], 
diabetes [170, 172], insulin resistance [170, 173], hypertension [174, 175], lipids [176] and 
metabolic syndrome [177, 178]. However, it has become imperative to study EAT 
considering that it is the only fat depot that directly contacts with the myocardium. Studies 
showed that it presents: 1) higher number of adipocytes and their size is smaller, when 
compared with perirenal fat [59]; 2) different fatty acid composition comparing to SAT 
[179] and  3)distinct relative expression levels of adipokines  when compared to 
subcutaneous or substernal fat [84, 180]. Despite all these findings only three studies have 
used proteomics to compare visceral and gonadal (GAT) and subcutaneous adipose tissue 
(SAT) [112] and EAT and SAT [107, 111] but none has provided such a broad general 
approach to the protein composition.  In this study it was found that epicardial and visceral 
adipose tissue share 96 and 85 identified proteins in obese and lean ZSF1, respectively. 
There seems to be no significant differences between EAT and VAT regarding unique 
proteins distribution in biological processes, molecular function and cellular components, 
thus suggesting some similarities between both tissues. In this study, obese ZSF1 EAT 
presents increased ApoaI and catalase when compared with VAT. Contrastingly, previous 
studies comparing EAT and SAT report that apolipoprotein-AI (ApoaI) was increase in 
EAT, while catalase was decrease in this tissue [107, 111]. Moreover, enoyl-Coa hidratase, 
mitochondrial, 60kDa heat shock protein, mitochondrial and gesolin are increased in VAT 
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when compared with GAT and SAT [112]. Nevertheless, in present study these proteins 
are increased in obese ZSF1 EAT comparing with VAT. Altogether, data from the present 
study suggests that epicardial adipose tissue behaves differently from the others fat depots 
assessed, providing new information on epicardial adipose tissue metabolism. 
Furthermore, the comparison of shared proteins between epicardial and visceral adipose 
tissue show that there are up-regulated proteins identified in both tissues, either in lean as 
obese ZSF1, which are involved in different processes and responses. Differences between 
epicardial and visceral adipose tissue suggest that although they share some proteins in 
similar abundances, their functions may be different.  
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 Once analysed the changes in proteome of epicardial and visceral adipose tissue 
induced by obesity, it is possible to conclude that although the epicardial and visceral 
adipose tissue share the same embryological origin, its proteome and respective functions 
and processes seem to be different, being an important fact for future adipose tissue 
studies.  
 In EAT, the decreased proteins involved in catabolic and metabolic metabolism 
seem to be a compensatory mechanism in order to decrease the fatty acid oxidation 
associated to obesity and cardiac dysfunction, stabilizing the balance between anabolic and 
catabolic processes and consequently improve cardiac function. 
 The obesity and its associated inflammation causes changes in epicardial adipose 
tissue extracellular matrix increasing collagen content through increase of lumican in order 
to accommodate the expansion of the adipose tissue. 
 The decreased expression of catalase and Aldh2 may be one of the possible factors 
that lead to oxidative stress in obese subjects in VAT. However, the increase of others 
antioxidants and anti-inflammatory proteins seems to be a compensatory mechanisms 
developed by metabolism to prevent the increase of ROS and inflammation resultant of 
obesity. Therefore, the increase of Aldh2, antioxidants and anti-inflammatory agents in 
obesity may be a starting point for developing therapeutic ways to improve the oxidative 
stress derived from obesity. 
 The increased A4 and A1-annexin involved in negative regulation of IL-8 secretion 
suggest defensive mechanisms in visceral adipose tissue in order to improve the 
inflammation and potential obesity-induced consequence. 
 The increase of contractile proteins found exclusively in obese ZSF1 adipose tissue 
are consistent with several reported myofilamentary changes in DHF suggesting that they 
may be a reflection of what happens in the heart. In fact, several studies in proteomic 
present these proteins in adipose tissue, raising a question that is not yet answered in the 
literature, how and why these cardiac contractile proteins go to adipose tissue. 
 Taken together, the obesity seems result in increase of energy production, oxidative 
stress and inflammation that may change expression, function and phosphorylation of 
proteins involved in cardiac function. Thus, future work should focus on therapeutic 
strategies to counteract these deleterious/compensatory processes in obesity aiming to 
improve patients’ quality of life. This work is a general approach to the protein 
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composition of visceral and epicardial adipose tissue, helping the future development in 
researches more specifics about diastolic dysfunction. 
 As stated in the discussion, the cardiac contractile proteins changes seem to be, in 
partly, caused by oxidative stress. This stress can impair the function and/or 
phosphorylation of these proteins and consequently cause changes in cardiac relaxation, 
thus leading to diastolic dysfunction. Therefore, in the future, a study about 
phosphoproteomics changes and its acute modulation in cardiac diastolic dysfunction 
would be interesting to elucidate the mechanisms involved in this disease. 
 Another possible study, to understand the mechanisms involved in diastolic 
dysfunction, would be to analyse the secretome using conditioned medium obtained by 
incubating the fat samples in a medium without serum. This conditioned medium would 
reflect the secretome that is released from fat tissue.  
 Lastly, once the present study was based on proteome of ZSF1 animal model, it 
would be useful and interesting to analyse samples from obese and lean human heart with 
cardiac diastolic dysfunction. 
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Appendix A – Analysis of proteins resulting from the studies of the Table 4. 
Supplemental Table A 1 - Genes of the proteins secreted by visceral and epicardial adipose tissue matching between studies of the Table 4. Genes in bold – most common genes 
Proteomic 
analysis of 
epicardial and 
subcutaneous 
adipose tissue 
reveals 
differences in 
proteins 
involved in 
oxidative stress 
 
Secretome 
analysis of rat 
adipose 
tissues shows 
location-
specific roles 
for each depot 
type. 
 
Characteriz
ation of the 
Human 
Visceral 
Adipose 
Tissue 
Secretome 
 
Changes in 
lipid transport-
involved 
proteins of 
epicardial 
adipose tissue 
associated with 
coronary artery 
disease 
 
A protein profile of visceral adipose tissues linked to  early 
pathogenesis of type 2 diabetes mellitus 
 
Proteomic analysis of 
visceral adipose tissue 
in pre-obese patients 
with type 2 diabetes 
 
Proteomic profile 
of visceral 
adipose tissues 
between low-fat 
diet-fed obesity-
resistant and 
obesity-prone 
C57BL/6 mice 
 
Proteomic 
analysis of 
epicardial and 
subcutaneous 
adipose tissue 
reveals 
differences in 
proteins 
involved in 
oxidative stress 
 
 VIM ACTB - ACTB ACTB - 
Secretome 
analysis of rat 
adipose tissues 
shows location-
specific roles for 
each depot type 
 
  
GSTP1 FABP4 BPNT1 PARK7 ALDH2 
- 
PGAM1 MIF GSTP1 PDIA3 GSTM2 
FABP4 PRDX2 CALR PDIA6   
GSTO1  CAPZB PDXK   
LDHB  GSTO1 PGAM1   
NID2  HIBCH PRDX2   
PARK7  LDHB PRDX3   
PRDX1 
PRDX2 
PRDX3 
 
 
 
MIF 
NID2 
NIT1 
PRDX5 
WDR1 
NIT2 
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Supplemental Table A1 – (Continue...) 
Characterization 
of the Human 
Visceral 
Adipose Tissue 
Secretome 
      A2M A2M CFB FASN LAMA4 PRDX2 ACTB  PRDX6 
      CST3 ACAA2 COL12A1 FBLN1 LDHB PRDX3 ALDH1A1    
      F13A1 ACOT1 COL15A1 FH LGALS3 PRDX6 IGKC     
      FABP4 ACTB COL1A1 FHL1 LGALS3BP PSMA1       
      FAH ACTN1 COL1A2 FN1 LRP1 PSMA3       
      GPI ACTN4 COL4A2 GARS LTA4H PSMA4       
      HBA1 ACY1 COL4A4 GDI1 LTBP2 PSMA6       
      HBB ADH5 COL6A1 GDI2 LYZ PSMB3       
      LYZ ADIPOQ COL6A2 GLO1 MAN2C1 PSMB4       
      MDH1 AKR1A1 COL6A3 GOT1 MCAM PSMB5       
      PEBP1 ALAD CRYZ GPD1 MDH1 PSMB7       
      PRDX2 ALB CST3 GPI ME1 PTX3       
       TF  ALDH1A1 CSTB GPX3 MPO PYGL       
      VIM ALDOA CTSD GSN MSN QDPR         
       YWHAG ANXA2 CTSZ GSS NID1 RBP4         
        APEH DPP3 GSTO1 NID2 SERPINB1         
        APEX1 DPT GSTP1 NQO2 SERPINB6         
        ARHGDIA ECH1 GSTT1 NRP1 SERPINF1         
        AZU1 ECM1 HBA1 OGN SH3BGRL         
        C19orf10 EFEMP1 HBB OLFML1 SOD1         
        C1S EHD2 HIST1H2BK P4HB SOD2         
        C7 ELANE HSP90AB1 PAFAH1B1 SOD3         
        CA1 EMILIN1 HSPA1A PARK7 SPARC         
        CA3 ENO1 HSPA4 PEBP1 SPON1         
        CALB2 ERAP1 HSPG2 PEPD SPTAN1         
        CAPN1 F13A1 IDH1 PGAM1 SPTBN1         
        CD14 FABP4 IGFBP7 PGD TAGLN         
        CD44 FABP5 IGHM PGLS TF         
        CDH5 FAH IGHM PLXNB2 TFRC         
        CES1 FAM49B IGKC PPIB TGFBI         
        TKT TXNRD1 VCP YWHAE THBS1         
!
!
!
!
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Supplemental Table A1 – (Continue...) 
 Changes in lipid 
transport-
involved 
proteins of 
epicardial 
adipose tissue 
associated with 
coronary artery 
disease 
        A2M FABP4 HBB MDH1 TF 
- - 
        ACTBL2 FAH HBD MIF TTR 
        APOA1 FGB HBG1 PEBP1 UGP2 
        CST3 GPI HSPE1 PRDX2 VCL 
        F13A1 HBA1 LYZ S100A8   
A protein 
profile of 
visceral 
adipose tissues 
linked to early 
pathogenesis 
of type 2 
diabetes 
mellitus 
  
                  ACTB SERPINC1 MGLL 
                  ALDH1A1   PRDX6 
                  ANXA1   TPM2 
                  APOA4     
                  IGKC     
 Proteomic 
analysis of 
visceral 
adipose tissue 
in pre-obese 
patients with 
type 2 diabetes 
 
                        
- 
                        
                        
                        
                        
!Proteomic 
profile of 
visceral 
adipose tissues 
between low-
fat diet-fed 
obesity-
resistant and 
obesity-prone 
C57BL/6 mice 
!
!! !! !! !! !! !! !! !! !! !! !! !! !!
!! !! !! !! !! !! !! !! !! !! !! !! !!
!! !! !! !! !! !! !! !! !! !! !! !! !!
!! !! !! !! !! !! !! !! !! !! !! !! !!
!! !! !! !! !! !! !! !! !! !! !! !! !!
!! !! !! !! !! !! !! !! !! !! !! !! !!
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Cellular component analysis 
Supplemental Figure A 1 - Distribution of visceral and epicardial proteins resulting from the studies of the Table 4 
according to cellular component with the PANTHER classification system (http://www.pantherdb.org). Blue – 
visceral adipose tissue; Red – epicardial adipose tissue 
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Appendix B – Proteins resulting of optimization of methodology 
for analysis of the both tissues 
 
Supplemental Table B 1 - Proteins of visceral adipose tissue extracted from protocol - Tris 
Protein name Gene name Entry name 
Accession 
number Mascot score 
Matching 
peptides 
Sequence 
coverage 
Actin, cytoplasmic 1 Actb ACTB_RAT P60711 236 4 (4) 4 (4) 
Serum albumin Alb ALBU_RAT P02770 385 8 (7) 8 (7) 
Annexin A2 Anxa2 ANXA2_RAT Q07936 112 2 (2) 2 (2) 
Carbonic anhydrase 3 Ca3 CAH3_RAT P14141 177 4 (4) 4 (4) 
Histone H2A type 1-C " H2A1C_RAT P0C169 122 2 (2) 2 (2) 
Histone H3.1 " H31_RAT Q6LED0 81 4 (4) 3 (3) 
Histone H4 Hist1h4b H4_RAT P62804 52 1 (1) 1 (1) 
Hemoglobin subunit 
alpha-1/2 Hba1 HBA_RAT P01946 228 2 (2) 2 (2) 
Hemoglobin subunit 
beta-1 Hbb HBB1_RAT P02091 56 1 (1) 1 (1) 
Lumican Lum LUM_RAT P51886 29 1 (1) 1 (1) 
Vimentin Vim VIME_RAT P31000 95 1 (1) 1 (1) 
 
 
 
Supplemental Table B 2 - Proteins of visceral adipose tissue extracted from protocol - Urea 
Protein name Gene name Entry name 
Accession 
number 
Mascot 
score 
Matching 
peptides 
Sequence 
coverage 
14-3-3 protein gamma  Ywhag 1433G_RAT P61983 73 4 (4) 4 (4) 
14-3-3 protein epsilon Ywhae 1433E_RAT P62260 146 7 (4) 7 (4) 
14-3-3 protein theta  Ywhaq 1433T_RAT P68255 55 4 (2) 4 (2) 
14-3-3 protein zeta/delta  Ywhaz  1433Z_RAT P63102 211 7 (5) 7 (5) 
Alpha-1-antiproteinase Serpina1 A1AT_RAT P17475 82 1 (1) 1 (1) 
Alpha-1-macroglobulin  A1m  A1M_RAT Q63041 62 9 (2) 4 (2) 
1-acylglycerol-3-phosphate O-acyltransferase 
ABHD5 Abhd5 ABHD5_RAT Q6QA69 51 4 (1) 3 (1) 
Aconitate hydratase, mitochondrial Aco2 ACON_RAT Q9ER34 81 8 (4) 7 (3) 
Long-chain-fatty-acid--CoA ligase 1  Acsl1  ACSL1_RAT P18163 225 12 (7) 10 (5) 
Long-chain-fatty-acid--CoA ligase 6  Acsl6  ACSL6_RAT P33124 92 4 (2) 3 (1) 
Actin, aortic smooth muscle  Acta2  ACTA_RAT P62738 1329 36 (34) 21 (21) 
Actin, cytoplasmic 2  Actg1 ACTG_RAT P63259 1641 45 (39) 24 (23) 
Alpha-actinin-1  Actn1 ACTN1_RAT Q9Z1P2 56 16 (4) 14 (4) 
Serum albumin Alb ALBU_RAT P02770 1833 55 (44) 25 (19) 
Aldehyde dehydrogenase, mitochondrial Aldh2 ALDH2_RAT P11884 100 7 (3) 7 (3) 
Fructose-bisphosphate aldolase A  Aldoa ALDOA_RAT P05065 129 9 (5) 8 (4) 
Aldose reductase  Akr1b1  ALDR_RAT P07943 142 6 (3) 5 (3) 
Annexin A1 Anxa1  ANXA2_RAT Q07936 868 27 (19) 15 (10) 
Annexin A2 Anxa2  ANXA3_RAT P14669 530 17 (15) 15 (14) 
Annexin A3 Anxa3 ANXA6_RAT P48037 122 5 (4) 5 (4) 
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Annexin A4 Anxa4 ANXA5_RAT P14668 51 7 (2) 7 (2) 
Annexin A5 Anxa5 ANXA1_RAT P07150 517 13 (13) 13 (13) 
Annexin A6 Anxa6 ANXA4_RAT P55260 332 15 (9) 10 (6) 
Membrane primary amine oxidase Aoc3 AOC3_RAT O08590 118 11 (5) 8 (3) 
Apolipoprotein A-I Apoa1 APOA1_RAT P04639 157 7 (5) 7 (5) 
Apolipoprotein E Apoe APOE_RAT P02650 39 6 (1) 4 (1) 
Actin-related protein 3  Actr3  ARP3_RAT Q4V7C7 49 4 (1) 4 (1) 
ATP synthase subunit alpha, mitochondrial Atp5a1 ATPA_RAT P15999 188 9 (4) 5 (3) 
ATP synthase subunit beta, mitochondrial  Atp5b ATPB_RAT P10719 221 8 (5) 7 (5) 
Cadherin-23 Cdh23 CAD23_RAT P58365 56 15 (3) 9 (1) 
Carbonic anhydrase 2 Ca2 CAH2_RAT P27139 52 6 (1) 2 (1) 
Carbonic anhydrase 3  Ca3 CAH3_RAT P14141 1302 33 (27) 22 (21) 
Calreticulin Calr CALR_RAT P18418 158 5 (4) 5 (4) 
Calumenin  Calu CALU_RAT O35783 37 2 (1) 2 (1) 
Calnexin Canx CALX_RAT P35565 85 4 (2) 3 (1) 
Macrophage-capping protein  Capg CAPG_RAT Q6AYC4 212 6 (4) 6 (4) 
F-actin-capping protein subunit beta  Capzb CAPZB_RAT Q5XI32 41 3 (1) 3 (1) 
Catalase  Cat CATA_RAT P04762 291 13 (9) 13 (9) 
Carbonyl reductase [NADPH] 1 Cbr1  CBR1_RAT P47727 59 2 (1) 1 (1) 
Carboxylesterase 1D Ces1d  CES1D_RAT P16303 71 3 (2) 3 (2) 
60 kDa heat shock protein, mitochondrial Hspd1 CH60_RAT P63039 131 4 (1) 4 (1) 
Citrate synthase, mitochondrial Cs CISY_RAT Q8VHF5 69 9 (2) 8 (2) 
Calponin-1 Cnn1 CNN1_RAT Q08290 42 5 (1) 5 (1) 
Collagen alpha-1(I) chain  Col1a1 CO1A1_RAT P02454 45 8 (2) 5 (2) 
Calpain small subunit 1 Capns1 CPNS1_RAT Q64537 39 1 (1) 1 (1) 
High affinity cationic amino acid transporter 
1  Slc7a1 CTR1_RAT P30823 34 4 (1) 2 (1) 
Cytochrome c, somatic Cycs CYC_RAT P62898 43 1 (1) 1 (1) 
Cystatin-B  Cstb CYTB_RAT P01041 39 1 (1) 1 (1) 
Desmin Des DESM_RAT P48675 244 11 (7) 7 (5) 
Destrin  Dstn DEST_RAT Q7M0E3 52 2 (1) 2 (1) 
Glutamate dehydrogenase 1, mitochondrial Glud1  DHE3_RAT P10860 44 3 (1) 3 (1) 
Succinate dehydrogenase [ubiquinone] iron-
sulfur subunit, mitochondrial Sdhb DHSB_RAT P21913 36 2 (1) 2 (1) 
D-dopachrome decarboxylase  Ddt DOPD_RAT P80254 46 1 (1) 1 (1) 
Dihydropyrimidinase-related protein 2 Dpysl2 DPYL2_RAT P47942 53 2 (2) 2 (2) 
Trifunctional enzyme subunit alpha, 
mitochondrial Hadha ECHA_RAT Q64428 108 7 (4) 5 (4) 
Elongation factor 1-gamma Eef1g EF1G_RAT Q68FR6 71 4 (3) 3 (3) 
EH domain-containing protein 2 Ehd2 EHD2_RAT Q4V8H8 278 16 (7) 12 (4) 
Alpha-enolase Eno1  ENOA_RAT P04764 335 10 (7) 7 (4) 
Endoplasmin Hsp90b1  ENPL_RAT Q66HD0 93 12 (3) 9 (3) 
Ectonucleoside triphosphate 
diphosphohydrolase 2 Entpd2 ENTP2_RAT O35795 46 1 (1) 1 (1) 
Endoplasmic reticulum resident protein 29  Erp29 ERP29_RAT P52555 171 5 (4) 5 (4) 
Fatty acid-binding protein, adipocyte Fabp4 FABP4_RAT P70623 322 9 (9) 5 (5) 
Fibulin-5  Fbln5  FBLN5_RAT Q9WVH8 70 2 (2) 2 (2) 
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Ferritin heavy chain  Fth1  FRIH_RAT P19132 70 3 (2) 3 (2) 
Ferritin light chain 1 Ftl1 FRIL1_RAT P02793 60 4 (2) 4 (2) 
Glyceraldehyde-3-phosphate dehydrogenase Gapdh  G3P_RAT P04797 66 6 (2) 3 (1) 
Guanine nucleotide-binding protein subunit 
beta-2-like 1 Gnb2l1 GBLP_RAT P63245 47 4 (1) 4 (1) 
Rho GDP-dissociation inhibitor 1  Arhgdia GDIR1_RAT Q5XI73 129 3 (3) 3 (3) 
Gelsolin  Gsn GELS_RAT Q68FP1 115 9 (3) 5 (1) 
Glutamine synthetase Glul GLNA_RAT P09606 65 4 (3) 4 (3) 
Guanine nucleotide-binding protein G(s) 
subunit alpha isoforms Xlas Gnas GNAS1_RAT Q63803 34 4 (1) 4 (1) 
Glycerol-3-phosphate dehydrogenase 
[NAD(+)], cytoplasmic  Gpd1 GPDA_RAT O35077 92 6 (3) 6 (3) 
Glutathione peroxidase 1 Gpx1 GPX1_RAT P04041 62 3 (2) 3 (2) 
78 kDa glucose-regulated protein Hspa5  GRP78_RAT P06761 516 19 (13) 17 (13) 
Glutathione S-transferase alpha-3  Gsta3  GSTA3_RAT P04904 60 4 (2) 4 (2) 
Glutathione S-transferase P Gstp1 GSTP1_RAT P04906 128 5 (3) 5 (3) 
Guanine deaminase Gda GUAD_RAT Q9WTT6 267 9 (7) 9 (7) 
Histone H2B type 1-A Hist1h2ba  H2B1A_RAT Q00729 52 4 (1) 4 (1) 
Hemoglobin subunit alpha-1/2 Hba1 HBA_RAT P01946 402 11 (8) 7 (6) 
Hemoglobin subunit beta-2  - HBB2_RAT P11517 361 11 (10) 8 (7) 
Hemoglobin subunit beta-1  Hbb HBB1_RAT P02091 333 10 (9) 8 (7) 
Hydroxyacyl-coenzyme A dehydrogenase, 
mitochondrial  Hadh HCDH_RAT Q9WVK7 41 2 (1) 2 (1) 
Hemopexin Hpx HEMO_RAT P20059 52 6 (3) 5 (3) 
Histidine triad nucleotide-binding protein 1 Hint1 HINT1_RAT P62959 40 2 (1) 2 (1) 
Heat shock cognate 71 kDa protein Hspa8  HSP7C_RAT P63018 343 14 (9) 13 (9) 
Heat shock protein beta-1 Hspb1  HSPB1_RAT P42930 128 6 (3) 5 (3) 
Isocitrate dehydrogenase [NAD] subunit 
alpha, mitochondrial  Idh3a IDH3A_RAT Q99NA5 33 3 (1) 3 (1) 
Ig gamma-2A chain C region Igg-2a IGG2A_RAT P20760 38 1 (1) 1 (1) 
Integrin beta-1 Itgb1 ITB1_RAT P49134 45 4 (1) 4 (1) 
Keratin, type I cytoskeletal 10 Krt10 K1C10_RAT Q6IFW6 100 7 (4) 3 (2) 
Keratin, type II cytoskeletal 6A Krt6a K2C6A_RAT Q4FZU2 156 12 (7) 7 (5) 
Keratin, type II cytoskeletal 1 Krt1  K2C1_RAT Q6IMF3 147 12 (5) 5 (3) 
Creatine kinase B-type  Ckb  KCRB_RAT P07335 62 4 (2) 4 (2) 
Laminin subunit beta-2  Lamb2 LAMB2_RAT P15800 38 12 (1) 11 (1) 
L-lactate dehydrogenase A chain  Ldha LDHA_RAT P04642 93 6 (3) 6 (3) 
L-lactate dehydrogenase B chain Ldhb  LDHB_RAT P42123 73 5 (1) 5 (1) 
Galectin-1 Lgals1 LEG1_RAT P11762 152 6 (4) 5 (4) 
Galectin-3 Lgals3 LEG3_RAT P08699 243 7 (4) 5 (4) 
Prelamin-A/C Lmna LMNA_RAT P48679 218 23 (8) 20 (8) 
Lumican Lum  LUM_RAT P51886 226 8 (7) 6 (6) 
Myristoylated alanine-rich C-kinase substrate Marcks  MARCS_RAT P30009 76 2 (1) 2 (1) 
Malate dehydrogenase, cytoplasmic Mdh1  MDHC_RAT O88989 72 2 (1) 2 (1) 
Malate dehydrogenase, mitochondrial Mdh2  MDHM_RAT P04636 177 8 (4) 8 (4) 
Monoglyceride lipase Mgll  MGLL_RAT Q8R431 144 8 (2) 8 (2) 
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Moesin Msn MOES_RAT O35763 63 7 (2) 5 (2) 
Myosin regulatory light chain RLC-A  Rlc-a MRLCA_RAT P13832 40 1 (1) 1 (1) 
Myosin-10 Myh10 MYH10_RAT Q9JLT0 85 11 (2) 11 (2) 
Myosin-11 Myh11 MYH11_RAT Q63862 215 17 (8) 16 (8) 
Myosin regulatory light polypeptide 9 Myl9  MYL9_RAT Q64122 55 19 (1) 17 (1) 
Myosin light polypeptide 6 Myl6 MYL6_RAT Q64119 223 5 (4) 4 (3) 
Myosin-9 Myh9 MYH9_RAT Q62812 66 1 (1) 1 (1) 
NADH-cytochrome b5 reductase 3 Cyb5r3  NB5R3_RAT P20070 157 7 (5) 6 (5) 
Nucleoside diphosphate kinase A  Nme1 NDKA_RAT Q05982 32 2 (1) 2 (1) 
NADH dehydrogenase [ubiquinone] 
flavoprotein 2, mitochondrial Ndufv2 NDUV2_RAT P19234 36 1 (1) 1 (1) 
Nidogen-2  Nid2 NID2_RAT B5DFC9 85 12 (4) 10 (4) 
Protein disulfide-isomerase A3  Pdia3  PDIA3_RAT P11598 192 9 (4) 8 (4) 
Protein disulfide-isomerase P4hb PDIA1_RAT P04785 608 17 (14) 17 (14) 
Protein disulfide-isomerase A6 Pdia6  PDIA6_RAT Q63081 208 6 (4) 4 (2) 
Peripherin Prph PERI_RAT P21807 99 9 (5) 7 (3) 
Phosphoglycerate mutase 1 Pgam1 PGAM1_RAT P25113 59 5 (2) 4 (2) 
Phosphoglycerate kinase 1 Pgk1  PGK1_RAT P16617 155 6 (3) 6 (3) 
Membrane-associated progesterone receptor 
component 1 Pgrmc1  PGRC1_RAT P70580 154 6 (4) 6 (4) 
Membrane-associated progesterone receptor 
component 2 Pgrmc2 PGRC2_RAT Q5XIU9 75 6 (2) 6 (2) 
Prohibitin Phb PHB_RAT P67779 44 3 (1) 3 (1) 
Perilipin-1 Plin1 PLIN1_RAT P43884 99 2 (1) 1 (1) 
Peptidyl-prolyl cis-trans isomerase A Ppia PPIA_RAT P10111 53 8 (3) 6 (3) 
Protein kinase C delta-binding protein  Prkcdbp PRDBP_RAT Q9Z1H9 43 2 (1) 2 (1) 
Peroxiredoxin-1  Prdx1  PRDX1_RAT Q63716 189 6 (5) 6 (5) 
Prolargin  Prelp PRELP_RAT Q9EQP5 96 5 (3) 5 (3) 
Profilin-1  Pfn1 PROF1_RAT P62963 170 4 (3) 4 (3) 
Polymerase I and transcript release factor Ptrf PTRF_RAT P85125 157 7 (6) 4 (3) 
Ras-related protein Rab-7a Rab7a  RAB7A_RAT P09527 32 3 (1) 2 (1) 
Ras-related C3 botulinum toxin substrate 1 Rac1 RAC1_RAT Q6RUV5 35 5 (1) 4 (1) 
Ras-related protein Rab-11B Rab11b RB11B_RAT O35509 106 6 (4) 6 (4) 
All-trans-retinol 13,14-reductase Retsat  RETST_RAT Q8VHE9 33 1 (1) 1 (1) 
Ubiquitin-60S ribosomal protein L40 Uba52  RL40_RAT P62986 45 4 (3) 3 (2) 
Heterogeneous nuclear ribonucleoproteins 
A2/B1  Hnrnpa2b1  ROA2_RAT A7VJC2 108 7 (4) 7 (4) 
Heterogeneous nuclear ribonucleoprotein A3 Hnrnpa3  ROA3_RAT Q6URK4 161 4 (1) 4 (1) 
40S ribosomal protein SA  Rpsa  RSSA_RAT P38983 55 4 (3) 3 (2) 
Protein S100-A10 S100a10 S10AA_RAT P05943 111 5 (3) 5 (3) 
Serpin H1 Serpinh1  SERPH_RAT P29457 224 10 (4) 5 (4) 
Superoxide dismutase [Cu-Zn]  Sod1 SODC_RAT P07632 44 2 (2) 2 (2) 
Serine protease inhibitor A3K  Serpina3k SPA3K_RAT P05545 39 4 (1) 4 (1) 
Serine protease inhibitor A3N Serpina3n  SPA3N_RAT P09006 66 3 (1) 3 (1) 
SPARC  Sparc SPRC_RAT P16975 57 1 (1) 1 (1) 
Spectrin alpha chain, non-erythrocytic 1 Sptan1  SPTN1_RAT P16086 294 34 (9) 29 (8) 
Gamma-synuclein  Sncg SYUG_RAT Q63544 97 5 (3) 5 (3) 
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Transgelin Tagln  TAGL_RAT P31232 90 7 (3) 6 (3) 
Tubulin alpha-1B chain Tuba1b TBA1B_RAT Q6P9V9 713 21 (18) 10 (10) 
Tubulin beta-2A chain Tubb2a TBB2A_RAT P85108 417 13 (10) 7 (5) 
Tubulin beta-4B chain  Tubb4b  TBB4B_RAT Q6P9T8 441 14 (11) 8 (6) 
Tubulin beta-5 chain Tubb5 TBB5_RAT P69897 332 13 (10) 8 (6) 
3-ketoacyl-CoA thiolase, mitochondrial Acaa2 THIM_RAT P13437 36 6 (2) 5 (2) 
Thioredoxin  Txn  THIO_RAT P11232 47 2 (1) 2 (1) 
Tubulointerstitial nephritis antigen-like  Tinagl1 TINAL_RAT Q9EQT5 55 4 (2) 3 (1) 
Transmembrane emp24 domain-containing 
protein 9 Tmed9 TMED9_RAT Q5I0E7 40 2 (1) 2 (1) 
Triosephosphate isomerase Tpi1 TPIS_RAT P48500 94 2 (1) 2 (1) 
Tropomyosin alpha-1 chain  Tpm1  TPM1_RAT P04692 266 16 (10) 13 (8) 
Tropomyosin beta chain  Tpm2 TPM2_RAT P58775 265 20 (9) 17 (7) 
Tropomyosin alpha-3 chain  Tpm3  TPM3_RAT Q63610 293 22 (11) 19 (9) 
Serotransferrin Tf TRFE_RAT P12346 258 16 (9) 15 (9) 
Vesicle-associated membrane protein-
associated protein A  Vapa  VAPA_RAT Q9Z270 55 3 (1) 3 (1) 
Voltage-dependent anion-selective channel 
protein 1  Vdac1 VDAC1_RAT Q9Z2L0 65 4 (2) 4 (2) 
Voltage-dependent anion-selective channel 
protein 2  Vdac2 VDAC2_RAT P81155 48 2 (1) 2 (1) 
Vimentin Vim VIME_RAT P31000 2191 63 (49) 32 (26) 
Vinculin  Vcl VINC_RAT P85972 86 14 (4) 13 (4) 
 
 
 
Supplemental Table B 3 - Proteins of visceral adipose tissue extracted from protocol – Tris and Urea. 
Protein name Gene name Entry name 
Accession 
number 
Mascot 
score 
Matching 
peptides 
Sequence 
coverage 
14-3-3 protein epsilon Ywhae 1433E_RAT P62260 156 12 (8) 8 (6) 
14-3-3 protein gamma  Ywhag 1433G_RAT P61983 36 2 (1) 2 (1) 
14-3-3 protein zeta/delta  Ywhaz 1433Z_RAT P63102 69 2 (2) 2 (2) 
40S ribosomal protein SA Rpsa  RSSA_RAT P38983 31 2 (1) 2 (1) 
78 kDa glucose-regulated protein Hspa5  GRP78_RAT P06761 87 8 (1) 8 (1) 
Aconitate hydratase, mitochondrial  Aco2 ACON_RAT Q9ER34 42 5 (2) 4 (1) 
Actin, aortic smooth muscle Acta2 ACTA_RAT P62738 39 4 (2) 3 (1) 
Actin, cytoplasmic 2  Actg1 ACTG_RAT P63259 591 26 (18) 13 (9) 
Aldehyde dehydrogenase, 
mitochondrial Aldh2 ALDH2_RAT P11884 940 34 (27) 16 (14) 
Aldose reductase (AR) Akr1b1  ALDR_RAT P07943 1398 54 (36) 27 (20) 
Alpha-enolase Eno1 ENOA_RAT P04764 30 5 (2) 5 (2) 
Annexin A1 Anxa1 ANXA1_RAT P07150 193 6 (6) 6 (6) 
Annexin A2 Anxa2 ANXA2_RAT Q07936 146 5 (3) 4 (3) 
Annexin A3 Anxa3 ANXA3_RAT P14669 406 13 (9) 10 (7) 
Annexin A4  Anxa4 ANXA4_RAT P55260 404 17 (14) 14 (12) 
Annexin A5 Anxa5 ANXA5_RAT P14668 54 4 (3) 4 (3) 
Annexin A6  Anxa6 ANXA6_RAT P48037 32 4 (1) 4 (1) 
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Apolipoprotein E  Apoe APOE_RAT P02650 192 9 (8) 9 (8) 
ATP synthase subunit alpha, 
mitochondrial Atp5a1 ATPA_RAT P15999 136 9 (2) 9 (2) 
ATP synthase subunit beta, 
mitochondrial  Atp5b ATPB_RAT P10719 37 8 (2) 4 (2) 
Cadherin-23 Cdh23 CAD23_RAT P58365 36 8 (1) 6 (1) 
Calnexin Canx CALX_RAT P35565 86 4 (3) 3 (2) 
Carbonic anhydrase 2  Ca2 CAH2_RAT P27139 173 4 (3) 4 (3) 
Carbonic anhydrase 3  Ca3 CAH3_RAT P14141 38 12 (3) 6 (1) 
Carbonyl reductase [NADPH] 1  Cbr1  CBR1_RAT P47727 47 7 (3) 2 (1) 
Catalase  Cat  CATA_RAT P04762 537 26 (19) 13 (9) 
Citrate synthase, mitochondrial  Cs CISY_RAT Q8VHF5 44 1 (1) 1 (1) 
Collagen alpha-1(I) chain Col1a1 CO1A1_RAT P02454 197 7 (2) 5 (2) 
Creatine kinase B-type  Ckb  KCRB_RAT P07335 91 11 (4) 9 (3) 
Cystatin-B Cstb  CYTB_RAT P01041 78 4 (1) 3 (1) 
Cystatin-C Cst3 CYTC_RAT P14841 34 5 (1) 4 (1) 
Cytochrome b5 Cyb5a CYB5_RAT P00173 98 9 (3) 7 (2) 
Cytochrome c, somatic Cycs CYC_RAT P62898 68 2 (1) 2 (1) 
D-dopachrome decarboxylase  Ddt DOPD_RAT P80254 46 1 (1) 1 (1) 
Decorin  Dcn PGS2_RAT Q01129 56 1 (1) 1 (1) 
Desmin Des DESM_RAT P48675 38 1 (1) 1 (1) 
Destrin  Dstn DEST_RAT Q7M0E3 94 7 (3) 6 (3) 
EH domain-containing protein 2 Ehd2 EHD2_RAT Q4V8H8 84 3 (2) 3 (2) 
Endoplasmic reticulum resident protein 
29  Erp29 ERP29_RAT P52555 40 1 (1) 1 (1) 
Endoplasmin Hsp90b1  ENPL_RAT Q66HD0 136 10 (5) 6 (4) 
Ezrin Ezr EZRI_RAT P31977 132 8 (4) 7 (4) 
Fatty acid-binding protein, adipocyte  Fabp4 FABP4_RAT P70623 39 8 (1) 7 (1) 
Ferritin heavy chain Fth1  FRIH_RAT P19132 40 3 (1) 3 (1) 
Fibrinogen beta chain Fgb  FIBB_RAT P14480 53 7 (1) 6 (1) 
Fructose-bisphosphate aldolase A Aldoa ALDOA_RAT P05065 302 11 (8) 4 (4) 
Galectin-1  Lgals1 LEG1_RAT P11762 35 2 (1) 2 (1) 
Galectin-3 Lgals3 LEG3_RAT P08699 29 2 (1) 2 (1) 
Gelsolin  Gsn GELS_RAT Q68FP1 49 6 (2) 5 (2) 
Glial fibrillary acidic protein Gfap GFAP_RAT P47819 32 4 (2) 4 (2) 
Glutathione S-transferase alpha-3  Gsta3 GSTA3_RAT P04904 59 8 (1) 5 (1) 
Glutathione S-transferase P  Gstp1 GSTP1_RAT P04906 60 3 (2) 3 (2) 
Glyceraldehyde-3-phosphate 
dehydrogenase Gapdh  G3P_RAT P04797 75 2 (2) 2 (2) 
Glycerol-3-phosphate dehydrogenase 
[NAD(+)], cytoplasmic  Gpd1 GPDA_RAT O35077 331 15 (9) 14 (9) 
Guanine deaminase Gda GUAD_RAT Q9WTT6 52 5 (1) 4 (1) 
Heat shock cognate 71 kDa protein Hspa8 HSP7C_RAT P63018 31 4 (1) 4 (1) 
Heat shock protein beta-1 (HspB1)  Hspb1  HSPB1_RAT P42930 127 7 (3) 7 (3) 
Hemoglobin subunit alpha-1/2  Hba1  HBA_RAT P01946 122 9 (7) 4 (3) 
Hemoglobin subunit beta-1 Hbb HBB1_RAT P02091 121 5 (4) 5 (4) 
Heterogeneous nuclear 
ribonucleoproteins A2/B1  Hnrnpa2b1 ROA2_RAT A7VJC2 68 6 (2) 4 (2) 
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Histidine triad nucleotide-binding 
protein 1 Hint1  HINT1_RAT P62959 76 4 (2) 3 (2) 
Histone H2A type 1-C - H2A1C_RAT P0C169 374 11 (9) 7 (7) 
Histone H2B type 1 - H2B1_RAT Q00715 380 10 (8) 8 (8) 
Histone H3.1 - H31_RAT Q6LED0 45 2 (1) 2 (1) 
Histone H4  Hist1h4b  H4_RAT P62804 365 12 (9) 12 (9) 
Ig gamma-2A chain C region Igg-2a IGG2A_RAT P20760 48 4 (2) 4 (2) 
Keratin, type I cytoskeletal 10 Krt10 K1C10_RAT Q6IFW6 31 1 (1) 1 (1) 
Keratin, type I cytoskeletal 19 Krt19  K1C19_RAT Q63279 157 11 (8) 4 (2) 
Keratin, type II cytoskeletal 1 Krt1 K2C1_RAT Q6IMF3 40 6 (1) 4 (1) 
Keratin, type II cytoskeletal 6A  Krt6a K2C6A_RAT Q4FZU2 219 14 (9) 5 (4) 
Long-chain-fatty-acid--CoA ligase 1  Acsl1  ACSL1_RAT P18163 280 17 (11) 5 (4) 
Long-chain-fatty-acid--CoA ligase 6  Acsl6  ACSL6_RAT P33124 35 2 (1) 2 (1) 
Lumican  Lum  LUM_RAT P51886 102 5 (3) 3 (3) 
Macrophage-capping protein Capg CAPG_RAT Q6AYC4 156 3 (3) 3 (3) 
Malate dehydrogenase, cytoplasmic Mdh1 MDHC_RAT O88989 111 6 (3) 6 (3) 
Malate dehydrogenase, mitochondrial Mdh2  MDHM_RAT P04636 83 7 (5) 3 (3) 
Membrane primary amine oxidase Aoc3 AOC3_RAT O08590 89 4 (2) 4 (2) 
Myosin light polypeptide 6 Myl6 MYL6_RAT Q64119 34 3 (1) 3 (1) 
Myosin regulatory light chain RLC-A  Rlc-a MRLCA_RAT P13832 96 2 (2) 1 (1) 
Myosin regulatory light polypeptide 9  Myl9  MYL9_RAT Q64122 43 7 (1) 7 (1) 
Myosin-11 Myh11 MYH11_RAT Q63862 179 5 (5) 5 (5) 
NADH-cytochrome b5 reductase 3  Cyb5r3 NB5R3_RAT P20070 89 3 (2) 2 (1) 
Nidogen-2 Nid2 NID2_RAT B5DFC9 79 6 (2) 4 (2) 
Nucleoside diphosphate kinase B  Nme2 NDKB_RAT P19804 40 2 (2) 2 (2) 
Peptidyl-prolyl cis-trans isomerase A Ppia PPIA_RAT P10111 69 15 (3) 10 (3) 
Peroxiredoxin-1  Prdx1  PRDX1_RAT Q63716 80 7 (3) 7 (3) 
Peroxiredoxin-2 Prdx2  PRDX2_RAT P35704 62 5 (1) 5 (1) 
Phosphoglycerate kinase 1 Pgk1 PGK1_RAT P16617 101 9 (3) 9 (3) 
Polymerase I and transcript release 
factor  Ptrf PTRF_RAT P85125 63 3 (1) 3 (1) 
Prelamin-A/C  Lmna LMNA_RAT P48679 29 2 (1) 2 (1) 
Profilin-1  Pfn1 PROF1_RAT P62963 137 3 (3) 3 (3) 
Protein disulfide-isomerase A3  Pdia3 PDIA3_RAT P11598 107 4 (3) 4 (3) 
Protein disulfide-isomerase A6 Pdia6  PDIA6_RAT Q63081 33 1 (1) 1 (1) 
Protein phosphatase 1 regulatory 
subunit 7  Ppp1r7 PP1R7_RAT Q5HZV9 159 3 (3) 3 (3) 
Protein S100-A10 S100a10 S10AA_RAT P05943 106 6 (4) 4 (3) 
Ras-related C3 botulinum toxin 
substrate 1 Rac1 RAC1_RAT Q6RUV5 29 3 (1) 3 (1) 
Rho GDP-dissociation inhibitor 1 Arhgdia GDIR1_RAT Q5XI73 45 2 (1) 2 (1) 
Serotransferrin  Tf TRFE_RAT P12346 62 3 (2) 3 (2) 
Serpin H1 Serpinh1  SERPH_RAT P29457 105 2 (2) 2 (2) 
Serum albumin Alb ALBU_RAT P02770 90 4 (1) 3 (1) 
SPARC Sparc SPRC_RAT P16975 67 3 (3) 3 (3) 
Spectrin alpha chain, non-erythrocytic 1  Sptan1 SPTN1_RAT P16086 41 2 (1) 2 (1) 
  
Appendix – Supplementary data 
110
Superoxide dismutase [Cu-Zn]  Sod1 SODC_RAT P07632 100 20 (3) 18 (3) 
Thioredoxin Txn THIO_RAT P11232 142 6 (6) 3 (3) 
Transgelin Tagln TAGL_RAT P31232 355 15 (10) 9 (5) 
Triosephosphate isomerase  Tpi1 TPIS_RAT P48500 106 7 (4) 6 (4) 
Tropomyosin alpha-3 chain  Tpm3 TPM3_RAT Q63610 198 8 (6) 6 (5) 
Tropomyosin alpha-4 chain Tpm4 TPM4_RAT P09495 87 5 (4) 5 (4) 
Tropomyosin beta chain  Tpm2 TPM2_RAT P58775 76 2 (2) 2 (2) 
Tubulin alpha-1B chain  Tuba1b TBA1B_RAT Q6P9V9 52 2 (1) 1 (1) 
Tubulin beta-2A chain Tubb2a TBB2A_RAT P85108 182 15 (7) 10 (5) 
Tubulin beta-4B chain Tubb4b  TBB4B_RAT Q6P9T8 179 14 (7) 10 (5) 
Tubulin beta-5 chain Tubb5 TBB5_RAT P69897 227 16 (9) 15 (9) 
Ubiquitin-conjugating enzyme E2 N  Ube2n UBE2N_RAT Q9EQX9 59 2 (1) 2 (1) 
Vimentin Vim VIME_RAT P31000 715 31 (25) 20 (17) 
 
 
 
Supplemental Table B 4 - Proteins of epicardial adipose tissue extracted from protocol - Tris 
Protein name Gene name Entry name 
Accession 
number 
Mascot 
score 
Matching 
peptides 
Sequence 
coverage 
Alpha-1-macroglobulin  A1m  A1M_RAT Q63041 59 5 (4) 5 (4) 
Aconitate hydratase, 
mitochondrial  Aco2 ACON_RAT Q9ER34 38 1 (1) 1 (1) 
Actin, aortic smooth muscle Acta2  ACTA_RAT P62738 160 5 (5) 5 (5) 
Actin, cytoplasmic 1 Actb ACTB_RAT P60711 263 7 (7) 7 (7) 
Serum albumin Alb ALBU_RAT P02770 627 24 (21) 18 (15) 
Annexin A2  Anxa2 ANXA2_RAT Q07936 184 6 (5) 6 (5) 
Casein kinase II subunit alpha Csnk2a1 CSK21_RAT P19139 16 9 (1) 2 (1) 
Fibrinogen alpha chain Fga FIBA_RAT P06399 351 17 (10) 11 (7) 
Fibrinogen beta chain Fgb FIBB_RAT P14480 348 13 (10) 10 (8) 
Fibrinogen gamma chain Fgg FIBG_RAT P02680 133 13 (9) 10 (7) 
Fibronectin Fn1 FINC_RAT P04937 42 7 (1) 6 (1) 
Histone H2A type 1-C - H2A1C_RAT P0C169 175 2 (2) 2 (2) 
Histone H3.1 - H31_RAT Q6LED0 77 6 (2) 3 (2) 
Hemoglobin subunit alpha-1/2  Hba1 HBA_RAT P01946 588 7 (6) 5 (4) 
Hemoglobin subunit beta-2 - HBB2_RAT P11517 748 10 (10) 8 (8) 
Hemoglobin subunit beta-1 Hbb HBB1_RAT P02091 376 7 (7) 6 (6) 
Lumican  Lum  LUM_RAT P51886 28 2 (1) 2 (1) 
Murinoglobulin-1  Mug1  MUG1_RAT Q03626 33 6 (3) 6 (3) 
Decorin  Dcn PGS2_RAT Q01129 51 2 (1) 2 (1) 
Plectin Plec  PLEC_RAT P30427 27 11 (1) 11 (1) 
Prolargin Prelp PRELP_RAT Q9EQP5 34 1 (1) 1 (1) 
Serpin H1  Serpinh1  SERPH_RAT P29457 77 2 (1) 2 (1) 
Serine protease inhibitor A3N  Serpina3n SPA3N_RAT P09006 65 2 (1) 2 (1) 
Tubulin alpha-1A chain  Tuba1a TBA1A_RAT P68370 61 2 (1) 2 (1) 
Serotransferrin Tf TRFE_RAT P12346 183 6 (5) 5 (4) 
Vimentin Vim VIME_RAT P31000 42 2 (1) 2 (1) 
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Supplemental Table B 5 - Proteins of epicardial adipose tissue extracted from protocol - Urea 
Protein name Gene name Entry name 
Accession 
number 
Mascot 
score 
Matching 
peptides 
Sequence 
coverage 
14-3-3 protein gamma Ywhag 1433G_RAT P61983 32 3 (2) 2 (2) 
Alpha-1-acid glycoprotein  Orm1 A1AG_RAT P02764 31 2 (1) 2 (1) 
Alpha-1-antiproteinase Serpina1 A1AT_RAT P17475 39 1 (1) 1 (1) 
Alpha-1-inhibitor 3  A1i3  A1I3_RAT P14046 182 8 (6) 8 (6) 
Alpha-1-macroglobulin  A1m A1M_RAT Q63041 194 9 (4) 9 (4) 
Aconitate hydratase, mitochondrial  Aco2 ACON_RAT Q9ER34 329 19 (10) 15 (10) 
Actin, cytoplasmic 1 Actb ACTB_RAT P60711 50 5 (1) 4 (1) 
Actin, alpha cardiac muscle 1  Actc1  ACTC_RAT P68035 570 26 (17) 12 (9) 
Alpha-actinin-1  Actn1 ACTN1_RAT Q9Z1P2 337 17 (12) 9 (7) 
Serum albumin Alb ALBU_RAT P02770 51 9 (1) 8 (1) 
Aldehyde dehydrogenase, mitochondrial  Aldh2 ALDH2_RAT P11884 2287 58 (48) 26 (22) 
Fructose-bisphosphate aldolase A Aldoa ALDOA_RAT P05065 35 4 (2) 4 (2) 
Annexin A2  Anxa2  ANXA2_RAT Q07936 55 4 (2) 3 (2) 
Annexin A3  Anxa3  ANXA3_RAT P14669 229 8 (5) 8 (5) 
Annexin A6 Anxa6 ANXA6_RAT P48037 73 7 (3) 4 (2) 
Annexin A5  Anxa5 ANXA5_RAT P14668 211 11 (5) 11 (5) 
Annexin A1 Anxa1  ANXA1_RAT P07150 185 8 (7) 8 (7) 
Membrane primary amine oxidase  Aoc3 AOC3_RAT O08590 54 5 (1) 5 (1) 
Apolipoprotein A-I  Apoa1 APOA1_RAT P04639 31 5 (1) 2 (1) 
Beta-2-glycoprotein 1  Apoh APOH_RAT P26644 321 15 (10) 15 (10) 
Apolipoprotein E  Apoe APOE_RAT P02650 156 8 (5) 7 (5) 
ATP synthase subunit alpha, 
mitochondrial Atp5a1 ATPA_RAT P15999 61 4 (3) 4 (3) 
ATP synthase subunit beta, 
mitochondrial Atp5b ATPB_RAT P10719 62 2 (1) 2 (1) 
Cadherin-23  Cdh23 CAD23_RAT P58365 253 11 (5) 10 (5) 
Carbonic anhydrase 2  Ca2 CAH2_RAT P27139 36 10 (3) 6 (1) 
Carbonic anhydrase 3  Ca3 CAH3_RAT P14141 38 6 (2) 3 (2) 
Catalase  Cat  CATA_RAT P04762 241 9 (7) 8 (7) 
Carbonyl reductase [NADPH] 1  Cbr1  CBR1_RAT P47727 124 8 (5) 8 (5) 
Ceruloplasmin  Cp CERU_RAT P13635 47 1 (1) 1 (1) 
60 kDa heat shock protein, mitochondrial  Hspd1  CH60_RAT P63039 96 6 (3) 6 (3) 
Citrate synthase, mitochondrial Cs CISY_RAT Q8VHF5 41 4 (1) 4 (1) 
Collagen alpha-1(I) chain  Col1a1 CO1A1_RAT P02454 48 6 (2) 6 (2) 
C-reactive protein Crp  CRP_RAT P48199 182 6 (3) 6 (3) 
Alpha-enolase  Eno1  ENOA_RAT P04764 36 4 (1) 3 (1) 
Beta-enolase  Eno3  ENOB_RAT P15429 45 5 (2) 5 (2) 
Endoplasmin Hsp90b1  ENPL_RAT Q66HD0 77 4 (2) 4 (2) 
Fatty acid-binding protein, adipocyte  Fabp4 FABP4_RAT P70623 31 2 (2) 2 (2) 
Alpha-2-HS-glycoprotein Ahsg FETUA_RAT P24090 50 2 (2) 1 (1) 
Fibrinogen alpha chain  Fga FIBA_RAT P06399 126 5 (3) 5 (3) 
Fibrinogen beta chain Fgb FIBB_RAT P14480 378 18 (15) 10 (9) 
Fibrinogen gamma chain Fgg FIBG_RAT P02680 463 20 (15) 15 (12) 
Fibronectin (FN) Fn1 FINC_RAT P04937 166 10 (6) 6 (5) 
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Gelsolin  Gsn GELS_RAT Q68FP1 184 22 (8) 19 (8) 
Glycerol-3-phosphate dehydrogenase 
[NAD(+)], cytoplasmic  Gpd1 GPDA_RAT O35077 78 6 (2) 3 (1) 
Glutathione peroxidase 3  Gpx3 GPX3_RAT P23764 44 2 (1) 2 (1) 
78 kDa glucose-regulated protein  Hspa5 GRP78_RAT P06761 39 2 (1) 2 (1) 
Glutathione S-transferase alpha-3  Gsta3  GSTA3_RAT P04904 118 4 (2) 4 (2) 
Glutathione S-transferase P  Gstp1 GSTP1_RAT P04906 34 3 (1) 3 (1) 
Guanine deaminase  Gda GUAD_RAT Q9WTT6 36 3 (2) 3 (2) 
Histone H2A type 1-C - H2A1C_RAT P0C169 100 1 (1) 1 (1) 
Hemoglobin subunit alpha-1/2 Hba1  HBA_RAT P01946 528 22 (16) 6 (6) 
Hemoglobin subunit beta-2  - HBB2_RAT P11517 1157 32 (23) 10 (10) 
Hemoglobin subunit beta-1 Hbb HBB1_RAT P02091 874 27 (18) 10 (9) 
Hemopexin Hpx HEMO_RAT P20059 118 5 (3) 5 (3) 
Heat shock cognate 71 kDa protein Hspa8  HSP7C_RAT P63018 247 5 (4) 5 (4) 
Heat shock protein beta-1 Hspb1  HSPB1_RAT P42930 35 4 (1) 3 (1) 
Ig gamma-2A chain C region Igg-2a IGG2A_RAT P20760 78 3 (1) 3 (1) 
Keratin, type I cytoskeletal 10 Krt10  K1C10_RAT Q6IFW6 58 5 (2) 3 (1) 
Keratin, type II cytoskeletal 1b Krt77  K2C1B_RAT Q6IG01 103 6 (4) 3 (2) 
Keratin, type II cytoskeletal 6A  Krt6a K2C6A_RAT Q4FZU2 33 8 (2) 4 (2) 
Creatine kinase M-type  Ckm  KCRM_RAT P00564 146 11 (5) 9 (5) 
T-kininogen 1  Map1 KNT1_RAT P01048 83 4 (3) 4 (3) 
Galectin-1  Lgals1 LEG1_RAT P11762 46 1 (1) 1 (1) 
Galectin-3 Lgals3 LEG3_RAT P08699 74 3 (3) 3 (3) 
Prelamin-A/C  Lmna  LMNA_RAT P48679 118 14 (5) 12 (5) 
Lumican  Lum LUM_RAT P51886 358 16 (12) 9 (9) 
Mast cell protease 1  Mcpt1 MCPT1_RAT P09650 47 2 (2) 1 (1) 
Myosin regulatory light chain RLC-A  Rlc-a MRLCA_RAT P13832 41 1 (1) 1 (1) 
Murinoglobulin-1 Mug1 MUG1_RAT Q03626 153 8 (4) 8 (4) 
Myosin light polypeptide 6 Myl6 MYL6_RAT Q64119 71 5 (2) 5 (2) 
Myelin protein P0  Mpz MYP0_RAT P06907 380 13 (10) 6 (4) 
NADH-cytochrome b5 reductase 3  Cyb5r3  NB5R3_RAT P20070 106 4 (3) 4 (3) 
Neurofilament light polypeptide  Nefl  NFL_RAT P19527 54 9 (3) 7 (3) 
Nidogen-2 Nid2 NID2_RAT B5DFC9 58 14 (4) 11 (4) 
Protein disulfide-isomerase A3  Pdia3 PDIA3_RAT P11598 43 2 (1) 2 (1) 
Protein disulfide-isomerase P4hb  PDIA1_RAT P04785 52 5 (2) 5 (2) 
Phosphoglycerate kinase 1  Pgk1 PGK1_RAT P16617 39 4 (1) 4 (1) 
Plasminogen Plg PLMN_RAT Q01177 35 3 (1) 3 (1) 
Serum paraoxonase/arylesterase 1 Pon1 PON1_RAT P55159 71 2 (1) 2 (1) 
Peptidyl-prolyl cis-trans isomerase A  Ppia PPIA_RAT P10111 34 3 (1) 3 (1) 
Periaxin Prx PRAX_RAT Q63425 70 15 (4) 12 (4) 
Prolargin Prelp PRELP_RAT Q9EQP5 134 10 (7) 10 (7) 
Polymerase I and transcript release factor  Ptrf PTRF_RAT P85125 42 5 (2) 4 (2) 
Ras-related C3 botulinum toxin substrate 
1 Rac1 RAC1_RAT Q6RUV5 34 6 (1) 3 (1) 
Serpin H1 Serpinh1  SERPH_RAT P29457 38 5 (2) 3 (2) 
Serine protease inhibitor A3K Serpina3k  SPA3K_RAT P05545 126 7 (2) 7 (2) 
Serine protease inhibitor A3N  Serpina3n SPA3N_RAT P09006 100 8 (2) 7 (2) 
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Spectrin alpha chain, non-erythrocytic 1 Sptan1 SPTN1_RAT P16086 190 27 (7) 23 (7) 
Tubulin alpha-1B chain Tuba1b  TBA1B_RAT Q6P9V9 160 11 (4) 8 (4) 
Tubulin beta-3 chain Tubb3 TBB3_RAT Q4QRB4 176 7 (3) 7 (3) 
Tubulin beta-4B chain Tubb4b  TBB4B_RAT Q6P9T8 170 10 (5) 10 (5) 
Tropomyosin beta chain  Tpm2 TPM2_RAT P58775 88 7 (4) 4 (3) 
Tropomyosin alpha-3 chain  Tpm3  TPM3_RAT Q63610 137 11 (5) 9 (5) 
Tropomyosin alpha-4 chain 
(Tropomyosin-4) (TM-4) Tpm4 TPM4_RAT P09495 148 9 (4) 7 (4) 
Serotransferrin Tf TRFE_RAT P12346 643 25 (18) 19 (16) 
Voltage-dependent anion-selective 
channel protein 1  Vdac1 VDAC1_RAT Q9Z2L0 33 3 (1) 3 (1) 
Vimentin Vim VIME_RAT P31000 540 23 (17) 13 (11) 
Vitamin D-binding protein  Gc VTDB_RAT P04276 58 6 (2) 5 (2) 
 
 
 
Supplemental Table B 6 - Proteins of epicardial adipose tissue extracted from protocol – Tris and Urea 
Protein name Gene name Entry name 
Accession 
number 
Mascot 
score 
Matching 
peptides 
Sequence 
coverage 
14-3-3 protein gamma Ywhag 1433G_RAT P61983 37 1 (1) 1 (1) 
14-3-3 protein epsilon  Ywhae 1433E_RAT P62260 30 2 (1) 2 (1) 
Alpha-1-antiproteinase Serpina1 A1AT_RAT P17475 39 1 (1) 1 (1) 
Alpha-1-inhibitor 3 A1i3  A1I3_RAT P14046 70 3 (3) 3 (3) 
Alpha-1-macroglobulin A1m A1M_RAT Q63041 167 11 (4) 10 (4) 
Aconitate hydratase, mitochondrial  Aco2 ACON_RAT Q9ER34 514 27 (17) 19 (16) 
Long-chain-fatty-acid--CoA ligase 6  Acsl6  ACSL6_RAT P33124 84 6 (1) 5 (1) 
Actin, cytoplasmic 1 (Beta-actin) Actb ACTB_RAT P60711 34 4 (1) 4 (1) 
Actin, alpha cardiac muscle 1  Actc1  ACTC_RAT P68035 552 24 (17) 18 (13) 
Serum albumin Alb ALBU_RAT P02770 381 16 (12) 11 (9) 
Aldehyde dehydrogenase, 
mitochondrial  Aldh2 ALDH2_RAT P11884 1804 54 (43) 25 (21) 
Fructose-bisphosphate aldolase A Aldoa ALDOA_RAT P05065 45 2 (2) 2 (2) 
Aldose reductase  Akr1b1 ALDR_RAT P07943 48 3 (2) 3 (2) 
Ankyrin repeat domain-containing 
protein 54 Ankrd54 ANR54_RAT Q566C8 33 2 (1) 2 (1) 
Annexin A2  Anxa2  ANXA2_RAT Q07936 27 4 (1) 1 (1) 
Annexin A5 Anxa5  ANXA5_RAT P14668 280 11 (8) 7 (6) 
Annexin A1  Anxa1  ANXA1_RAT P07150 377 15 (10) 11 (8) 
Membrane primary amine oxidase  Aoc3 AOC3_RAT O08590 190 7 (7) 7 (7) 
Apolipoprotein A-I  Apoa1 APOA1_RAT P04639 62 6 (3) 3 (2) 
Apolipoprotein A-IV  Apoa4 APOA4_RAT P02651 143 9 (6) 7 (6) 
Beta-2-glycoprotein 1  Apoh APOH_RAT P26644 32 4 (2) 4 (2) 
Apolipoprotein E  Apoe APOE_RAT P02650 111 8 (5) 7 (5) 
ATP synthase subunit beta, 
mitochondrial  Atp5b ATPB_RAT P10719 33 3 (1) 2 (1) 
Protein bassoon Bsn BSN_RAT O88778 236 12 (5) 9 (5) 
Cadherin-23  Cdh23 CAD23_RAT P58365 28 7 (1) 7 (1) 
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Carbonic anhydrase 2 Ca2 CAH2_RAT P27139 47 11 (1) 7 (1) 
Carbonic anhydrase 3  Ca3 CAH3_RAT P14141 49 4 (1) 3 (1) 
Catalase Cat  CATA_RAT P04762 159 8 (5) 8 (5) 
Mast cell carboxypeptidase A  Cpa3 CBPA3_RAT P21961 60 5 (3) 5 (3) 
Carbonyl reductase [NADPH] 1  Cbr1  CBR1_RAT P47727 244 12 (10) 7 (5) 
Cadherin EGF LAG seven-pass G-
type receptor 3  Celsr3  CELR3_RAT O88278 46 1 (1) 1 (1) 
Ceruloplasmin  Cp CERU_RAT P13635 28 14 (1) 13 (1) 
Citrate synthase, mitochondrial  Cs CISY_RAT Q8VHF5 66 6 (4) 5 (4) 
C-reactive protein Crp CRP_RAT P48199 63 4 (1) 4 (1) 
Alpha-enolase Eno1 ENOA_RAT P04764 41 3 (1) 2 (1) 
Fatty acid-binding protein, adipocyte Fabp4 FABP4_RAT P70623 112 4 (3) 3 (3) 
Fibrinogen alpha chain  Fga FIBA_RAT P06399 65 3 (1) 2 (1) 
Fibrinogen beta chain Fgb  FIBB_RAT P14480 1348 43 (34) 15 (13) 
Fibrinogen gamma chain Fgg FIBG_RAT P02680 735 24 (20) 15 (13) 
Fibronectin Fn1 FINC_RAT P04937 320 21 (19) 11 (10) 
Gelsolin  Gsn GELS_RAT Q68FP1 102 20 (5) 16 (5) 
Glycerol-3-phosphate dehydrogenase 
[NAD(+)], cytoplasmic  Gpd1 GPDA_RAT O35077 25 4 (1) 4 (1) 
78 kDa glucose-regulated protein Hspa5  GRP78_RAT P06761 32 1 (1) 1 (1) 
Guanine deaminase  Gda GUAD_RAT Q9WTT6 56 5 (2) 5 (2) 
Histone H2A type 1-C  H2A1C_RAT P0C169 72 3 (2) 3 (2) 
Histone H2B type 1  H2B1_RAT Q00715 67 2 (2) 1 (1) 
Hemoglobin subunit alpha-1/2  Hba1  HBA_RAT P01946 1099 19 (17) 7 (6) 
Hemoglobin subunit beta-2   HBB2_RAT P11517 1459 31 (30) 8 (8) 
Hemoglobin subunit beta-1 Hbb HBB1_RAT P02091 1315 27 (25) 9 (8) 
Hemopexin Hpx HEMO_RAT P20059 69 5 (2) 5 (2) 
Haptoglobin Hp  HPT_RAT P06866 26 5 (1) 4 (1) 
Heat shock-related 70 kDa protein 2 Hspa2  HSP72_RAT P14659 52 7 (1) 7 (1) 
Ig gamma-2A chain C region Igg-2a IGG2A_RAT P20760 49 3 (1) 3 (1) 
Keratin, type I cytoskeletal 10  Krt10  K1C10_RAT Q6IFW6 96 12 (6) 5 (2) 
Keratin, type I cytoskeletal 17  Krt17  K1C17_RAT Q6IFU8 37 5 (2) 3 (1) 
Keratin, type II cytoskeletal 6A  Krt6a K2C6A_RAT Q4FZU2 324 14 (10) 5 (3) 
Keratin, type II cytoskeletal 1 Krt1 K2C1_RAT Q6IMF3 193 11 (10) 5 (4) 
Creatine kinase M-type  Ckm  KCRM_RAT P00564 68 4 (2) 3 (2) 
KH domain-containing, RNA-
binding, signal transduction-
associated protein 2 
Khdrbs2  KHDR2_RAT Q920F3 
25 4 (1) 3 (1) 
T-kininogen 1 Map1 KNT1_RAT P01048 30 4 (1) 4 (1) 
Galectin-1 Lgals1 LEG1_RAT P11762 44 1 (1) 1 (1) 
Galectin-3 Lgals3 LEG3_RAT P08699 69 3 (2) 3 (2) 
Prelamin-A/C Lmna  LMNA_RAT P48679 27 10 (1) 9 (1) 
Latrophilin-2 Lphn2 LPHN2_RAT O88923 27 3 (1) 3 (1) 
Lumican Lum  LUM_RAT P51886 55 5 (5) 3 (3) 
Myelin basic protein  Mbp MBP_RAT P02688 60 4 (2) 4 (2) 
Monoglyceride lipase  Mgll  MGLL_RAT Q8R431 28 2 (1) 2 (1) 
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Multidrug resistance-associated 
protein 6  Abcc6  MRP6_RAT O88269 27 5 (1) 2 (1) 
Murinoglobulin-1 Mug1  MUG1_RAT Q03626 185 12 (5) 11 (5) 
Myosin light polypeptide 6 Myl6 MYL6_RAT Q64119 62 1 (1) 1 (1) 
Myelin protein P0 Mpz P0 MYP0_RAT P06907 285 10 (6) 5 (3) 
NADH-cytochrome b5 reductase 3  Cyb5r3 NB5R3_RAT P20070 54 3 (1) 3 (1) 
Nucleoside diphosphate kinase A  Nme1 NDKA_RAT Q05982 26 1 (1) 1 (1) 
Neurofilament light polypeptide Nefl  NFL_RAT P19527 35 6 (3) 6 (3) 
Phosphoglycerate kinase 1  Pgk1  PGK1_RAT P16617 56 3 (1) 3 (1) 
Decorin Dcn PGS2_RAT Q01129 114 5 (3) 4 (2) 
Serum paraoxonase/arylesterase 1 Pon1  PON1_RAT P55159 100 1 (1) 1 (1) 
Peptidyl-prolyl cis-trans isomerase A  Ppia PPIA_RAT P10111 26 1 (1) 1 (1) 
Ryanodine receptor 2 Ryr2 RYR2_RAT B0LPN4 35 28 (10) 10 (1) 
Serpin H1 Serpinh1  SERPH_RAT P29457 100 5 (1) 4 (1) 
Serine protease inhibitor A3K  Serpina3k  SPA3K_RAT P05545 65 3 (2) 3 (2) 
Serine protease inhibitor A3N  Serpina3n SPA3N_RAT P09006 31 2 (2) 2 (2) 
Spectrin alpha chain, non-
erythrocytic 1 Sptan1 SPTN1_RAT P16086 35 23 (1) 14 (1) 
Synaptonemal complex protein 3 Sycp3 SYCP3_RAT Q63520 27 4 (1) 4 (1) 
Synaptotagmin-like protein 5 Sytl5  SYTL5_RAT Q812E4 28 7 (1) 4 (1) 
Tubulin alpha-1A chain Tuba1a  TBA1A_RAT P68370 128 9 (5) 4 (2) 
3-ketoacyl-CoA thiolase, 
mitochondrial  Acaa2 THIM_RAT P13437 51 4 (2) 4 (2) 
Tropomyosin alpha-1 chain  Tpm1  TPM1_RAT P04692 43 9 (2) 6 (2) 
Tropomyosin alpha-4 chain  Tpm4 TPM4_RAT P09495 62 9 (2) 7 (2) 
Serotransferrin Tf TRFE_RAT P12346 517 19 (15) 17 (13) 
Vimentin Vim VIME_RAT P31000 500 20 (15) 16 (14) 
Vitamin D-binding protein Gc  VTDB_RAT P04276 37 2 (1) 2 (1) 
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Appendix C – Identified proteins of visceral and epicardial 
adipose tissue 
Supplemental Table C 1 - Proteins of visceral adipose tissue identified in lean ZSF1 
Entry Entry name Protein Name 
Gene 
name 
MW 
(kDa) 
Q6QA69  ABHD5_RAT 1-acylglycerol-3-phosphate O-acyltransferase ABHD5 Abhd5 39079 
P60711  ACTB_RAT Actin, cytoplasmic 1 Actb 41710 
P85970 ARPC2_RAT Actin-related protein 2/3 complex subunit 2  Arpc2 34370 
Q5XI32  CAPZB_RAT F-actin-capping protein subunit beta Capzb 30609 
P41350  CAV1_RAT Caveolin-1 Cav1  20539 
P10252  CD48_RAT CD48 antigen  Cd48  27662 
P26772  CH10_RAT 10 kDa heat shock protein, mitochondrial Hspe1 10895 
P45592  COF1_RAT Cofilin-1 Cfl1 18521 
Q91ZN1  COR1A_RAT Coronin-1A Coro1a  51033 
P63255  CRIP1_RAT Cysteine-rich protein 1  Crip1  8544 
P10860  DHE3_RAT Glutamate dehydrogenase 1, mitochondrial Glud1  61377 
Q4KLP0 DHTK1_RAT Probable 2-oxoglutarate dehydrogenase E1 component DHKTD1, mitochondrial  Dhtkd1 102576 
P31977  EZRI_RAT Ezrin  Ezr  69348 
P63245  GBLP_RAT Guanine nucleotide-binding protein subunit beta-2-like 1 Gnb2l1 35055 
P48721  GRP75_RAT Stress-70 protein, mitochondria Hspa9  73812 
P0C169  H2A1C_RAT Histone H2A type 1-C type-1c 14097 
P62804  H4_RAT Histone H4 Hist1h4b 11360 
P82995  HS90A_RAT Heat shock protein HSP 90-alpha  Hsp90aa1  84762 
P35704  PRDX2_RAT Peroxiredoxin-2 Prdx2  21770 
Q9Z0V6  PRDX3_RAT Thioredoxin-dependent peroxide reductase, mitochondrial  Prdx3 28277 
Q63797  PSME1_RAT Proteasome activator complex subunit 1 Psme1 28559 
Q63798  PSME2_RAT Proteasome activator complex subunit 2 Psme2 26840 
P09527  RAB7A_RAT Ras-related protein Rab-7a Rab7a  23489 
P62494  RB11A_RAT Ras-related protein Rab-11A Rab11a  24378 
P19945  RLA0_RAT 60S acidic ribosomal protein P0 Rplp0 Arbp 34194 
P19944  RLA1_RAT 60S acidic ribosomal protein P1 Rplp1 11491 
P38983  RSSA_RAT 40S ribosomal protein SA Rpsa  32803 
P05964  S10A6_RAT Protein S100-A6 S100a6  10028 
P05943  S10AA_RAT Protein S100-A10 S100a10 11068 
P10960  SAP_RAT Sulfated glycoprotein 1  Psap  61084 
P29457  SERPH_RAT Serpin H1  Serpinh1  46488 
P16086 SPTN1_RAT Spectrin alpha chain, non-erythrocytic 1 Sptan1  284462 
P63029  TCTP_RAT Translationally-controlled tumor protein Tpt1  19450 
P17764  THIL_RAT Acetyl-CoA acetyltransferase, mitochondrial  Acat1 44666 
P50137  TKT_RAT Transketolase Tkt 67601 
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Supplemental Table C 2 - Proteins of visceral adipose tissue identified in obese ZSF1 
Entry Entry name Protein Name Gene name 
MW 
(kDa) 
P63259  ACTG_RAT Actin, cytoplasmic 2 Actg1  41766 
Q9Z1P2  ACTN1_RAT Alpha-actinin-1 Actn1 102896 
P36972  APT_RAT Adenine phosphoribosyltransferase Aprt 19533 
P58365  CAD23_RAT Cadherin-23  Cdh23 365230 
P16303 CES1D_RAT Carboxylesterase 1D  Ces1d  62108 
P61023  CHP1_RAT Calcineurin B homologous protein 1  Chp1  22418 
Q9Z0W7  CLIC4_RAT Chloride intracellular channel protein 4  Clic4 28615 
P08649  CO4_RAT Complement C4 C4  192042 
B0BNA5 COTL1_RAT Coactosin-like protein Cotl1  15922 
Q64537  CPNS1_RAT Calpain small subunit 1 Capns1  28552 
P48675  DESM_RAT Desmin Des 53424 
Q64428  ECHA_RAT Trifunctional enzyme subunit alpha, mitochondrial Hadha 82613 
Q9Z1X1 ESYT1_RAT Extended synaptotagmin-1 Esyt1  121084 
P13803  ETFA_RAT Electron transfer flavoprotein subunit alpha, mitochondrial  Etfa 34929 
Q9WVH8  FBLN5_RAT Fibulin-5 Fbln5  50127 
P24090  FETUA_RAT Alpha-2-HS-glycoprotein  Ahsg  37958 
Q9QX79  FETUB_RAT Fetuin-B Fetub 41506 
P47819  GFAP_RAT Glial fibrillary acidic protein Gfap 49927 
O35077  GPDA_RAT Glycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic  Gpd1 37428 
Q99NA5  IDH3A_RAT Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial Idh3a 39588 
Q3T1J1  IF5A1_RAT Eukaryotic translation initiation factor 5A-1  Eif5a 16821 
Q63862  MYH11_RAT Myosin-11 Myh11 152398 
Q62812  MYH9_RAT Myosin-9 Myh9 226197 
O35264  PA1B2_RAT Platelet-activating factor acetylhydrolase IB subunit beta  Pafah1b2  25565 
P47853  PGS1_RAT Biglycan  Bgn 41680 
O35244  PRDX6_RAT Peroxiredoxin-6 Prdx6  24803 
Q8VHE9  RETST_RAT All-trans-retinol 13,14-reductase  Retsat  67487 
P09006  SPA3N_RAT Serine protease inhibitor A3N Serpina3n 46622 
Q505J8  SYFA_RAT Phenylalanine--tRNA ligase alpha subunit Farsa  57684 
Q5XFX0 TAGL2_RAT Transgelin-2 Tagln2 22379 
P85108  TBB2A_RAT Tubulin beta-2A chain Tubb2a 49875 
P69897  TBB5_RAT Tubulin beta-5 chain Tubb5 49639 
Q9EQT5  TINAL_RAT Tubulointerstitial nephritis antigen-like  Tinagl1 52786 
Q7M767  UB2V2_RAT Ubiquitin-conjugating enzyme E2 variant 2   16342 
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Supplemental Table C 3 - Visceral adipose tissue common proteins between obese and lean ZSF1 model 
Entry Entry Name Protein name Gene name 
emPAI 
ratio 
MW 
(kDa) 
P19804 NDKB_RAT Nucleoside diphosphate kinase B  Nme2 2.89 17272 
P02466 CO1A2_RAT Collagen alpha-2(I) chain Col1a2 2.67 129486 
P12346 TRFE_RAT Serotransferrin (Transferrin)  Tf 2.53 76346 
P14668 ANXA5_RAT Annexin A5 Anxa5  2.02 35722 
P02793 FRIL1_RAT Ferritin light chain 1 Ftl1  1.51 20736 
P08699 LEG3_RAT Galectin-3  Lgals3 1.38 27184 
P02454 CO1A1_RAT Collagen alpha-1(I) chain Col1a1 1.33 137869 
P42930 HSPB1_RAT Heat shock protein beta-1  Hspb1  1.30 22879 
P09495 TPM4_RAT Tropomyosin alpha-4 chain Tpm4 1.23 28492 
Q4V8H8 EHD2_RAT EH domain-containing protein 2 Ehd2 1.18 61199 
P17475 A1AT_RAT Alpha-1-antiproteinase Serpina1 1.14 46107 
P11598 PDIA3_RAT Protein disulfide-isomerase A3 Pdia3  1.11 56588 
P55260 ANXA4_RAT Annexin A4 Anxa4  1.08 35826 
Q63716 PRDX1_RAT Peroxiredoxin-1  Prdx1  1.06 22095 
P35565 CALX_RAT Calnexin Canx 1.00 67213 
P07150 ANXA1_RAT Annexin A1 Anxa1  0.95 38805 
P02091 HBB1_RAT Hemoglobin subunit beta-1 Hbb 0.77 15969 
P02767 TTHY_RAT Transthyretin  Ttr  0.76 15710 
P07632 SODC_RAT Superoxide dismutase Sod1 0.73 15902 
P61983 1433G_RAT 14-3-3 protein gamma Ywhag 0.66 28285 
P70623 FABP4_RAT Fatty acid-binding protein, adipocyte Fabp4 0.57 14699 
P63039 CH60_RAT 60 kDa heat shock protein, mitochondrial Hspd1  0.57 60917 
P04692 TPM1_RAT Tropomyosin alpha-1 chain Tpm1  0.56 32661 
Q9WTT6 GUAD_RAT Guanine deaminase Gda 0.53 50984 
P11762 LEG1_RAT Galectin-1  Lgals1 0.49 14847 
P52555 ERP29_RAT Endoplasmic reticulum resident protein 29 Erp29 0.46 28557 
Q07936 ANXA2_RAT Annexin A2  Anxa2  0.45 38654 
P58775 TPM2_RAT Tropomyosin beta chain Tpm2 0.43 32817 
P25113 PGAM1_RAT Phosphoglycerate mutase 1 Pgam1 0.43 28814 
P02770 ALBU_RAT Serum albumin Alb 0.42 68686 
P31000 VIME_RAT Vimentin Vim 0.41 53700 
P85973 PNPH_RAT Purine nucleoside phosphorylase Pnp  0.38 32281 
P62836 RAP1A_RAT Ras-related protein Rap-1A  Rap1a  0.37 20974 
P05065 ALDOA_RAT Fructose-bisphosphate aldolase A Aldoa 0.35 39327 
P62738 ACTA_RAT Actin, aortic smooth muscle Acta2  0.34 41982 
P04639 APOA1_RAT Apolipoprotein A-I Apoa1 0.29 30043 
P63018 HSP7C_RAT Heat shock cognate 71 kDa protein  Hspa8  0.29 70827 
Q6IMF3 K2C1_RAT Keratin, type II cytoskeletal 1 Krt1  0.20 64791 
P62982 RS27A_RAT Ubiquitin-40S ribosomal protein S27a Rps27a  0.20 17939 
P14141 CAH3_RAT Carbonic anhydrase 3 Ca3 0.19 29413 
P68370 TBA1A_RAT Tubulin alpha-1A chain Tuba1a  0.16 50104 
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Q6P9V9 TBA1B_RAT Tubulin alpha-1B chain  Tuba1b  0.15 50120 
Q6P9T8 TBB4B_RAT Tubulin beta-4B chain Tubb4b  0.12 49769 
P19132 FRIH_RAT Ferritin heavy chain  Fth1  0.05 21113 
P24368 PPIB_RAT Peptidyl-prolyl cis-trans isomerase B  Ppib 0.02 23788 
P04631 S100B_RAT Protein S100-B  S100b 0.01 10737 
P01946 HBA_RAT Hemoglobin subunit alpha-1/2 Hba1  0.01 15319 
P35213 1433B_RAT 14-3-3 protein beta/alpha Ywhab 0.00 28037 
P68255 1433T_RAT 14-3-3 protein theta Ywhaq 0.00 27761 
P18163 ACSL1_RAT Long-chain-fatty-acid--CoA ligase 1 Acsl1 0.00 78128 
P33124 ACSL6_RAT Long-chain-fatty-acid--CoA ligase 6  Acsl6  0.00 78130 
P07943 ALDR_RAT Aldose reductase (AR)  Akr1b1  0.00 35774 
P48037 ANXA6_RAT Annexin A6 Anxa6  0.00 75706 
P35434 ATPD_RAT ATP synthase subunit delta, mitochondrial  Atp5d 0.00 17584 
Q62736 CALD1_RAT Non-muscle caldesmon  Cald1 0.00 60548 
P62161 CALM_RAT Calmodulin  Calm1  0.00 16827 
P18418 CALR_RAT Calreticulin Calr 0.00 47966 
P47727 CBR1_RAT Carbonyl reductase  Cbr1  0.00 30559 
P27274 CD59_RAT CD59 glycoprotein  Cd59 0.00 13781 
P00173 CYB5_RAT Cytochrome b5 Cyb5a  0.00 15346 
P62898 CYC_RAT Cytochrome c, somatic Cycs 0.00 11598 
Q7M0E3 DEST_RAT Destrin Dstn 0.00 18522 
P14604 ECHM_RAT Enoyl-CoA hydratase, mitochondrial Echs1 0.00 31496 
Q66HD0 ENPL_RAT Endoplasmin Hsp90b1  0.00 92713 
Q5XI73 GDIR1_RAT Rho GDP-dissociation inhibitor 1 Arhgdia 0.00 23393 
Q68FP1 GELS_RAT Gelsolin Gsn 0.00 86014 
P04041 GPX1_RAT Glutathione peroxidase 1 Gpx1 0.00 22292 
P04904 GSTA3_RAT Glutathione S-transferase alpha-3 Gsta3  0.00 25303 
P04906 GSTP1_RAT Glutathione S-transferase P Gstp1 0.00 23424 
P11517 HBB2_RAT Hemoglobin subunit beta-2   0.00 15972 
P20059 HEMO_RAT Hemopexin Hpx 0.00 51318 
Q10758 K2C8_RAT Keratin, type II cytoskeletal 8 Krt8  0.00 53985 
P04642 LDHA_RAT L-lactate dehydrogenase A chain  Ldha  0.00 36427 
P48679 LMNA_RAT Prelamin-A/C Lmna  0.00 74279 
P51886 LUM_RAT Lumican Lum  0.00 38255 
O88989 MDHC_RAT Malate dehydrogenase, cytoplasmic  Mdh1  0.00 36460 
P04636 MDHM_RAT Malate dehydrogenase, mitochondrial  Mdh2  0.00 35661 
Q8R431 MGLL_RAT Monoglyceride lipase  Mgll  0.00 33478 
P08011 MGST1_RAT Microsomal glutathione S-transferase 1 Mgst1  0.00 17460 
Q64119 MYL6_RAT Myosin light polypeptide 6  Myl6 0.00 16964 
Q64122 MYL9_RAT Myosin regulatory light polypeptide 9  Myl9  0.00 19708 
P19234 NDUV2_RAT NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial Ndufv2 0.00 27361 
Q63081 PDIA6_RAT Protein disulfide-isomerase A6 Pdia6  0.00 48143 
P70580 PGRC1_RAT Membrane-associated progesterone receptor component 1  Pgrmc1  0.00 21585 
P10111 PPIA_RAT Peptidyl-prolyl cis-trans isomerase A Ppia 0.00 17863 
Q9EQP5 PRELP_RAT Prolargin Prelp 0.00 43152 
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P85125 PTRF_RAT Polymerase I and transcript release factor Ptrf 0.00 43882 
Q6RUV5 RAC1_RAT Ras-related C3 botulinum toxin substrate 1 Rac1 0.00 21436 
B0LPN4 RYR2_RAT Ryanodine receptor 2 Ryr2 0.00 562594 
Q63544 SYUG_RAT Gamma-synuclein Sncg 0.00 12969 
P31232 TAGL_RAT Transgelin Tagln  0.00 22588 
P48500 TPIS_RAT Triosephosphate isomerase Tpi1 0.00 26832 
P85972 VINC_RAT Vinculin Vcl 0.00 116542 
P20070 NB5R3_RAT NADH-cytochrome b5 reductase 3  Cyb5r3  -0.02 34153 
P04785 PDIA1_RAT Protein disulfide-isomerase P4hb  -0.04 56916 
P15999 ATPA_RAT ATP synthase subunit alpha, mitochondrial Atp5a1 -0.17 59717 
Q6IFW6 K1C10_RAT Keratin, type I cytoskeletal 10 Krt10  -0.21 56470 
P10719 ATPB_RAT ATP synthase subunit beta, mitochondrial  Atp5b -0.23 56318 
P62630 EF1A1_RAT Elongation factor 1-alpha 1 Eef1a1  -0.26 50082 
Q63610 TPM3_RAT Tropomyosin alpha-3 chain  Tpm3  -0.26 28989 
Q4FZU2 K2C6A_RAT Keratin, type II cytoskeletal 6A Krt6a -0.26 59213 
P63102 1433Z_RAT 14-3-3 protein zeta/delta  Ywhaz  -0.26 27754 
O35783 CALU_RAT Calumenin Calu -0.27 36973 
A7VJC2 ROA2_RAT Heterogeneous nuclear ribonucleoproteins A2/B1  Hnrnpa2b1 -0.31 37455 
P62963 PROF1_RAT Profilin-1 Pfn1 -0.33 14948 
P40307 PSB2_RAT Proteasome subunit beta type-2  Psmb2 -0.36 22898 
P20760 IGG2A_RAT Ig gamma-2A chain C region Igg-2a -0.37 35163 
P16617 PGK1_RAT Phosphoglycerate kinase 1 Pgk1  -0.38 44510 
P02650 APOE_RAT Apolipoprotein E Apoe -0.39 35731 
P13832 MRLCA_RAT Myosin regulatory light chain RLC-A Rlc-a -0.40 19883 
P06761 GRP78_RAT 78 kDa glucose-regulated protein  Hspa5  -0.48 72302 
P04762 CATA_RAT Catalase Cat -0.48 59719 
P07335 KCRB_RAT Creatine kinase B-type  Ckb  -0.50 42698 
P05545 SPA3K_RAT Serine protease inhibitor A3K  Serpina3k -0.50 46532 
O08590 AOC3_RAT Membrane primary amine oxidase  Aoc3 -0.53 84928 
P11884 ALDH2_RAT Aldehyde dehydrogenase, mitochondrial Aldh2 -0.53 56453 
P62260 1433E_RAT 14-3-3 protein epsilon  Ywhae -0.53 29155 
P27139 CAH2_RAT Carbonic anhydrase 2 Ca2 -0.53 29096 
Q4V7C7 ARP3_RAT Actin-related protein 3 Actr3  -0.53 47327 
Q8CFN2 CDC42_RAT Cell division control protein 42 homolog Cdc42 -0.56 21245 
P04797 G3P_RAT Glyceraldehyde-3-phosphate dehydrogenase Gapdh  -0.68 35805 
Q8VHF5 CISY_RAT Citrate synthase, mitochondrial Cs -0.68 51833 
P43884 PLIN1_RAT Perilipin-1  Plin1  -0.70 55579 
Q9ER34 ACON_RAT Aconitate hydratase, mitochondrial  Aco2 -0.71 85380 
Q9EQX9 UBE2N_RAT Ubiquitin-conjugating enzyme E2 N  Ube2n -0.76 17113 
P04764 ENOA_RAT Alpha-enolase  Eno1  -0.77 47098 
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Supplemental Table C 4 - Proteins of epicardial adipose tissue identified in lean ZSF1 
Entry Entry name Protein name Gene name 
MW 
(kDa) 
P11951 CX6C2_RAT Cytochrome c oxidase subunit 6C-2 Cox6c2 8449 
P35171 CX7A2_RAT Cytochrome c oxidase subunit 7A2, mitochondrial Cox7a2 9347 
Q7TQ16 QCR8_RAT Cytochrome b-c1 complex subunit 8 Uqcrq 9843 
P80254 DOPD_RAT D-dopachrome decarboxylase Ddt 13125 
P47967 LEG5_RAT Galectin-5 Lgals5 16186 
P10888 COX41_RAT Cytochrome c oxidase subunit 4 isoform 1, mitochondrial Cox4i1 19502 
B2RZ37 REEP5_RAT Receptor expression-enhancing protein 5 Reep5 21417 
P35704 PRDX2_RAT Peroxiredoxin-2 Prdx2 21770 
P29117 PPIF_RAT Peptidyl-prolyl cis-trans isomerase F, mitochondrial Ppif 21796 
P31232 TAGL_RAT Transgelin Tagln 22588 
P29410 KAD2_RAT Adenylate kinase 2, mitochondrial Ak2 26363 
P19234 NDUV2_RAT NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial Ndufv2 27361 
P09650 MCPT1_RAT Mast cell protease 1 Mcpt1 28599 
P20788 UCRI_RAT Cytochrome b-c1 complex subunit Rieske, mitochondrial Uqcrfs1 29427 
Q497B0 NIT2_RAT Omega-amidase NIT2 Nit2 30682 
P23965 ECI1_RAT Enoyl-CoA delta isomerase 1, mitochondrial Eci1 32234 
Q09073 ADT2_RAT ADP/ATP translocase 2 Slc25a5 32880 
P97521 MCAT_RAT Mitochondrial carnitine/acylcarnitine carrier protein Slc25a20 33132 
P13086 SUCA_RAT Succinyl-CoA ligase [ADP/GDP-forming] subunit alpha, mitochondrial Suclg1 36125 
Q62651 ECH1_RAT Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial Ech1 36148 
P04642 LDHA_RAT L-lactate dehydrogenase A chain Ldha 36427 
O88989 MDHC_RAT Malate dehydrogenase, cytoplasmic Mdh1 36460 
Q6QA69 ABHD5_RAT 1-acylglycerol-3-phosphate O-acyltransferase ABHD5 Abhd5 39079 
Q924T8 CLTR1_RAT Cysteinyl leukotriene receptor 1 Cysltr1 39117 
Q561S0 NDUAA_RAT NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10, mitochondrial Ndufa10 40468 
P62738 ACTA_RAT Actin, aortic smooth muscle Acta2 41982 
P09606 GLNA_RAT Glutamine synthetase Glul 42240 
Q68FX0 IDH3B_RAT Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Idh3B 42327 
Q5BK63 NDUA9_RAT NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, mitochondrial Ndufa9 42532 
Q9EQP5 PRELP_RAT Prolargin Prelp 43152 
P26284 ODPA_RAT Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial Pdha1 43199 
P15651 ACADS_RAT Short-chain specific acyl-CoA dehydrogenase, mitochondrial Acads 44737 
P12007 IVD_RAT Isovaleryl-CoA dehydrogenase, mitochondrial Ivd 46406 
P08503 ACADM_RAT Medium-chain specific acyl-CoA dehydrogenase, mitochondrial Acadm 46526 
Q01205 ODO2_RAT 
Dihydrolipoyllysine-residue succinyltransferase 
component of 2-oxoglutarate dehydrogenase complex, 
mitochondrial 
Dlst 48894 
P68370 TBA1A_RAT Tubulin alpha-1A chain Tuba1a 50104 
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P56574 IDHP_RAT Isocitrate dehydrogenase [NADP], mitochondrial Idh2 50935 
Q60587 ECHB_RAT Trifunctional enzyme subunit beta, mitochondrial Hadhb 51382 
Q68FY0 QCR1_RAT Cytochrome b-c1 complex subunit 1, mitochondrial Uqcrc1 52815 
Q6P6R2 DLDH_RAT Dihydrolipoyl dehydrogenase, mitochondrial Dld 54004 
P43884 PLIN1_RAT Perilipin-1 Plin1 55579 
P11884 ALDH2_RAT Aldehyde dehydrogenase, mitochondrial Aldh2 56453 
Q6IFW6 K1C10_RAT Keratin, type I cytoskeletal 10 Krt10 56470 
Q02253 MMSA_RAT Methylmalonate-semialdehyde dehydrogenase [acylating], mitochondrial Aldh6a1 57771 
P07633 PCCB_RAT Propionyl-CoA carboxylase beta chain, mitochondrial Pccb 58589 
Q4FZU2 K2C6A_RAT Keratin, type II cytoskeletal 6A Krt6a 59213 
Q4V8H8 EHD2_RAT EH domain-containing protein 2 Ehd2 61199 
P10860 DHE3_RAT Glutamate dehydrogenase 1, mitochondrial Glud1 61377 
P08461 ODP2_RAT Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial Dlat 67123 
P50137 TKT_RAT Transketolase Tkt 67601 
Q920L2 DHSA_RAT Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial Sdha 71570 
P18886 CPT2_RAT Carnitine O-palmitoyltransferase 2, mitochondrial Cpt2 74063 
P18163 ACSL1_RAT Long-chain-fatty-acid--CoA ligase 1 Acsl1 78128 
Q66HF1 NDUS1_RAT NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial Ndufs1 79362 
P35571 GPDM_RAT Glycerol-3-phosphate dehydrogenase, mitochondrial Gpd2 80921 
P02466 CO1A2_RAT Collagen alpha-2(I) chain Col1a2 129486 
P52873 PYC_RAT Pyruvate carboxylase, mitochondrial Pc 129695 
Q9WUJ3 MYOME_RAT Myomegalin Pde4dip 261881 
B0LPN4 RYR2_RAT Ryanodine receptor 2 Ryr2 562594 
 
 
Supplemental Table C 5 - Proteins of epicardial adipose tissue identified in obese ZSF1 
Entry Entry name Protein name Gene name 
MW 
(kDa) 
P61959 SUMO2_RAT Small ubiquitin-related modifier 2 Sumo2 10864 
P06759 APOC3_RAT Apolipoprotein C-III Apoc3 11110 
P20767 LAC2_RAT Ig lambda-2 chain C region  11311 
P62804 H4_RAT Histone H4 Hist1h4b 11360 
P19944 RLA1_RAT 60S acidic ribosomal protein P1 Rplp1 11491 
Q5I0H3 SUMO1_RAT Small ubiquitin-related modifier 1 Sumo1 11550 
P07151 B2MG_RAT Beta-2-microglobulin B2m 13711 
Q00715 H2B1_RAT Histone H2B type 1  13982 
P55797 APOC4_RAT Apolipoprotein C-IV Apoc4 14522 
P62963 PROF1_RAT Profilin-1 Pfn1 14948 
P84245 H33_RAT Histone H3.3 H3f3b 15319 
Q80T18 GMFG_RAT Glia maturation factor gamma Gmfg 16769 
Q3T1J1 IF5A1_RAT Eukaryotic translation initiation factor 5A-1 Eif5a 16821 
P13668 STMN1_RAT Stathmin Stmn1 17278 
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P41498 PPAC_RAT Low molecular weight phosphotyrosine protein phosphatase Acp1 18140 
P01830 THY1_RAT Thy-1 membrane glycoprotein Thy1 18161 
P45592 COF1_RAT Cofilin-1 Cfl1 18521 
Q7M0E3 DEST_RAT Destrin Dstn 18522 
P31044 PEBP1_RAT Phosphatidylethanolamine-binding protein 1 Pebp1 20788 
P19132 FRIH_RAT Ferritin heavy chain Fth1 21113 
Q8CFN2 CDC42_RAT Cell division control protein 42 homolog Cdc42 21245 
Q6RUV5 RAC1_RAT Ras-related C3 botulinum toxin substrate 1 Rac1 21436 
P14630 APOM_RAT Apolipoprotein M Apom 21499 
Q63716 PRDX1_RAT Peroxiredoxin-1 Prdx1 22095 
Q5XI73 GDIR1_RAT Rho GDP-dissociation inhibitor 1 Arhgdia 23393 
P24368 PPIB_RAT Peptidyl-prolyl cis-trans isomerase B Ppib 23788 
P52925 HMGB2_RAT High mobility group protein B2 Hmgb2 24144 
P00502 GSTA1_RAT Glutathione S-transferase alpha-1 Gsta1 25591 
P48500 TPIS_RAT Triosephosphate isomerase Tpi1 26832 
Q6MG61 CLIC1_RAT Chloride intracellular channel protein 1 Clic1 26964 
P63102 1433Z_RAT 14-3-3 protein zeta/delta Ywhaz 27754 
P68255 1433T_RAT 14-3-3 protein theta Ywhaq 27761 
P35213 1433B_RAT 14-3-3 protein beta/alpha Ywhab 28037 
P52555 ERP29_RAT Endoplasmic reticulum resident protein 29 Erp29 28557 
Q63610 TPM3_RAT Tropomyosin alpha-3 chain Tpm3 28989 
P30009 MARCS_RAT Myristoylated alanine-rich C-kinase substrate Marcks 29777 
P67779 PHB_RAT Prohibitin Phb 29802 
P85973 PNPH_RAT Purine nucleoside phosphorylase (PNP) Pnp 32281 
P38983 RSSA_RAT 40S ribosomal protein SA Rpsa 32803 
P26644 APOH_RAT Beta-2-glycoprotein 1 Apoh 33175 
P04256 ROA1_RAT Heterogeneous nuclear ribonucleoprotein A1 Hnrnpa1 34191 
P19945 RLA0_RAT 60S acidic ribosomal protein P0 Rplp0 34194 
P07943 ALDR_RAT Aldose reductase Akr1b1 35774 
P04797 G3P_RAT Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) Gapdh 35805 
P55260 ANXA4_RAT Annexin A4 Anxa4 35826 
P55159 PON1_RAT Serum paraoxonase/arylesterase 1 Pon1 39333 
P04897 GNAI2_RAT Guanine nucleotide-binding protein G(i) subunit alpha-2 Gnai2 40473 
Q9QX79 FETUB_RAT Fetuin-B Fetub 41506 
P70473 AMACR_RAT Alpha-methylacyl-CoA racemase Amacr 41801 
P68035 ACTC_RAT Actin, alpha cardiac muscle 1 Actc1 41992 
Q4V898 RBMX_RAT RNA-binding motif protein, X chromosome Rbmx 42232 
P02651 APOA4_RAT Apolipoprotein A-IV Apoa4 44429 
P31211 CBG_RAT Corticosteroid-binding globulin Serpina6 44642 
Q794E4 HNRPF_RAT Heterogeneous nuclear ribonucleoprotein F Hnrnpf 45701 
Q4V7C7 ARP3_RAT Actin-related protein 3 Actr3 47327 
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O35254 GORS1_RAT Golgi reassembly-stacking protein 1 Gorasp1 47643 
Q5BJY9 K1C18_RAT Keratin, type I cytoskeletal 18 Krt18 47732 
P01048 KNT1_RAT T-kininogen 1 Map1 47745 
Q63081 PDIA6_RAT Protein disulfide-isomerase A6 Pdia6 48143 
P69897 TBB5_RAT Tubulin beta-5 chain Tubb5 49639 
P62630 EF1A1_RAT Elongation factor 1-alpha 1 Eef1a1 50082 
Q6P9V9 TBA1B_RAT Tubulin alpha-1B chain Tuba1b 50120 
Q4QRB4 TBB3_RAT Tubulin beta-3 chain Tubb3 50386 
P50399 GDIB_RAT Rab GDP dissociation inhibitor beta Gdi2 50505 
P02680 FIBG_RAT Fibrinogen gamma chain Fgg 50600 
Q6IG12 K2C7_RAT Keratin, type II cytoskeletal 7 Krt7 50678 
P61980 HNRPK_RAT Heterogeneous nuclear ribonucleoprotein K Hnrnpk 50944 
Q91ZN1 COR1A_RAT Coronin-1A Coro1a 51033 
Q6IFV1 K1C14_RAT Keratin, type I cytoskeletal 14 Krt14 52651 
Q10758 K2C8_RAT Keratin, type II cytoskeletal 8 Krt8 53985 
P00689 AMYP_RAT Pancreatic alpha-amylase Amy2 57141 
P28480 TCPA_RAT T-complex protein 1 subunit alpha Tcp1 60322 
Q9EQ25 S38A4_RAT Sodium-coupled neutral amino acid transporter 4 Slc38a4 60573 
Q6P6Q2 K2C5_RAT Keratin, type II cytoskeletal 5 Krt5 61788 
Q3KR86 IMMT_RAT MICOS complex subunit Mic60 Immt 67135 
Q32PX7 FUBP1_RAT Far upstream element-binding protein 1 Fubp1 67155 
P35565 CALX_RAT Calnexin Canx 67213 
O35763 MOES_RAT Moesin Msn 67697 
P08934 KNG1_RAT Kininogen-1 Kng1 70889 
P06761 GRP78_RAT 78 kDa glucose-regulated protein Hspa5 72302 
Q62826 HNRPM_RAT Heterogeneous nuclear ribonucleoprotein M Hnrnpm 73733 
P34058 HS90B_RAT Heat shock protein HSP 90-beta Hsp90ab1 83229 
P82995 HS90A_RAT Heat shock protein HSP 90-alpha Hsp90aa1 84762 
P06399 FIBA_RAT Fibrinogen alpha chain Fga 86632 
O08629 TIF1B_RAT Transcription intermediary factor 1-beta Trim28 88900 
Q01177 PLMN_RAT Plasminogen Plg 90477 
Q66HD0 ENPL_RAT Endoplasmin Hsp90b1 92713 
P05197 EF2_RAT Elongation factor 2 Eef2 95223 
Q63416 ITIH3_RAT Inter-alpha-trypsin inhibitor heavy chain H3 Itih3 99036 
Q9QXQ0 ACTN4_RAT Alpha-actinin-4 Actn4 104849 
Q5U300 UBA1_RAT Ubiquitin-like modifier-activating enzyme 1 Uba1 117713 
Q1JU68 EIF3A_RAT Eukaryotic translation initiation factor 3 subunit A Eif3a 163097 
P14046 A1I3_RAT Alpha-1-inhibitor 3 A1i3 163670 
Q03626 MUG1_RAT Murinoglobulin-1 Mug1 165221 
P01026 CO3_RAT Complement C3 C3 186342 
Q62812 MYH9_RAT Myosin-9 Myh9 226197 
P04937 FINC_RAT Fibronectin Fn1 272341 
P58365 CAD23_RAT Cadherin-23 Cdh23 365230 
P30427 PLEC_RAT Plectin Plec 533214 
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Supplemental Table C 6 - Proteins of epicardial adipose tissue common between obese and lean ZSF1 model. 
Values above zero correspond to values of up-regulated proteins in obese ZSF1; Values below zero correspond 
to values down-regulated proteins in obese ZSF1.  
Entry Entry Name Protein name 
Gene 
name 
emPAI 
ratio 
MW 
(kDa) 
P14480 FIBB_RAT Fibrinogen beta chain Fgb 4.98 54201 
A7VJC2 ROA2_RAT Heterogeneous nuclear ribonucleoproteins A2/B1 Hnrnpa2b1 3.26 37455 
Q63041 A1M_RAT Alpha-1-macroglobulin A1m 2.32 167019 
P17475 A1AT_RAT Alpha-1-antiproteinase Serpina1 2.24 46107 
P20059 HEMO_RAT Hemopexin Hpx 2.20 51318 
P02770 ALBU_RAT Serum albumin Alb 2.12 68686 
P04639 APOA1_RAT Apolipoprotein A-I Apoa1 2.09 30043 
P12346 TRFE_RAT Serotransferrin Tf 2.08 76346 
P48037 ANXA6_RAT Annexin A6 Anxa6 1.89 75706 
P02793 FRIL1_RAT Ferritin light chain 1 Ftl1 1.78 20736 
P05545 SPA3K_RAT Serine protease inhibitor A3K Serpina3k 1.75 46532 
P11598 PDIA3_RAT Protein disulfide-isomerase A3 Pdia3 1.66 56588 
P0C169 H2A1C_RAT Histone H2A type 1-C  1.43 14097 
P26772 CH10_RAT 10 kDa heat shock protein, mitochondrial Hspe1 1.35 10895 
P14141 CAH3_RAT Carbonic anhydrase 3 Car3 1.22 29413 
P51886 LUM_RAT Lumican Lum 1.19 38255 
P04762 CATA_RAT Catalase Cat 1.17 59719 
P60711 ACTB_RAT Actin, cytoplasmic 1 Actb 1.14 41710 
Q8R431 MGLL_RAT Monoglyceride lipase Mgll 1.04 33478 
P62982 RS27A_RAT Ubiquitin-40S ribosomal protein S27a Rps27a 0.93 17939 
Q6P9T8 TBB4B_RAT Tubulin beta-4B chain Tubb4b 0.89 49769 
P02454 CO1A1_RAT Collagen alpha-1(I) chain Col1a1 0.81 137869 
P02650 APOE_RAT Apolipoprotein E Apoe 0.69 35731 
P23764 GPX3_RAT Glutathione peroxidase 3 Gpx3 0.67 25409 
Q6URK4 ROA3_RAT Heterogeneous nuclear ribonucleoprotein A3 Hnrnpa3 0.66 39628 
P29457 SERPH_RAT Serpin H1 Serpinh1 0.63 46488 
Q07936 ANXA2_RAT Annexin A2 Anxa2 0.50 38654 
P63018 HSP7C_RAT Heat shock cognate 71 kDa protein Hspa8 0.48 70827 
P42930 HSPB1_RAT Heat shock protein beta-1 Hspb1 0.47 22879 
P10719 ATPB_RAT ATP synthase subunit beta, mitochondrial Atp5b 0.45 56318 
P09006 SPA3N_RAT Serine protease inhibitor A3N Serpina3n 0.44 46622 
P14668 ANXA5_RAT Annexin A5 Anxa5 0.43 35722 
P18418 CALR_RAT Calreticulin Calr 0.42 47966 
P13635 CERU_RAT Ceruloplasmin Cp 0.39 120764 
P85125 PTRF_RAT Polymerase I and transcript release factor Ptrf 0.33 43882 
P16617 PGK1_RAT Phosphoglycerate kinase 1 Pgk1 0.31 44510 
P04764 ENOA_RAT Alpha-enolase Eno1 0.27 47098 
P07632 SODC_RAT Superoxide dismutase [Cu-Zn] Sod1 0.13 15902 
O35077 GPDA_RAT Glycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic Gpd1 0.13 37428 
P58775 TPM2_RAT Tropomyosin beta chain Tpm2 0.08 32817 
P10818 CX6A1_RAT Cytochrome c oxidase subunit 6A1, mitochondrial Cox6a1 0.00 12293 
P12075 COX5B_RAT Cytochrome c oxidase subunit 5B, mitochondrial Cox5b 0.00 13906 
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P70623 FABP4_RAT Fatty acid-binding protein, adipocyte Fabp4 0.00 14699 
P11762 LEG1_RAT Galectin-1 Lgals1 0.00 14847 
P62161 CALM_RAT Calmodulin Calm1 0.00 16827 
Q64119 MYL6_RAT Myosin light polypeptide 6 Myl6 0.00 16964 
P19804 NDKB_RAT Nucleoside diphosphate kinase B Nme2 0.00 17272 
Q64122 MYL9_RAT Myosin regulatory light polypeptide 9 Myl9 0.00 19708 
P13832 MRLCA_RAT Myosin regulatory light chain RLC-A Rlc-a 0.00 19883 
P04906 GSTP1_RAT Glutathione S-transferase P Gstp1 0.00 23424 
P61983 1433G_RAT 14-3-3 protein gamma Ywhag 0.00 28285 
P20760 IGG2A_RAT Ig gamma-2A chain C region Igg-2a 0.00 35163 
Q64591 DECR_RAT 2,4-dienoyl-CoA reductase, mitochondrial Decr1 0.00 36110 
P07150 ANXA1_RAT Annexin A1 Anxa1 0.00 38805 
P16036 MPCP_RAT Phosphate carrier protein, mitochondrial Slc25a3 0.00 39419 
P85834 EFTU_RAT Elongation factor Tu, mitochondrial Tufm 0.00 49491 
P31000 VIME_RAT Vimentin Vim 0.00 53700 
P15999 ATPA_RAT ATP synthase subunit alpha, mitochondrial Atp5a1 0.00 59717 
Q6UPE1 ETFD_RAT Electron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial Etfdh 0.00 68155 
Q5BJQ0 ADCK3_RAT Chaperone activity of bc1 complex-like, mitochondrial Adck3 0.00 72180 
Q68FP1 GELS_RAT Gelsolin Gsn 0.00 86014 
P08649 CO4_RAT Complement C4 C4 0.00 192042 
P16086 SPTN1_RAT Spectrin alpha chain, non-erythrocytic 1 Sptan1 -0.22 284462 
Q68FU3 ETFB_RAT Electron transfer flavoprotein subunit beta Etfb -0.31 27670 
P05065 ALDOA_RAT Fructose-bisphosphate aldolase A Aldoa -0.37 39327 
P48721 GRP75_RAT Stress-70 protein, mitochondrial Hspa9 -0.45 73812 
P01946 HBA_RAT Hemoglobin subunit alpha-1/2 Hba1 -0.50 15319 
O08590 AOC3_RAT Membrane primary amine oxidase Aoc3 -0.55 84928 
P24090 FETUA_RAT Alpha-2-HS-glycoprotein Ahsg -0.62 37958 
O55171 ACOT2_RAT Acyl-coenzyme A thioesterase 2, mitochondrial Acot2 -0.68 49670 
P10111 PPIA_RAT Peptidyl-prolyl cis-trans isomerase A Ppia -0.72 17863 
P21913 DHSB_RAT Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial Sdhb -0.73 31809 
Q6IG01 K2C1B_RAT Keratin, type II cytoskeletal 1b Krt77 -0.78 57220 
P17764 THIL_RAT Acetyl-CoA acetyltransferase, mitochondrial Acat1 -0.80 44666 
P05943 S10AA_RAT Protein S100-A10 S100a10 -0.82 11068 
P02091 HBB1_RAT Hemoglobin subunit beta-1 Hbb -0.88 15969 
P13437 THIM_RAT 3-ketoacyl-CoA thiolase, mitochondrial Acaa2 -0.89 41844 
Q99NA5 IDH3A_RAT Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial Idh3a -0.93 39588 
P04276 VTDB_RAT Vitamin D-binding protein Gc -1.00 53509 
P14604 ECHM_RAT Enoyl-CoA hydratase, mitochondrial Echs1 -1.08 31496 
Q68FT1 COQ9_RAT Ubiquinone biosynthesis protein COQ9, mitochondrial Coq9 -1.09 35123 
P04636 MDHM_RAT Malate dehydrogenase, mitochondrial Mdh2 -1.11 35661 
B0BNN3 CAH1_RAT Carbonic anhydrase 1 Ca1 -1.15 28282 
P14408 FUMH_RAT Fumarate hydratase, mitochondrial Fh -1.15 54429 
Q9R063 PRDX5_RAT Peroxiredoxin-5, mitochondrial Prdx5 -1.17 22165 
Q9WVK7 HCDH_RAT Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial Hadh -1.20 34426 
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P02767 TTHY_RAT Transthyretin Ttr -1.25 15710 
Q8VHF5 CISY_RAT Citrate synthase, mitochondrial Cs -1.28 51833 
P11517 HBB2_RAT Hemoglobin subunit beta-2  -1.34 15972 
Q64428 ECHA_RAT Trifunctional enzyme subunit alpha, mitochondrial Hadha -1.38 82613 
P32551 QCR2_RAT Cytochrome b-c1 complex subunit 2, mitochondrial Uqcrc2 -1.50 48366 
P27139 CAH2_RAT Carbonic anhydrase 2 Ca2 -1.64 29096 
P00173 CYB5_RAT Cytochrome b5 Cyb5a -1.71 15346 
P15650 ACADL_RAT Long-chain specific acyl-CoA dehydrogenase, mitochondrial Acadl -1.71 47842 
P63039 CH60_RAT 60 kDa heat shock protein, mitochondrial Hspd1 -1.84 60917 
P04633 UCP1_RAT Mitochondrial brown fat uncoupling protein 1 Ucp1 -1.91 33190 
P11240 COX5A_RAT Cytochrome c oxidase subunit 5A, mitochondrial Cox5a -2.04 16119 
P45953 ACADV_RAT Very long-chain specific acyl-CoA dehydrogenase, mitochondrial Acadvl -2.19 70705 
P62898 CYC_RAT Cytochrome c, somatic Cycs -2.25 11598 
P13803 ETFA_RAT Electron transfer flavoprotein subunit alpha, mitochondrial Etfa -2.30 34929 
Q9ER34 ACON_RAT Aconitate hydratase, mitochondrial Aco2 -2.38 85380 
Q5XI78 ODO1_RAT 2-oxoglutarate dehydrogenase, mitochondrial Ogdh -2.82 116221 
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Supplemental Figure C 1 - ClueGo and CluePedia significance analysis of protein-protein interaction considering common proteins present in visceral adipose tissue of obese 
and lean ZSF1 rat (based on emPAI values). 
  
Number of mapped genes Significance color code 
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Supplemental Figure C 2 - ClueGo and CluePedia significance analysis of protein-protein interaction considering common proteins present in epicardial adipose tissue of 
obese and lean ZSF1 rat (based on emPAI values). 
Number of mapped genes Significance color code 
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Appendix D – Characterization and comparison of epicardial 
and visceral adipose tissue proteome 
 
Supplemental Table D 1 - Proteins of common between epicardial and visceral adipose tissue in lean ZSF1 model. 
Values above zero correspond to values of up-regulated proteins in epicardial adipose tissue in lean ZSF1; Values 
below zero correspond to values up-regulated in visceral adipose tissue in lean ZSF1 
Entry Entry name Protein name 
Gene 
name 
emPAI 
Ratio 
Q9ER34 ACON_RAT Aconitate hydratase, mitochondrial  Aco2 11.53 
P63039 CH60_RAT 60 kDa heat shock protein, mitochondrial Hspd1  7.71 
P02091 HBB1_RAT Hemoglobin subunit beta-1 Hbb 5.56 
P11517 HBB2_RAT Hemoglobin subunit beta-2  5.51 
P04636 MDHM_RAT Malate dehydrogenase, mitochondrial  Mdh2  4.89 
P62898 CYC_RAT Cytochrome c, somatic Cycs 4.50 
P17764 THIL_RAT Acetyl-CoA acetyltransferase, mitochondrial  Acat1 4.50 
Q8VHF5 CISY_RAT Citrate synthase, mitochondrial Cs 3.00 
P19234 NDUV2_RAT NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial  Ndufv2 2.59 
P48721 GRP75_RAT Stress-70 protein, mitochondrial Hspa9  2.33 
P12346 TRFE_RAT Serotransferrin  Tf 1.95 
P19804 NDKB_RAT Nucleoside diphosphate kinase B Nme2 1.64 
P14604 ECHM_RAT Enoyl-CoA hydratase, mitochondrial  Echs1 1.40 
P05065 ALDOA_RAT Fructose-bisphosphate aldolase A Aldoa 1.00 
P01946 HBA_RAT Hemoglobin subunit alpha-1/2  Hba1  0.88 
P16086 SPTN1_RAT Spectrin alpha chain, non-erythrocytic 1 Sptan1  0.75 
P50137 TKT_RAT Transketolase Tkt 0.71 
P27139 CAH2_RAT Carbonic anhydrase 2 Ca2 0.65 
P18163 ACSL1_RAT Long-chain-fatty-acid--CoA ligase 1 Acsl1  0.48 
P02466 CO1A2_RAT Collagen alpha-2(I) chain Col1a2 0.33 
P02454 CO1A1_RAT Collagen alpha-1(I) chain  Col1a1 0.33 
P70623 FABP4_RAT Fatty acid-binding protein, adipocyte  Fabp4 0.20 
Q68FP1 GELS_RAT Gelsolin  Gsn 0.20 
P62161 CALM_RAT Calmodulin Calm1 0.19 
P05943 S10AA_RAT Protein S100-A10  S100a10 0.18 
P02767 TTHY_RAT Transthyretin  Ttr  0.17 
P07632 SODC_RAT Superoxide dismutase [Cu-Zn]  Sod1 0.17 
P85125 PTRF_RAT Polymerase I and transcript release factor  Ptrf 0.16 
P26772 CH10_RAT 10 kDa heat shock protein, mitochondrial  Hspe1 0.15 
P35704 PRDX2_RAT Peroxiredoxin-2  Prdx2  0.14 
P42930 HSPB1_RAT Heat shock protein beta-1  Hspb1  0.14 
P11884 ALDH2_RAT Aldehyde dehydrogenase, mitochondrial  Aldh2 0.09 
P31000 VIME_RAT Vimentin Vim 0.07 
B0LPN4 RYR2_RAT Ryanodine receptor 2 Ryr2 0.00 
P00173 CYB5_RAT Cytochrome b5 Cyb5a -0.06 
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P16617 PGK1_RAT Phosphoglycerate kinase 1 Pgk1  -0.07 
O08590 AOC3_RAT Membrane primary amine oxidase Aoc3 -0.08 
P61983 1433G_RAT 14-3-3 protein gamma Ywhag -0.14 
P10111 PPIA_RAT Peptidyl-prolyl cis-trans isomerase A Ppia -0.16 
P17475 A1AT_RAT Alpha-1-antiproteinase  Serpina1 -0.18 
P63018 HSP7C_RAT Heat shock cognate 71 kDa protein  Hspa8  -0.18 
P04764 ENOA_RAT Alpha-enolase  Eno1  -0.18 
P02770 ALBU_RAT Serum albumin Alb -0.20 
P29457 SERPH_RAT Serpin H1  Serpinh1  -0.27 
P20760 IGG2A_RAT Ig gamma-2A chain C region Igg-2a -0.27 
Q4V8H8 EHD2_RAT EH domain-containing protein 2 Ehd2 -0.27 
P10860 DHE3_RAT Glutamate dehydrogenase 1, mitochondrial  Glud1  -0.27 
P62738 ACTA_RAT Actin, aortic smooth muscle Acta2  -0.28 
P02650 APOE_RAT Apolipoprotein E  Apoe -0.30 
Q6QA69 ABHD5_RAT 1-acylglycerol-3-phosphate O-acyltransferase ABHD5 Abhd5 -0.30 
P04906 GSTP1_RAT Glutathione S-transferase P Gstp1 -0.30 
Q6P9T8 TBB4B_RAT Tubulin beta-4B chain  Tubb4b  -0.31 
Q4FZU2 K2C6A_RAT Keratin, type II cytoskeletal 6A Krt6a -0.32 
P68370 TBA1A_RAT Tubulin alpha-1A chain  Tuba1a  -0.34 
P60711 ACTB_RAT Actin, cytoplasmic 1  Actb -0.35 
P18418 CALR_RAT Calreticulin  Calr -0.35 
P04639 APOA1_RAT Apolipoprotein A-I  Apoa1 -0.36 
P10719 ATPB_RAT ATP synthase subunit beta, mitochondrial  Atp5b -0.36 
P20059 HEMO_RAT Hemopexin Hpx -0.44 
Q8R431 MGLL_RAT Monoglyceride lipase Mgll -0.45 
P05545 SPA3K_RAT Serine protease inhibitor A3K  Serpina3k  -0.45 
Q9EQP5 PRELP_RAT Prolargin  Prelp -0.45 
P11598 PDIA3_RAT Protein disulfide-isomerase A3 Pdia3  -0.47 
P14668 ANXA5_RAT Annexin A5 Anxa5  -0.48 
Q64122 MYL9_RAT Myosin regulatory light polypeptide 9 Myl9  -0.48 
P04642 LDHA_RAT L-lactate dehydrogenase A chain Ldha  -0.48 
O88989 MDHC_RAT Malate dehydrogenase, cytoplasmic Mdh1 -0.48 
P02793 FRIL1_RAT Ferritin light chain 1 Ftl1  -0.49 
Q64119 MYL6_RAT Myosin light polypeptide 6  Myl6 -0.52 
P62982 RS27A_RAT Ubiquitin-40S ribosomal protein S27a  Rps27a -0.54 
P04762 CATA_RAT Catalase  Cat  -0.58 
Q6IFW6 K1C10_RAT Keratin, type I cytoskeletal 10  Krt10  -0.58 
Q07936 ANXA2_RAT Annexin A2 Anxa2  -0.61 
P51886 LUM_RAT Lumican Lum -0.62 
P15999 ATPA_RAT ATP synthase subunit alpha, mitochondrial Atp5a1 -0.67 
P43884 PLIN1_RAT Perilipin-1 Plin1  -0.67 
P58775 TPM2_RAT Tropomyosin beta chain  Tpm2 -0.68 
P13832 MRLCA_RAT Myosin regulatory light chain RLC-A  Rlc-a -0.70 
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P48037 ANXA6_RAT Annexin A6  Anxa6  -0.73 
P0C169 H2A1C_RAT Histone H2A type 1-C 0 -0.74 
A7VJC2 ROA2_RAT Heterogeneous nuclear ribonucleoproteins A2/B1  Hnrnpa2b1  -0.76 
P31232 TAGL_RAT Transgelin Tagln  -0.79 
P11762 LEG1_RAT Galectin-1  Lgals1 -0.82 
P07150 ANXA1_RAT Annexin A1  Anxa1  -0.82 
P14141 CAH3_RAT Carbonic anhydrase 3  Car3 -0.84 
 
 
Supplemental Table D 2 - Proteins of common between epicardial and visceral adipose tissue in obese ZSF1 
model. Values above zero correspond to values of up-regulated proteins in epicardial adipose tissue in obese 
ZSF1; Values below zero correspond to values up-regulated in visceral adipose tissue in obese ZSF1 
Entry Entry name Protein name 
Gene 
name 
emPAI 
Ratio 
Q9ER34 ACON_RAT Aconitate hydratase, mitochondrial  Aco2 7.20 
Q8VHF5 CISY_RAT Citrate synthase, mitochondrial Cs 4.11 
P04764 ENOA_RAT Alpha-enolase  Eno1  3.35 
P05545 SPA3K_RAT Serine protease inhibitor A3K  Serpina3k  2.70 
Q99NA5 IDH3A_RAT Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial  Idh3a 2.67 
P12346 TRFE_RAT Serotransferrin  Tf 2.52 
A7VJC2 ROA2_RAT Heterogeneous nuclear ribonucleoproteins A2/B1  Hnrnpa2b1  2.28 
Q62812 MYH9_RAT Myosin-9  Myh9 2.25 
P69897 TBB5_RAT Tubulin beta-5 chain Tubb5 2.13 
P04636 MDHM_RAT Malate dehydrogenase, mitochondrial  Mdh2  1.72 
P04797 G3P_RAT Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) Gapdh  1.58 
P11517 HBB2_RAT Hemoglobin subunit beta-2  1.57 
P20059 HEMO_RAT Hemopexin Hpx 1.56 
P02770 ALBU_RAT Serum albumin Alb 1.46 
P09006 SPA3N_RAT Serine protease inhibitor A3N  Serpina3n  1.30 
P04639 APOA1_RAT Apolipoprotein A-I  Apoa1 1.10 
Q64428 ECHA_RAT Trifunctional enzyme subunit alpha, mitochondrial  Hadha 1.06 
P02091 HBB1_RAT Hemoglobin subunit beta-1 Hbb 1.01 
P16617 PGK1_RAT Phosphoglycerate kinase 1 Pgk1  0.86 
P04762 CATA_RAT Catalase  Cat  0.85 
P02650 APOE_RAT Apolipoprotein E  Apoe 0.85 
P17475 A1AT_RAT Alpha-1-antiproteinase  Serpina1 0.82 
P07943 ALDR_RAT Aldose reductase Akr1b1  0.77 
Q6P9V9 TBA1B_RAT Tubulin alpha-1B chain Tuba1b  0.67 
P63039 CH60_RAT 60 kDa heat shock protein, mitochondrial Hspd1  0.55 
Q4V7C7 ARP3_RAT Actin-related protein 3 Actr3  0.53 
P85125 PTRF_RAT Polymerase I and transcript release factor  Ptrf 0.45 
P06761 GRP78_RAT 78 kDa glucose-regulated protein Hspa5  0.37 
O08590 AOC3_RAT Membrane primary amine oxidase Aoc3 0.32 
P01946 HBA_RAT Hemoglobin subunit alpha-1/2  Hba1  0.32 
Q68FP1 GELS_RAT Gelsolin  Gsn 0.20 
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P48500 TPIS_RAT Triosephosphate isomerase Tpi1 0.20 
P62161 CALM_RAT Calmodulin Calm1 0.19 
P24090 FETUA_RAT Alpha-2-HS-glycoprotein  Ahsg  0.17 
P62898 CYC_RAT Cytochrome c, somatic Cycs 0.16 
P20760 IGG2A_RAT Ig gamma-2A chain C region Igg-2a 0.15 
P13803 ETFA_RAT Electron transfer flavoprotein subunit alpha, mitochondrial  Etfa 0.15 
P05065 ALDOA_RAT Fructose-bisphosphate aldolase A Aldoa 0.15 
P10719 ATPB_RAT ATP synthase subunit beta, mitochondrial  Atp5b 0.14 
Q3T1J1 IF5A1_RAT Eukaryotic translation initiation factor 5A-1 Eif5a 0.14 
Q8R431 MGLL_RAT Monoglyceride lipase Mgll 0.14 
Q8CFN2 CDC42_RAT Cell division control protein 42 homolog Cdc42 0.14 
Q6RUV5 RAC1_RAT Ras-related C3 botulinum toxin substrate 1  Rac1 0.14 
Q6P9T8 TBB4B_RAT Tubulin beta-4B chain  Tubb4b  0.14 
P14604 ECHM_RAT Enoyl-CoA hydratase, mitochondrial  Echs1 0.13 
P19132 FRIH_RAT Ferritin heavy chain  Fth1  0.13 
P27139 CAH2_RAT Carbonic anhydrase 2 Ca2 0.13 
Q9QX79 FETUB_RAT Fetuin-B  Fetub 0.09 
Q66HD0 ENPL_RAT Endoplasmin  Hsp90b1  0.00 
P58365 CAD23_RAT Cadherin-23  Cdh23 0.00 
P48037 ANXA6_RAT Annexin A6  Anxa6  0.00 
P02454 CO1A1_RAT Collagen alpha-1(I) chain  Col1a1 0.00 
Q5XI73 GDIR1_RAT Rho GDP-dissociation inhibitor 1  Arhgdia -0.07 
O35077 GPDA_RAT Glycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic  Gpd1 -0.11 
P63018 HSP7C_RAT Heat shock cognate 71 kDa protein  Hspa8  -0.11 
P51886 LUM_RAT Lumican Lum -0.13 
P18418 CALR_RAT Calreticulin  Calr -0.14 
P35565 CALX_RAT Calnexin Canx -0.14 
Q63081 PDIA6_RAT Protein disulfide-isomerase A6  Pdia6  -0.18 
P11598 PDIA3_RAT Protein disulfide-isomerase A3 Pdia3  -0.20 
P70623 FABP4_RAT Fatty acid-binding protein, adipocyte  Fabp4 -0.24 
P31000 VIME_RAT Vimentin Vim -0.24 
P07632 SODC_RAT Superoxide dismutase [Cu-Zn]  Sod1 -0.26 
P62982 RS27A_RAT Ubiquitin-40S ribosomal protein S27a  Rps27a -0.27 
P62630 EF1A1_RAT Elongation factor 1-alpha 1  Eef1a1  -0.29 
P02793 FRIL1_RAT Ferritin light chain 1 Ftl1  -0.30 
P04906 GSTP1_RAT Glutathione S-transferase P Gstp1 -0.30 
P42930 HSPB1_RAT Heat shock protein beta-1  Hspb1  -0.32 
P19804 NDKB_RAT Nucleoside diphosphate kinase B Nme2 -0.32 
P63102 1433Z_RAT 14-3-3 protein zeta/delta Ywhaz  -0.35 
Q10758 K2C8_RAT Keratin, type II cytoskeletal 8 Krt8  -0.38 
P08649 CO4_RAT Complement C4 C4  -0.40 
P35213 1433B_RAT 14-3-3 protein beta/alpha Ywhab -0.47 
P55260 ANXA4_RAT Annexin A4  Anxa4  -0.48 
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Q64122 MYL9_RAT Myosin regulatory light polypeptide 9 Myl9  -0.48 
Q7M0E3 DEST_RAT Destrin  Dstn -0.48 
P61983 1433G_RAT 14-3-3 protein gamma Ywhag -0.48 
P85973 PNPH_RAT Purine nucleoside phosphorylase (PNP)  Pnp -0.48 
P10111 PPIA_RAT Peptidyl-prolyl cis-trans isomerase A Ppia -0.49 
P24368 PPIB_RAT Peptidyl-prolyl cis-trans isomerase B Ppib -0.50 
P13832 MRLCA_RAT Myosin regulatory light chain RLC-A  Rlc-a -0.50 
Q64119 MYL6_RAT Myosin light polypeptide 6  Myl6 -0.52 
P15999 ATPA_RAT ATP synthase subunit alpha, mitochondrial Atp5a1 -0.60 
Q07936 ANXA2_RAT Annexin A2 Anxa2  -0.62 
P52555 ERP29_RAT Endoplasmic reticulum resident protein 29 Erp29 -0.65 
Q63716 PRDX1_RAT Peroxiredoxin-1 Prdx1  -0.66 
P68255 1433T_RAT 14-3-3 protein theta  Ywhaq -0.68 
P14141 CAH3_RAT Carbonic anhydrase 3  Car3 -0.68 
P00173 CYB5_RAT Cytochrome b5 Cyb5a -0.71 
Q63610 TPM3_RAT Tropomyosin alpha-3 chain Tpm3  -0.71 
P02767 TTHY_RAT Transthyretin  Ttr  -0.72 
P58775 TPM2_RAT Tropomyosin beta chain  Tpm2 -0.76 
P14668 ANXA5_RAT Annexin A5 Anxa5  -0.77 
P62963 PROF1_RAT Profilin-1  Pfn1 -0.82 
P11762 LEG1_RAT Galectin-1  Lgals1 -0.88 
P07150 ANXA1_RAT Annexin A1  Anxa1  -0.91 
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Supplemental Figure D 1 - ClueGo and CluePedia significance analysis of protein-protein interaction considering proteins present in epicardial and visceral 
adipose tissue of lean ZSF1 rat (based on emPAI values). 
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Number of mapped genes Significance color code 
Supplemental Figure D 2 - ClueGo and CluePedia significance analysis of protein-protein interaction considering proteins present in epicardial and visceral 
adipose tissue of obese ZSF1 rat (based on emPAI values). 
 
